<!DOCTYPE html>
<!-- Created by pdf2htmlEX (https://github.com/coolwanglu/pdf2htmlex) -->
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta name="generator" content="pdf2htmlEX"/>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
<style type="text/css">
/*! 
 * Base CSS for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/coolwanglu/pdf2htmlEX/blob/master/share/LICENSE
 */#sidebar{position:absolute;top:0;left:0;bottom:0;width:250px;padding:0;margin:0;overflow:auto}#page-container{position:absolute;top:0;left:0;margin:0;padding:0;border:0}@media screen{#sidebar.opened+#page-container{left:250px}#page-container{bottom:0;right:0;overflow:auto}.loading-indicator{display:none}.loading-indicator.active{display:block;position:absolute;width:64px;height:64px;top:50%;left:50%;margin-top:-32px;margin-left:-32px}.loading-indicator img{position:absolute;top:0;left:0;bottom:0;right:0}}@media print{@page{margin:0}html{margin:0}body{margin:0;-webkit-print-color-adjust:exact}#sidebar{display:none}#page-container{width:auto;height:auto;overflow:visible;background-color:transparent}.d{display:none}}.pf{position:relative;background-color:white;overflow:hidden;margin:0;border:0}.pc{position:absolute;border:0;padding:0;margin:0;top:0;left:0;width:100%;height:100%;overflow:hidden;display:block;transform-origin:0 0;-ms-transform-origin:0 0;-webkit-transform-origin:0 0}.pc.opened{display:block}.bf{position:absolute;border:0;margin:0;top:0;bottom:0;width:100%;height:100%;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}.bi{position:absolute;border:0;margin:0;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}@media print{.pf{margin:0;box-shadow:none;page-break-after:always;page-break-inside:avoid}@-moz-document url-prefix(){.pf{overflow:visible;border:1px solid #fff}.pc{overflow:visible}}}.c{position:absolute;border:0;padding:0;margin:0;overflow:hidden;display:block}.t{position:absolute;white-space:pre;font-size:1px;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%;unicode-bidi:bidi-override;-moz-font-feature-settings:"liga" 0}.t:after{content:''}.t:before{content:'';display:inline-block}.t span{position:relative;unicode-bidi:bidi-override}._{display:inline-block;color:transparent;z-index:-1}::selection{background:rgba(127,255,255,0.4)}::-moz-selection{background:rgba(127,255,255,0.4)}.pi{display:none}.d{position:absolute;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%}.it{border:0;background-color:rgba(255,255,255,0.0)}.ir:hover{cursor:pointer}</style>
<style type="text/css">
/*! 
 * Fancy styles for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/coolwanglu/pdf2htmlEX/blob/master/share/LICENSE
 */@keyframes fadein{from{opacity:0}to{opacity:1}}@-webkit-keyframes fadein{from{opacity:0}to{opacity:1}}@keyframes swing{0{transform:rotate(0)}10%{transform:rotate(0)}90%{transform:rotate(720deg)}100%{transform:rotate(720deg)}}@-webkit-keyframes swing{0{-webkit-transform:rotate(0)}10%{-webkit-transform:rotate(0)}90%{-webkit-transform:rotate(720deg)}100%{-webkit-transform:rotate(720deg)}}@media screen{#sidebar{background-color:#2f3236;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI0IiBoZWlnaHQ9IjQiPgo8cmVjdCB3aWR0aD0iNCIgaGVpZ2h0PSI0IiBmaWxsPSIjNDAzYzNmIj48L3JlY3Q+CjxwYXRoIGQ9Ik0wIDBMNCA0Wk00IDBMMCA0WiIgc3Ryb2tlLXdpZHRoPSIxIiBzdHJva2U9IiMxZTI5MmQiPjwvcGF0aD4KPC9zdmc+")}#outline{font-family:Georgia,Times,"Times New Roman",serif;font-size:13px;margin:2em 1em}#outline ul{padding:0}#outline li{list-style-type:none;margin:1em 0}#outline li>ul{margin-left:1em}#outline a,#outline a:visited,#outline a:hover,#outline a:active{line-height:1.2;color:#e8e8e8;text-overflow:ellipsis;white-space:nowrap;text-decoration:none;display:block;overflow:hidden;outline:0}#outline a:hover{color:#0cf}#page-container{background-color:#9e9e9e;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI1IiBoZWlnaHQ9IjUiPgo8cmVjdCB3aWR0aD0iNSIgaGVpZ2h0PSI1IiBmaWxsPSIjOWU5ZTllIj48L3JlY3Q+CjxwYXRoIGQ9Ik0wIDVMNSAwWk02IDRMNCA2Wk0tMSAxTDEgLTFaIiBzdHJva2U9IiM4ODgiIHN0cm9rZS13aWR0aD0iMSI+PC9wYXRoPgo8L3N2Zz4=");-webkit-transition:left 500ms;transition:left 500ms}.pf{margin:13px auto;box-shadow:1px 1px 3px 1px #333;border-collapse:separate}.pc.opened{-webkit-animation:fadein 100ms;animation:fadein 100ms}.loading-indicator.active{-webkit-animation:swing 1.5s ease-in-out .01s infinite alternate none;animation:swing 1.5s ease-in-out .01s infinite alternate none}.checked{background:no-repeat url(data:image/png;base64,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)}}</style>
<style type="text/css">
.ff0{font-family:sans-serif;visibility:hidden;}
@font-face{font-family:ff1;src:url('data:application/font-woff;base64,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')format("woff");}.ff1{font-family:ff1;line-height:0.942000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2;src:url('data:application/font-woff;base64,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')format("woff");}.ff2{font-family:ff2;line-height:0.963000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff3;src:url('data:application/font-woff;base64,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')format("woff");}.ff3{font-family:ff3;line-height:0.969000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff4;src:url('data:application/font-woff;base64,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')format("woff");}.ff4{font-family:ff4;line-height:0.969000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff5;src:url('data:application/font-woff;base64,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')format("woff");}.ff5{font-family:ff5;line-height:0.942000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff6;src:url('data:application/font-woff;base64,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')format("woff");}.ff6{font-family:ff6;line-height:0.719000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff7;src:url('data:application/font-woff;base64,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')format("woff");}.ff7{font-family:ff7;line-height:0.963000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff8;src:url('data:application/font-woff;base64,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')format("woff");}.ff8{font-family:ff8;line-height:0.919000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff9;src:url('data:application/font-woff;base64,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')format("woff");}.ff9{font-family:ff9;line-height:0.942000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffa;src:url('data:application/font-woff;base64,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')format("woff");}.ffa{font-family:ffa;line-height:0.700000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffb;src:url('data:application/font-woff;base64,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')format("woff");}.ffb{font-family:ffb;line-height:0.957000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffc;src:url('data:application/font-woff;base64,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')format("woff");}.ffc{font-family:ffc;line-height:0.942000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffd;src:url('data:application/font-woff;base64,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')format("woff");}.ffd{font-family:ffd;line-height:0.949000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ffe;src:url('data:application/font-woff;base64,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')format("woff");}.ffe{font-family:ffe;line-height:0.969000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:fff;src:url('data:application/font-woff;base64,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')format("woff");}.fff{font-family:fff;line-height:0.969000;font-style:normal;font-weight:normal;visibility:visible;}
.m0{transform:matrix(0.250000,0.000000,0.000000,0.250000,0,0);-ms-transform:matrix(0.250000,0.000000,0.000000,0.250000,0,0);-webkit-transform:matrix(0.250000,0.000000,0.000000,0.250000,0,0);}
.v0{vertical-align:0.000000px;}
.ls6{letter-spacing:-2.600000px;}
.ls10{letter-spacing:-1.920000px;}
.lsa{letter-spacing:-0.680000px;}
.lsd{letter-spacing:-0.600000px;}
.ls2{letter-spacing:-0.520000px;}
.lsc{letter-spacing:-0.480000px;}
.ls8{letter-spacing:-0.400000px;}
.ls3{letter-spacing:-0.320000px;}
.lsb{letter-spacing:-0.280000px;}
.ls7{letter-spacing:-0.240000px;}
.ls1{letter-spacing:-0.200000px;}
.ls0{letter-spacing:0.000000px;}
.ls5{letter-spacing:0.200000px;}
.ls9{letter-spacing:0.204000px;}
.ls4{letter-spacing:0.320000px;}
.lse{letter-spacing:0.400000px;}
.lsf{letter-spacing:1.000000px;}
.sc_{text-shadow:none;}
.sc0{text-shadow:-0.015em 0 transparent,0 0.015em transparent,0.015em 0 transparent,0 -0.015em  transparent;}
@media screen and (-webkit-min-device-pixel-ratio:0){
.sc_{-webkit-text-stroke:0px transparent;}
.sc0{-webkit-text-stroke:0.015em transparent;text-shadow:none;}
}
.wsbd{word-spacing:-10.350000px;}
.wsc2{word-spacing:-9.200000px;}
.ws53{word-spacing:-3.480000px;}
.wsef{word-spacing:-2.920000px;}
.wsf0{word-spacing:-2.440000px;}
.wsaf{word-spacing:-2.240000px;}
.wsd0{word-spacing:-2.160000px;}
.ws44{word-spacing:-2.120000px;}
.wse1{word-spacing:-1.920000px;}
.wsd2{word-spacing:-1.880000px;}
.ws4b{word-spacing:-1.840000px;}
.ws7e{word-spacing:-1.800000px;}
.wsa{word-spacing:-1.760000px;}
.wsdb{word-spacing:-1.720000px;}
.ws16{word-spacing:-1.640000px;}
.ws3b{word-spacing:-1.600000px;}
.wsb9{word-spacing:-1.560000px;}
.ws5c{word-spacing:-1.520000px;}
.ws4d{word-spacing:-1.480000px;}
.wsc8{word-spacing:-1.440000px;}
.ws4{word-spacing:-1.400000px;}
.wsdc{word-spacing:-1.320000px;}
.ws1a{word-spacing:-1.280000px;}
.ws26{word-spacing:-1.240000px;}
.ws71{word-spacing:-1.200000px;}
.ws88{word-spacing:-1.160000px;}
.ws1{word-spacing:-1.120000px;}
.ws9e{word-spacing:-1.080000px;}
.ws20{word-spacing:-1.040000px;}
.ws19{word-spacing:-1.000000px;}
.ws72{word-spacing:-0.960000px;}
.wsa3{word-spacing:-0.920000px;}
.ws9{word-spacing:-0.880000px;}
.ws73{word-spacing:-0.840000px;}
.ws11{word-spacing:-0.800000px;}
.ws5b{word-spacing:-0.760000px;}
.ws23{word-spacing:-0.720000px;}
.wsa2{word-spacing:-0.680000px;}
.wse8{word-spacing:-0.640000px;}
.ws1e{word-spacing:-0.600000px;}
.ws2b{word-spacing:-0.520000px;}
.ws91{word-spacing:-0.480000px;}
.wse{word-spacing:-0.440000px;}
.ws61{word-spacing:-0.400000px;}
.wsac{word-spacing:-0.360000px;}
.ws24{word-spacing:-0.320000px;}
.ws4c{word-spacing:-0.240000px;}
.ws48{word-spacing:-0.204000px;}
.ws5{word-spacing:-0.200000px;}
.ws82{word-spacing:-0.160000px;}
.ws70{word-spacing:-0.120000px;}
.ws4a{word-spacing:-0.080000px;}
.ws3{word-spacing:-0.040000px;}
.ws0{word-spacing:0.000000px;}
.ws83{word-spacing:0.040000px;}
.ws8b{word-spacing:0.080000px;}
.wsc0{word-spacing:0.120000px;}
.ws7c{word-spacing:0.160000px;}
.wsb8{word-spacing:0.200000px;}
.ws36{word-spacing:0.240000px;}
.ws6c{word-spacing:0.280000px;}
.ws2e{word-spacing:0.320000px;}
.ws2a{word-spacing:0.360000px;}
.ws81{word-spacing:0.440000px;}
.ws8e{word-spacing:0.480000px;}
.ws29{word-spacing:0.520000px;}
.wsd5{word-spacing:0.560000px;}
.ws42{word-spacing:0.600000px;}
.ws3f{word-spacing:0.640000px;}
.wsf{word-spacing:0.680000px;}
.ws2f{word-spacing:0.720000px;}
.wsf8{word-spacing:0.760000px;}
.wscd{word-spacing:0.800000px;}
.wsd{word-spacing:0.840000px;}
.ws40{word-spacing:0.880000px;}
.wsd8{word-spacing:0.920000px;}
.ws63{word-spacing:0.960000px;}
.ws57{word-spacing:1.000000px;}
.wsc4{word-spacing:1.040000px;}
.ws18{word-spacing:1.120000px;}
.ws2{word-spacing:1.160000px;}
.ws8a{word-spacing:1.200000px;}
.ws80{word-spacing:1.240000px;}
.ws12{word-spacing:1.280000px;}
.ws92{word-spacing:1.320000px;}
.wseb{word-spacing:1.360000px;}
.ws7a{word-spacing:1.400000px;}
.ws6d{word-spacing:1.480000px;}
.wsed{word-spacing:1.520000px;}
.ws9c{word-spacing:1.560000px;}
.ws79{word-spacing:1.600000px;}
.ws84{word-spacing:1.640000px;}
.ws2d{word-spacing:1.680000px;}
.wsa0{word-spacing:1.760000px;}
.wse6{word-spacing:1.800000px;}
.ws31{word-spacing:1.840000px;}
.ws7{word-spacing:1.880000px;}
.ws9f{word-spacing:1.920000px;}
.ws45{word-spacing:1.960000px;}
.ws74{word-spacing:2.000000px;}
.ws90{word-spacing:2.040000px;}
.wsc5{word-spacing:2.080000px;}
.ws28{word-spacing:2.120000px;}
.wsd7{word-spacing:2.160000px;}
.wsde{word-spacing:2.200000px;}
.wsb5{word-spacing:2.240000px;}
.ws22{word-spacing:2.280000px;}
.ws7f{word-spacing:2.320000px;}
.ws21{word-spacing:2.360000px;}
.ws75{word-spacing:2.400000px;}
.ws6{word-spacing:2.440000px;}
.ws6b{word-spacing:2.480000px;}
.ws94{word-spacing:2.520000px;}
.ws35{word-spacing:2.600000px;}
.ws17{word-spacing:2.680000px;}
.ws43{word-spacing:2.720000px;}
.ws8d{word-spacing:2.760000px;}
.ws69{word-spacing:2.840000px;}
.wse5{word-spacing:2.920000px;}
.wse7{word-spacing:2.960000px;}
.wsf6{word-spacing:3.000000px;}
.ws4e{word-spacing:3.080000px;}
.ws93{word-spacing:3.120000px;}
.ws98{word-spacing:3.160000px;}
.wsd9{word-spacing:3.280000px;}
.ws8{word-spacing:3.400000px;}
.ws51{word-spacing:3.440000px;}
.ws99{word-spacing:3.480000px;}
.ws95{word-spacing:3.520000px;}
.ws3d{word-spacing:3.560000px;}
.ws1d{word-spacing:3.640000px;}
.ws30{word-spacing:3.680000px;}
.wsc7{word-spacing:3.720000px;}
.wscc{word-spacing:3.760000px;}
.ws15{word-spacing:3.800000px;}
.ws85{word-spacing:3.840000px;}
.ws10{word-spacing:3.880000px;}
.ws7b{word-spacing:3.920000px;}
.ws52{word-spacing:3.960000px;}
.ws56{word-spacing:4.080000px;}
.ws5d{word-spacing:4.120000px;}
.ws87{word-spacing:4.200000px;}
.wse0{word-spacing:4.240000px;}
.wsab{word-spacing:4.320000px;}
.wsee{word-spacing:4.360000px;}
.wsad{word-spacing:4.440000px;}
.wsb{word-spacing:4.480000px;}
.wsb0{word-spacing:4.520000px;}
.ws34{word-spacing:4.560000px;}
.wsb1{word-spacing:4.600000px;}
.ws6f{word-spacing:4.640000px;}
.ws7d{word-spacing:4.680000px;}
.wsf2{word-spacing:4.720000px;}
.ws27{word-spacing:4.800000px;}
.wsf4{word-spacing:4.840000px;}
.ws9d{word-spacing:4.920000px;}
.ws25{word-spacing:4.960000px;}
.wsf7{word-spacing:5.000000px;}
.wsc{word-spacing:5.040000px;}
.wsec{word-spacing:5.120000px;}
.ws5a{word-spacing:5.160000px;}
.ws50{word-spacing:5.240000px;}
.ws13{word-spacing:5.280000px;}
.ws96{word-spacing:5.320000px;}
.wse2{word-spacing:5.360000px;}
.wsbe{word-spacing:5.400000px;}
.wsbb{word-spacing:5.440000px;}
.wsf1{word-spacing:5.480000px;}
.ws1c{word-spacing:5.520000px;}
.ws65{word-spacing:5.560000px;}
.ws78{word-spacing:5.600000px;}
.ws9b{word-spacing:5.640000px;}
.wsce{word-spacing:5.680000px;}
.ws49{word-spacing:5.840000px;}
.wsb6{word-spacing:5.920000px;}
.wsdf{word-spacing:5.960000px;}
.wsc6{word-spacing:6.000000px;}
.wsd6{word-spacing:6.080000px;}
.ws77{word-spacing:6.160000px;}
.ws86{word-spacing:6.200000px;}
.ws89{word-spacing:6.360000px;}
.wsf5{word-spacing:6.400000px;}
.wscf{word-spacing:6.440000px;}
.wsb2{word-spacing:6.480000px;}
.ws4f{word-spacing:6.600000px;}
.wsb7{word-spacing:6.680000px;}
.wsc9{word-spacing:6.720000px;}
.wsca{word-spacing:6.760000px;}
.wsb4{word-spacing:6.840000px;}
.ws62{word-spacing:6.880000px;}
.ws6a{word-spacing:6.920000px;}
.wsd4{word-spacing:7.000000px;}
.wsa7{word-spacing:7.040000px;}
.ws32{word-spacing:7.160000px;}
.ws3c{word-spacing:7.200000px;}
.ws14{word-spacing:7.240000px;}
.ws60{word-spacing:7.280000px;}
.ws41{word-spacing:7.320000px;}
.wsdd{word-spacing:7.600000px;}
.wsa1{word-spacing:7.760000px;}
.wsba{word-spacing:7.880000px;}
.ws9a{word-spacing:8.120000px;}
.wsa6{word-spacing:8.160000px;}
.ws59{word-spacing:8.240000px;}
.wsda{word-spacing:8.280000px;}
.wsae{word-spacing:8.320000px;}
.ws3a{word-spacing:8.440000px;}
.wsa4{word-spacing:8.520000px;}
.wse4{word-spacing:8.640000px;}
.ws58{word-spacing:8.680000px;}
.ws37{word-spacing:8.800000px;}
.ws67{word-spacing:8.840000px;}
.wsa5{word-spacing:8.880000px;}
.ws1f{word-spacing:8.960000px;}
.ws5f{word-spacing:9.000000px;}
.wsf3{word-spacing:9.080000px;}
.wscb{word-spacing:9.240000px;}
.ws55{word-spacing:9.320000px;}
.wse3{word-spacing:9.440000px;}
.ws8f{word-spacing:9.640000px;}
.ws68{word-spacing:9.680000px;}
.ws1b{word-spacing:9.720000px;}
.ws5e{word-spacing:10.280000px;}
.wsea{word-spacing:10.320000px;}
.ws3e{word-spacing:10.440000px;}
.wsbf{word-spacing:10.720000px;}
.ws97{word-spacing:11.200000px;}
.ws66{word-spacing:11.480000px;}
.wsa9{word-spacing:11.560000px;}
.ws2c{word-spacing:11.680000px;}
.wsc3{word-spacing:11.720000px;}
.ws76{word-spacing:11.880000px;}
.ws8c{word-spacing:11.920000px;}
.wsc1{word-spacing:12.000000px;}
.wsb3{word-spacing:12.040000px;}
.ws38{word-spacing:12.280000px;}
.ws64{word-spacing:12.360000px;}
.ws6e{word-spacing:12.480000px;}
.wsbc{word-spacing:13.680000px;}
.wsa8{word-spacing:13.760000px;}
.wse9{word-spacing:14.120000px;}
.wsaa{word-spacing:14.240000px;}
.ws33{word-spacing:14.360000px;}
.ws54{word-spacing:14.480000px;}
.wsd1{word-spacing:16.080000px;}
.wsd3{word-spacing:16.320000px;}
.ws39{word-spacing:16.960000px;}
.ws47{word-spacing:17.840000px;}
.ws46{word-spacing:20.800000px;}
._7{margin-left:-559.647200px;}
._f{margin-left:-27.240000px;}
._4{margin-left:-21.380000px;}
._26{margin-left:-15.578000px;}
._a{margin-left:-13.200000px;}
._3{margin-left:-10.350000px;}
._10{margin-left:-8.880000px;}
._e{margin-left:-7.115200px;}
._1f{margin-left:-5.322000px;}
._14{margin-left:-3.502000px;}
._2{margin-left:-2.345600px;}
._0{margin-left:-1.056000px;}
._1{width:1.046400px;}
._d{width:2.425600px;}
._8{width:3.880000px;}
._6{width:5.040000px;}
._1d{width:6.164000px;}
._9{width:7.424000px;}
._1c{width:8.489600px;}
._11{width:10.097600px;}
._c{width:11.913600px;}
._1e{width:13.022400px;}
._5{width:20.000400px;}
._b{width:37.500000px;}
._23{width:97.002000px;}
._24{width:99.518000px;}
._25{width:110.602000px;}
._19{width:163.234000px;}
._22{width:174.386000px;}
._21{width:200.768000px;}
._1a{width:202.096000px;}
._20{width:272.384000px;}
._17{width:299.472000px;}
._16{width:313.208000px;}
._18{width:328.141600px;}
._15{width:359.686000px;}
._1b{width:364.378000px;}
._12{width:368.256000px;}
._27{width:408.696400px;}
._13{width:425.376000px;}
.fc3{color:rgb(128,130,133);}
.fc2{color:rgb(141,189,220);}
.fc1{color:rgb(0,0,0);}
.fc0{color:rgb(66,145,197);}
.fs5{font-size:20.000000px;}
.fs8{font-size:22.080000px;}
.fs7{font-size:27.600000px;}
.fs0{font-size:32.000000px;}
.fs6{font-size:34.000000px;}
.fs4{font-size:36.000000px;}
.fs2{font-size:40.000000px;}
.fs3{font-size:50.000000px;}
.fs1{font-size:52.000000px;}
.y4{bottom:37.245600px;}
.y3{bottom:47.245600px;}
.y61{bottom:52.500000px;}
.y102{bottom:52.858500px;}
.y9e{bottom:53.259000px;}
.y2{bottom:57.245600px;}
.y84{bottom:58.862000px;}
.y43{bottom:64.258600px;}
.ybd{bottom:64.258700px;}
.yce{bottom:64.259000px;}
.yda{bottom:64.500000px;}
.y101{bottom:64.858500px;}
.yd9{bottom:65.258600px;}
.y9d{bottom:65.259000px;}
.y144{bottom:65.630600px;}
.ydf{bottom:70.759100px;}
.y83{bottom:72.861500px;}
.ybc{bottom:74.258700px;}
.y42{bottom:76.258600px;}
.ycd{bottom:76.259000px;}
.y100{bottom:76.858500px;}
.yd8{bottom:77.258600px;}
.y9c{bottom:77.259000px;}
.y143{bottom:77.630600px;}
.ybb{bottom:84.258700px;}
.yde{bottom:84.758600px;}
.y82{bottom:86.861000px;}
.y41{bottom:88.258600px;}
.ycc{bottom:88.259000px;}
.yff{bottom:88.858000px;}
.yd7{bottom:89.258600px;}
.y9b{bottom:89.259000px;}
.y142{bottom:89.630600px;}
.yba{bottom:94.258700px;}
.yb9{bottom:97.778700px;}
.y1a{bottom:98.283000px;}
.ycb{bottom:100.259000px;}
.yfe{bottom:100.858000px;}
.y81{bottom:100.860500px;}
.y9a{bottom:101.259000px;}
.y141{bottom:101.631000px;}
.y9f{bottom:105.500000px;}
.ydd{bottom:106.256000px;}
.y40{bottom:106.259000px;}
.y60{bottom:107.259000px;}
.y19{bottom:110.283000px;}
.yca{bottom:112.259000px;}
.yfd{bottom:112.858000px;}
.y99{bottom:113.259000px;}
.y140{bottom:113.631000px;}
.y80{bottom:114.860000px;}
.yb8{bottom:117.259000px;}
.y3f{bottom:118.259000px;}
.y5f{bottom:119.259000px;}
.y18{bottom:122.283000px;}
.yc9{bottom:124.259000px;}
.yfc{bottom:124.858000px;}
.y98{bottom:125.259000px;}
.y13f{bottom:125.631000px;}
.y156{bottom:128.259000px;}
.y7f{bottom:128.859500px;}
.yb7{bottom:129.259000px;}
.y3e{bottom:130.259000px;}
.ydc{bottom:131.152000px;}
.y5e{bottom:131.259000px;}
.y17{bottom:134.283000px;}
.yc8{bottom:136.259000px;}
.yfb{bottom:136.858000px;}
.y97{bottom:137.259000px;}
.y13e{bottom:137.631000px;}
.y155{bottom:140.259000px;}
.ydb{bottom:141.148000px;}
.yb6{bottom:141.259000px;}
.y3d{bottom:142.259000px;}
.y7e{bottom:142.859000px;}
.y5d{bottom:143.259000px;}
.y16{bottom:146.283000px;}
.yd6{bottom:148.259000px;}
.yfa{bottom:148.858000px;}
.y118{bottom:149.259000px;}
.y154{bottom:152.259000px;}
.yb5{bottom:153.259000px;}
.y3c{bottom:154.259000px;}
.y13d{bottom:155.631000px;}
.y15{bottom:158.283000px;}
.yd5{bottom:160.259000px;}
.yf9{bottom:160.858000px;}
.y117{bottom:161.259000px;}
.y5c{bottom:162.259000px;}
.y153{bottom:164.259000px;}
.y7d{bottom:164.356000px;}
.y3b{bottom:166.259000px;}
.y13c{bottom:167.631000px;}
.yb4{bottom:171.259000px;}
.y96{bottom:172.259000px;}
.yf8{bottom:172.858000px;}
.y116{bottom:173.259000px;}
.y5b{bottom:174.259000px;}
.y152{bottom:176.259000px;}
.y14{bottom:176.283000px;}
.y3a{bottom:178.259000px;}
.y13b{bottom:179.631000px;}
.yb3{bottom:183.259000px;}
.y95{bottom:184.259000px;}
.y161{bottom:184.283000px;}
.yf7{bottom:184.858000px;}
.y5a{bottom:186.259000px;}
.y151{bottom:188.259000px;}
.y13{bottom:188.283000px;}
.y7c{bottom:189.252000px;}
.y39{bottom:190.259000px;}
.y115{bottom:191.259000px;}
.y13a{bottom:191.631000px;}
.yb2{bottom:195.259000px;}
.y94{bottom:196.259000px;}
.y160{bottom:196.283000px;}
.yf6{bottom:196.858000px;}
.y59{bottom:198.259000px;}
.y7b{bottom:199.248000px;}
.y150{bottom:200.259000px;}
.y38{bottom:202.259000px;}
.y114{bottom:203.259000px;}
.y139{bottom:203.631000px;}
.y12{bottom:206.283000px;}
.yb1{bottom:207.259000px;}
.y93{bottom:208.259000px;}
.y15f{bottom:208.283000px;}
.yf5{bottom:208.858000px;}
.y58{bottom:210.259000px;}
.y14f{bottom:212.259000px;}
.y37{bottom:214.259000px;}
.y113{bottom:215.259000px;}
.y138{bottom:215.631000px;}
.yb0{bottom:219.259000px;}
.y92{bottom:220.259000px;}
.y15e{bottom:220.283000px;}
.yf4{bottom:220.858000px;}
.y57{bottom:222.259000px;}
.y14e{bottom:224.259000px;}
.y36{bottom:226.259000px;}
.y7a{bottom:226.858000px;}
.y112{bottom:227.259000px;}
.y11{bottom:230.283000px;}
.yaf{bottom:231.259000px;}
.y91{bottom:232.259000px;}
.y15d{bottom:232.283000px;}
.yf3{bottom:232.858000px;}
.y137{bottom:233.631000px;}
.y129{bottom:234.259000px;}
.y14d{bottom:236.259000px;}
.y35{bottom:238.259000px;}
.y79{bottom:238.858000px;}
.y111{bottom:239.259000px;}
.y56{bottom:241.259000px;}
.yae{bottom:243.259000px;}
.y90{bottom:244.259000px;}
.y15c{bottom:244.283000px;}
.yf2{bottom:244.858000px;}
.y128{bottom:246.259000px;}
.y14c{bottom:248.259000px;}
.y34{bottom:250.259000px;}
.y78{bottom:250.858000px;}
.y110{bottom:251.259000px;}
.y55{bottom:253.259000px;}
.yd4{bottom:256.259000px;}
.y15b{bottom:256.283000px;}
.yf1{bottom:256.858000px;}
.y136{bottom:257.631000px;}
.y127{bottom:258.259000px;}
.y14b{bottom:260.259000px;}
.y8f{bottom:261.259000px;}
.y33{bottom:262.259000px;}
.y77{bottom:262.858000px;}
.y10f{bottom:263.259000px;}
.y54{bottom:265.259000px;}
.yc7{bottom:268.259000px;}
.y10{bottom:268.283000px;}
.yf0{bottom:268.858000px;}
.y135{bottom:269.631000px;}
.y126{bottom:270.259000px;}
.y8e{bottom:273.259000px;}
.y32{bottom:274.259000px;}
.y76{bottom:274.858000px;}
.yc6{bottom:280.259000px;}
.yf{bottom:280.283000px;}
.y10e{bottom:281.259000px;}
.y134{bottom:281.631000px;}
.y125{bottom:282.259000px;}
.yad{bottom:283.259000px;}
.y53{bottom:284.259000px;}
.y8d{bottom:285.259000px;}
.y31{bottom:286.259000px;}
.y15a{bottom:286.283000px;}
.yef{bottom:286.858000px;}
.yc5{bottom:292.259000px;}
.ye{bottom:292.283000px;}
.y10d{bottom:293.259000px;}
.y133{bottom:293.631000px;}
.y124{bottom:294.259000px;}
.yac{bottom:295.259000px;}
.y52{bottom:296.259000px;}
.y8c{bottom:297.259000px;}
.y30{bottom:298.259000px;}
.y159{bottom:298.283000px;}
.y75{bottom:298.858000px;}
.yc4{bottom:304.259000px;}
.yd{bottom:304.283000px;}
.y10c{bottom:305.259000px;}
.y132{bottom:305.631000px;}
.y123{bottom:306.259000px;}
.yab{bottom:307.259000px;}
.y51{bottom:308.259000px;}
.y8b{bottom:309.259000px;}
.y2f{bottom:310.259000px;}
.y158{bottom:310.283000px;}
.y74{bottom:310.858000px;}
.yc3{bottom:316.259000px;}
.yc{bottom:316.283000px;}
.y131{bottom:317.631000px;}
.y122{bottom:318.259000px;}
.ya9{bottom:319.259000px;}
.y50{bottom:320.259000px;}
.y8a{bottom:321.259000px;}
.y2e{bottom:322.259000px;}
.y157{bottom:322.283000px;}
.y73{bottom:322.858000px;}
.y10b{bottom:323.259000px;}
.yaa{bottom:323.659000px;}
.yd3{bottom:328.259000px;}
.yb{bottom:328.283000px;}
.yee{bottom:328.858000px;}
.y130{bottom:329.631000px;}
.y121{bottom:330.259000px;}
.ya8{bottom:331.259000px;}
.y4f{bottom:332.259000px;}
.y89{bottom:333.259000px;}
.y2d{bottom:334.259000px;}
.y72{bottom:334.858000px;}
.y10a{bottom:335.259000px;}
.yd2{bottom:340.259000px;}
.ya{bottom:340.283000px;}
.yed{bottom:340.858000px;}
.y12f{bottom:341.631000px;}
.y120{bottom:342.259000px;}
.ya7{bottom:343.259000px;}
.y4e{bottom:344.259000px;}
.y2c{bottom:346.259000px;}
.y71{bottom:346.858000px;}
.y109{bottom:347.259000px;}
.y88{bottom:351.259000px;}
.yd1{bottom:352.259000px;}
.y9{bottom:352.283000px;}
.yec{bottom:352.858000px;}
.y12e{bottom:353.631000px;}
.y11f{bottom:354.259000px;}
.ya6{bottom:355.259000px;}
.y2b{bottom:358.259000px;}
.y70{bottom:358.858000px;}
.y108{bottom:359.259000px;}
.y4d{bottom:363.259000px;}
.yd0{bottom:364.259000px;}
.y8{bottom:364.283000px;}
.yeb{bottom:364.858000px;}
.y12d{bottom:365.631000px;}
.y11e{bottom:366.259000px;}
.ya5{bottom:367.259000px;}
.y2a{bottom:370.259000px;}
.y6f{bottom:370.858000px;}
.y107{bottom:371.259000px;}
.y4c{bottom:375.259000px;}
.ycf{bottom:376.259000px;}
.y7{bottom:376.283000px;}
.yea{bottom:376.858000px;}
.y87{bottom:377.259000px;}
.y12c{bottom:377.631000px;}
.y11d{bottom:378.259000px;}
.ya4{bottom:379.259000px;}
.y29{bottom:382.259000px;}
.y6e{bottom:382.858000px;}
.y106{bottom:383.259000px;}
.y4b{bottom:387.259000px;}
.yc2{bottom:388.259000px;}
.y6{bottom:388.283000px;}
.ye9{bottom:388.858000px;}
.y86{bottom:389.259000px;}
.y11c{bottom:390.259000px;}
.ya3{bottom:391.259000px;}
.y28{bottom:394.259000px;}
.y6d{bottom:394.858000px;}
.y4a{bottom:399.259000px;}
.yc1{bottom:400.259000px;}
.ye8{bottom:400.858000px;}
.y85{bottom:401.259000px;}
.y11b{bottom:402.259000px;}
.y27{bottom:406.259000px;}
.y12a{bottom:406.262000px;}
.y6c{bottom:406.858000px;}
.y14a{bottom:407.992000px;}
.ya2{bottom:409.259000px;}
.yc0{bottom:412.259000px;}
.ye7{bottom:412.858000px;}
.y105{bottom:413.259000px;}
.y11a{bottom:414.259000px;}
.y49{bottom:417.259000px;}
.y149{bottom:417.988000px;}
.y26{bottom:418.259000px;}
.y6b{bottom:418.858000px;}
.ya1{bottom:421.259000px;}
.ybf{bottom:424.259000px;}
.y1b{bottom:424.273000px;}
.ye6{bottom:424.858000px;}
.y104{bottom:425.259000px;}
.y148{bottom:427.984000px;}
.y25{bottom:430.259000px;}
.y6a{bottom:430.858000px;}
.y119{bottom:432.259000px;}
.ybe{bottom:436.259000px;}
.ye5{bottom:436.858000px;}
.y147{bottom:437.980000px;}
.ya0{bottom:439.259000px;}
.y24{bottom:442.259000px;}
.y69{bottom:442.858000px;}
.y103{bottom:443.259000px;}
.y48{bottom:448.259000px;}
.ye4{bottom:448.858000px;}
.y5{bottom:451.299000px;}
.y23{bottom:454.259000px;}
.y68{bottom:454.858000px;}
.y12b{bottom:455.000000px;}
.y47{bottom:460.259000px;}
.y146{bottom:460.682000px;}
.ye3{bottom:460.858000px;}
.y22{bottom:466.259000px;}
.y67{bottom:466.858000px;}
.y46{bottom:472.259000px;}
.ye2{bottom:472.858000px;}
.y21{bottom:478.259000px;}
.y66{bottom:478.858000px;}
.y45{bottom:484.259000px;}
.ye1{bottom:484.858000px;}
.y20{bottom:490.259000px;}
.y65{bottom:490.858000px;}
.y44{bottom:496.259000px;}
.ye0{bottom:496.858000px;}
.y64{bottom:502.858000px;}
.y1f{bottom:508.259000px;}
.y63{bottom:514.858000px;}
.y1e{bottom:520.259000px;}
.y145{bottom:529.052000px;}
.y1d{bottom:532.259000px;}
.y62{bottom:532.858000px;}
.y0{bottom:547.500000px;}
.y1c{bottom:555.682000px;}
.y1{bottom:555.691000px;}
.he{height:15.985920px;}
.h8{height:17.000000px;}
.h1{height:17.500000px;}
.hd{height:19.982400px;}
.h2{height:23.072000px;}
.h3{height:23.168000px;}
.h11{height:23.584000px;}
.ha{height:24.514000px;}
.hb{height:24.616000px;}
.h7{height:25.956000px;}
.h5{height:28.960000px;}
.h6{height:36.050000px;}
.h4{height:37.492000px;}
.h10{height:109.500000px;}
.hc{height:459.000000px;}
.hf{height:500.500000px;}
.h9{height:512.000000px;}
.h0{height:612.283000px;}
.w1{width:1.000000px;}
.w3{width:35.000000px;}
.w5{width:260.500000px;}
.w4{width:294.500000px;}
.w2{width:295.000000px;}
.w0{width:396.850000px;}
.x5{left:42.000000px;}
.x6{left:48.824300px;}
.x10{left:51.565900px;}
.x7{left:52.804900px;}
.x8{left:57.805000px;}
.x2{left:60.000000px;}
.xb{left:61.470000px;}
.x3{left:63.954900px;}
.x11{left:65.425000px;}
.x4{left:68.955000px;}
.x12{left:70.425000px;}
.xd{left:72.615000px;}
.xa{left:76.574900px;}
.x13{left:136.336000px;}
.xc{left:162.330000px;}
.xe{left:258.910000px;}
.xf{left:262.374000px;}
.x9{left:300.561000px;}
.x0{left:353.500000px;}
.x1{left:357.504000px;}
@media print{
.v0{vertical-align:0.000000pt;}
.ls6{letter-spacing:-3.466667pt;}
.ls10{letter-spacing:-2.560000pt;}
.lsa{letter-spacing:-0.906667pt;}
.lsd{letter-spacing:-0.800000pt;}
.ls2{letter-spacing:-0.693333pt;}
.lsc{letter-spacing:-0.640000pt;}
.ls8{letter-spacing:-0.533333pt;}
.ls3{letter-spacing:-0.426667pt;}
.lsb{letter-spacing:-0.373333pt;}
.ls7{letter-spacing:-0.320000pt;}
.ls1{letter-spacing:-0.266667pt;}
.ls0{letter-spacing:0.000000pt;}
.ls5{letter-spacing:0.266667pt;}
.ls9{letter-spacing:0.272000pt;}
.ls4{letter-spacing:0.426667pt;}
.lse{letter-spacing:0.533333pt;}
.lsf{letter-spacing:1.333333pt;}
.wsbd{word-spacing:-13.800000pt;}
.wsc2{word-spacing:-12.266667pt;}
.ws53{word-spacing:-4.640000pt;}
.wsef{word-spacing:-3.893333pt;}
.wsf0{word-spacing:-3.253333pt;}
.wsaf{word-spacing:-2.986667pt;}
.wsd0{word-spacing:-2.880000pt;}
.ws44{word-spacing:-2.826667pt;}
.wse1{word-spacing:-2.560000pt;}
.wsd2{word-spacing:-2.506667pt;}
.ws4b{word-spacing:-2.453333pt;}
.ws7e{word-spacing:-2.400000pt;}
.wsa{word-spacing:-2.346667pt;}
.wsdb{word-spacing:-2.293333pt;}
.ws16{word-spacing:-2.186667pt;}
.ws3b{word-spacing:-2.133333pt;}
.wsb9{word-spacing:-2.080000pt;}
.ws5c{word-spacing:-2.026667pt;}
.ws4d{word-spacing:-1.973333pt;}
.wsc8{word-spacing:-1.920000pt;}
.ws4{word-spacing:-1.866667pt;}
.wsdc{word-spacing:-1.760000pt;}
.ws1a{word-spacing:-1.706667pt;}
.ws26{word-spacing:-1.653333pt;}
.ws71{word-spacing:-1.600000pt;}
.ws88{word-spacing:-1.546667pt;}
.ws1{word-spacing:-1.493333pt;}
.ws9e{word-spacing:-1.440000pt;}
.ws20{word-spacing:-1.386667pt;}
.ws19{word-spacing:-1.333333pt;}
.ws72{word-spacing:-1.280000pt;}
.wsa3{word-spacing:-1.226667pt;}
.ws9{word-spacing:-1.173333pt;}
.ws73{word-spacing:-1.120000pt;}
.ws11{word-spacing:-1.066667pt;}
.ws5b{word-spacing:-1.013333pt;}
.ws23{word-spacing:-0.960000pt;}
.wsa2{word-spacing:-0.906667pt;}
.wse8{word-spacing:-0.853333pt;}
.ws1e{word-spacing:-0.800000pt;}
.ws2b{word-spacing:-0.693333pt;}
.ws91{word-spacing:-0.640000pt;}
.wse{word-spacing:-0.586667pt;}
.ws61{word-spacing:-0.533333pt;}
.wsac{word-spacing:-0.480000pt;}
.ws24{word-spacing:-0.426667pt;}
.ws4c{word-spacing:-0.320000pt;}
.ws48{word-spacing:-0.272000pt;}
.ws5{word-spacing:-0.266667pt;}
.ws82{word-spacing:-0.213333pt;}
.ws70{word-spacing:-0.160000pt;}
.ws4a{word-spacing:-0.106667pt;}
.ws3{word-spacing:-0.053333pt;}
.ws0{word-spacing:0.000000pt;}
.ws83{word-spacing:0.053333pt;}
.ws8b{word-spacing:0.106667pt;}
.wsc0{word-spacing:0.160000pt;}
.ws7c{word-spacing:0.213333pt;}
.wsb8{word-spacing:0.266667pt;}
.ws36{word-spacing:0.320000pt;}
.ws6c{word-spacing:0.373333pt;}
.ws2e{word-spacing:0.426667pt;}
.ws2a{word-spacing:0.480000pt;}
.ws81{word-spacing:0.586667pt;}
.ws8e{word-spacing:0.640000pt;}
.ws29{word-spacing:0.693333pt;}
.wsd5{word-spacing:0.746667pt;}
.ws42{word-spacing:0.800000pt;}
.ws3f{word-spacing:0.853333pt;}
.wsf{word-spacing:0.906667pt;}
.ws2f{word-spacing:0.960000pt;}
.wsf8{word-spacing:1.013333pt;}
.wscd{word-spacing:1.066667pt;}
.wsd{word-spacing:1.120000pt;}
.ws40{word-spacing:1.173333pt;}
.wsd8{word-spacing:1.226667pt;}
.ws63{word-spacing:1.280000pt;}
.ws57{word-spacing:1.333333pt;}
.wsc4{word-spacing:1.386667pt;}
.ws18{word-spacing:1.493333pt;}
.ws2{word-spacing:1.546667pt;}
.ws8a{word-spacing:1.600000pt;}
.ws80{word-spacing:1.653333pt;}
.ws12{word-spacing:1.706667pt;}
.ws92{word-spacing:1.760000pt;}
.wseb{word-spacing:1.813333pt;}
.ws7a{word-spacing:1.866667pt;}
.ws6d{word-spacing:1.973333pt;}
.wsed{word-spacing:2.026667pt;}
.ws9c{word-spacing:2.080000pt;}
.ws79{word-spacing:2.133333pt;}
.ws84{word-spacing:2.186667pt;}
.ws2d{word-spacing:2.240000pt;}
.wsa0{word-spacing:2.346667pt;}
.wse6{word-spacing:2.400000pt;}
.ws31{word-spacing:2.453333pt;}
.ws7{word-spacing:2.506667pt;}
.ws9f{word-spacing:2.560000pt;}
.ws45{word-spacing:2.613333pt;}
.ws74{word-spacing:2.666667pt;}
.ws90{word-spacing:2.720000pt;}
.wsc5{word-spacing:2.773333pt;}
.ws28{word-spacing:2.826667pt;}
.wsd7{word-spacing:2.880000pt;}
.wsde{word-spacing:2.933333pt;}
.wsb5{word-spacing:2.986667pt;}
.ws22{word-spacing:3.040000pt;}
.ws7f{word-spacing:3.093333pt;}
.ws21{word-spacing:3.146667pt;}
.ws75{word-spacing:3.200000pt;}
.ws6{word-spacing:3.253333pt;}
.ws6b{word-spacing:3.306667pt;}
.ws94{word-spacing:3.360000pt;}
.ws35{word-spacing:3.466667pt;}
.ws17{word-spacing:3.573333pt;}
.ws43{word-spacing:3.626667pt;}
.ws8d{word-spacing:3.680000pt;}
.ws69{word-spacing:3.786667pt;}
.wse5{word-spacing:3.893333pt;}
.wse7{word-spacing:3.946667pt;}
.wsf6{word-spacing:4.000000pt;}
.ws4e{word-spacing:4.106667pt;}
.ws93{word-spacing:4.160000pt;}
.ws98{word-spacing:4.213333pt;}
.wsd9{word-spacing:4.373333pt;}
.ws8{word-spacing:4.533333pt;}
.ws51{word-spacing:4.586667pt;}
.ws99{word-spacing:4.640000pt;}
.ws95{word-spacing:4.693333pt;}
.ws3d{word-spacing:4.746667pt;}
.ws1d{word-spacing:4.853333pt;}
.ws30{word-spacing:4.906667pt;}
.wsc7{word-spacing:4.960000pt;}
.wscc{word-spacing:5.013333pt;}
.ws15{word-spacing:5.066667pt;}
.ws85{word-spacing:5.120000pt;}
.ws10{word-spacing:5.173333pt;}
.ws7b{word-spacing:5.226667pt;}
.ws52{word-spacing:5.280000pt;}
.ws56{word-spacing:5.440000pt;}
.ws5d{word-spacing:5.493333pt;}
.ws87{word-spacing:5.600000pt;}
.wse0{word-spacing:5.653333pt;}
.wsab{word-spacing:5.760000pt;}
.wsee{word-spacing:5.813333pt;}
.wsad{word-spacing:5.920000pt;}
.wsb{word-spacing:5.973333pt;}
.wsb0{word-spacing:6.026667pt;}
.ws34{word-spacing:6.080000pt;}
.wsb1{word-spacing:6.133333pt;}
.ws6f{word-spacing:6.186667pt;}
.ws7d{word-spacing:6.240000pt;}
.wsf2{word-spacing:6.293333pt;}
.ws27{word-spacing:6.400000pt;}
.wsf4{word-spacing:6.453333pt;}
.ws9d{word-spacing:6.560000pt;}
.ws25{word-spacing:6.613333pt;}
.wsf7{word-spacing:6.666667pt;}
.wsc{word-spacing:6.720000pt;}
.wsec{word-spacing:6.826667pt;}
.ws5a{word-spacing:6.880000pt;}
.ws50{word-spacing:6.986667pt;}
.ws13{word-spacing:7.040000pt;}
.ws96{word-spacing:7.093333pt;}
.wse2{word-spacing:7.146667pt;}
.wsbe{word-spacing:7.200000pt;}
.wsbb{word-spacing:7.253333pt;}
.wsf1{word-spacing:7.306667pt;}
.ws1c{word-spacing:7.360000pt;}
.ws65{word-spacing:7.413333pt;}
.ws78{word-spacing:7.466667pt;}
.ws9b{word-spacing:7.520000pt;}
.wsce{word-spacing:7.573333pt;}
.ws49{word-spacing:7.786667pt;}
.wsb6{word-spacing:7.893333pt;}
.wsdf{word-spacing:7.946667pt;}
.wsc6{word-spacing:8.000000pt;}
.wsd6{word-spacing:8.106667pt;}
.ws77{word-spacing:8.213333pt;}
.ws86{word-spacing:8.266667pt;}
.ws89{word-spacing:8.480000pt;}
.wsf5{word-spacing:8.533333pt;}
.wscf{word-spacing:8.586667pt;}
.wsb2{word-spacing:8.640000pt;}
.ws4f{word-spacing:8.800000pt;}
.wsb7{word-spacing:8.906667pt;}
.wsc9{word-spacing:8.960000pt;}
.wsca{word-spacing:9.013333pt;}
.wsb4{word-spacing:9.120000pt;}
.ws62{word-spacing:9.173333pt;}
.ws6a{word-spacing:9.226667pt;}
.wsd4{word-spacing:9.333333pt;}
.wsa7{word-spacing:9.386667pt;}
.ws32{word-spacing:9.546667pt;}
.ws3c{word-spacing:9.600000pt;}
.ws14{word-spacing:9.653333pt;}
.ws60{word-spacing:9.706667pt;}
.ws41{word-spacing:9.760000pt;}
.wsdd{word-spacing:10.133333pt;}
.wsa1{word-spacing:10.346667pt;}
.wsba{word-spacing:10.506667pt;}
.ws9a{word-spacing:10.826667pt;}
.wsa6{word-spacing:10.880000pt;}
.ws59{word-spacing:10.986667pt;}
.wsda{word-spacing:11.040000pt;}
.wsae{word-spacing:11.093333pt;}
.ws3a{word-spacing:11.253333pt;}
.wsa4{word-spacing:11.360000pt;}
.wse4{word-spacing:11.520000pt;}
.ws58{word-spacing:11.573333pt;}
.ws37{word-spacing:11.733333pt;}
.ws67{word-spacing:11.786667pt;}
.wsa5{word-spacing:11.840000pt;}
.ws1f{word-spacing:11.946667pt;}
.ws5f{word-spacing:12.000000pt;}
.wsf3{word-spacing:12.106667pt;}
.wscb{word-spacing:12.320000pt;}
.ws55{word-spacing:12.426667pt;}
.wse3{word-spacing:12.586667pt;}
.ws8f{word-spacing:12.853333pt;}
.ws68{word-spacing:12.906667pt;}
.ws1b{word-spacing:12.960000pt;}
.ws5e{word-spacing:13.706667pt;}
.wsea{word-spacing:13.760000pt;}
.ws3e{word-spacing:13.920000pt;}
.wsbf{word-spacing:14.293333pt;}
.ws97{word-spacing:14.933333pt;}
.ws66{word-spacing:15.306667pt;}
.wsa9{word-spacing:15.413333pt;}
.ws2c{word-spacing:15.573333pt;}
.wsc3{word-spacing:15.626667pt;}
.ws76{word-spacing:15.840000pt;}
.ws8c{word-spacing:15.893333pt;}
.wsc1{word-spacing:16.000000pt;}
.wsb3{word-spacing:16.053333pt;}
.ws38{word-spacing:16.373333pt;}
.ws64{word-spacing:16.480000pt;}
.ws6e{word-spacing:16.640000pt;}
.wsbc{word-spacing:18.240000pt;}
.wsa8{word-spacing:18.346667pt;}
.wse9{word-spacing:18.826667pt;}
.wsaa{word-spacing:18.986667pt;}
.ws33{word-spacing:19.146667pt;}
.ws54{word-spacing:19.306667pt;}
.wsd1{word-spacing:21.440000pt;}
.wsd3{word-spacing:21.760000pt;}
.ws39{word-spacing:22.613333pt;}
.ws47{word-spacing:23.786667pt;}
.ws46{word-spacing:27.733333pt;}
._7{margin-left:-746.196267pt;}
._f{margin-left:-36.320000pt;}
._4{margin-left:-28.506667pt;}
._26{margin-left:-20.770667pt;}
._a{margin-left:-17.600000pt;}
._3{margin-left:-13.800000pt;}
._10{margin-left:-11.840000pt;}
._e{margin-left:-9.486933pt;}
._1f{margin-left:-7.096000pt;}
._14{margin-left:-4.669333pt;}
._2{margin-left:-3.127467pt;}
._0{margin-left:-1.408000pt;}
._1{width:1.395200pt;}
._d{width:3.234133pt;}
._8{width:5.173333pt;}
._6{width:6.720000pt;}
._1d{width:8.218667pt;}
._9{width:9.898667pt;}
._1c{width:11.319467pt;}
._11{width:13.463467pt;}
._c{width:15.884800pt;}
._1e{width:17.363200pt;}
._5{width:26.667200pt;}
._b{width:50.000000pt;}
._23{width:129.336000pt;}
._24{width:132.690667pt;}
._25{width:147.469333pt;}
._19{width:217.645333pt;}
._22{width:232.514667pt;}
._21{width:267.690667pt;}
._1a{width:269.461333pt;}
._20{width:363.178667pt;}
._17{width:399.296000pt;}
._16{width:417.610667pt;}
._18{width:437.522133pt;}
._15{width:479.581333pt;}
._1b{width:485.837333pt;}
._12{width:491.008000pt;}
._27{width:544.928533pt;}
._13{width:567.168000pt;}
.fs5{font-size:26.666667pt;}
.fs8{font-size:29.440000pt;}
.fs7{font-size:36.800000pt;}
.fs0{font-size:42.666667pt;}
.fs6{font-size:45.333333pt;}
.fs4{font-size:48.000000pt;}
.fs2{font-size:53.333333pt;}
.fs3{font-size:66.666667pt;}
.fs1{font-size:69.333333pt;}
.y4{bottom:49.660800pt;}
.y3{bottom:62.994133pt;}
.y61{bottom:70.000000pt;}
.y102{bottom:70.478000pt;}
.y9e{bottom:71.012000pt;}
.y2{bottom:76.327467pt;}
.y84{bottom:78.482667pt;}
.y43{bottom:85.678133pt;}
.ybd{bottom:85.678267pt;}
.yce{bottom:85.678667pt;}
.yda{bottom:86.000000pt;}
.y101{bottom:86.478000pt;}
.yd9{bottom:87.011467pt;}
.y9d{bottom:87.012000pt;}
.y144{bottom:87.507467pt;}
.ydf{bottom:94.345467pt;}
.y83{bottom:97.148667pt;}
.ybc{bottom:99.011600pt;}
.y42{bottom:101.678133pt;}
.ycd{bottom:101.678667pt;}
.y100{bottom:102.478000pt;}
.yd8{bottom:103.011467pt;}
.y9c{bottom:103.012000pt;}
.y143{bottom:103.507467pt;}
.ybb{bottom:112.344933pt;}
.yde{bottom:113.011467pt;}
.y82{bottom:115.814667pt;}
.y41{bottom:117.678133pt;}
.ycc{bottom:117.678667pt;}
.yff{bottom:118.477333pt;}
.yd7{bottom:119.011467pt;}
.y9b{bottom:119.012000pt;}
.y142{bottom:119.507467pt;}
.yba{bottom:125.678267pt;}
.yb9{bottom:130.371600pt;}
.y1a{bottom:131.044000pt;}
.ycb{bottom:133.678667pt;}
.yfe{bottom:134.477333pt;}
.y81{bottom:134.480667pt;}
.y9a{bottom:135.012000pt;}
.y141{bottom:135.508000pt;}
.y9f{bottom:140.666667pt;}
.ydd{bottom:141.674667pt;}
.y40{bottom:141.678667pt;}
.y60{bottom:143.012000pt;}
.y19{bottom:147.044000pt;}
.yca{bottom:149.678667pt;}
.yfd{bottom:150.477333pt;}
.y99{bottom:151.012000pt;}
.y140{bottom:151.508000pt;}
.y80{bottom:153.146667pt;}
.yb8{bottom:156.345333pt;}
.y3f{bottom:157.678667pt;}
.y5f{bottom:159.012000pt;}
.y18{bottom:163.044000pt;}
.yc9{bottom:165.678667pt;}
.yfc{bottom:166.477333pt;}
.y98{bottom:167.012000pt;}
.y13f{bottom:167.508000pt;}
.y156{bottom:171.012000pt;}
.y7f{bottom:171.812667pt;}
.yb7{bottom:172.345333pt;}
.y3e{bottom:173.678667pt;}
.ydc{bottom:174.869333pt;}
.y5e{bottom:175.012000pt;}
.y17{bottom:179.044000pt;}
.yc8{bottom:181.678667pt;}
.yfb{bottom:182.477333pt;}
.y97{bottom:183.012000pt;}
.y13e{bottom:183.508000pt;}
.y155{bottom:187.012000pt;}
.ydb{bottom:188.197333pt;}
.yb6{bottom:188.345333pt;}
.y3d{bottom:189.678667pt;}
.y7e{bottom:190.478667pt;}
.y5d{bottom:191.012000pt;}
.y16{bottom:195.044000pt;}
.yd6{bottom:197.678667pt;}
.yfa{bottom:198.477333pt;}
.y118{bottom:199.012000pt;}
.y154{bottom:203.012000pt;}
.yb5{bottom:204.345333pt;}
.y3c{bottom:205.678667pt;}
.y13d{bottom:207.508000pt;}
.y15{bottom:211.044000pt;}
.yd5{bottom:213.678667pt;}
.yf9{bottom:214.477333pt;}
.y117{bottom:215.012000pt;}
.y5c{bottom:216.345333pt;}
.y153{bottom:219.012000pt;}
.y7d{bottom:219.141333pt;}
.y3b{bottom:221.678667pt;}
.y13c{bottom:223.508000pt;}
.yb4{bottom:228.345333pt;}
.y96{bottom:229.678667pt;}
.yf8{bottom:230.477333pt;}
.y116{bottom:231.012000pt;}
.y5b{bottom:232.345333pt;}
.y152{bottom:235.012000pt;}
.y14{bottom:235.044000pt;}
.y3a{bottom:237.678667pt;}
.y13b{bottom:239.508000pt;}
.yb3{bottom:244.345333pt;}
.y95{bottom:245.678667pt;}
.y161{bottom:245.710667pt;}
.yf7{bottom:246.477333pt;}
.y5a{bottom:248.345333pt;}
.y151{bottom:251.012000pt;}
.y13{bottom:251.044000pt;}
.y7c{bottom:252.336000pt;}
.y39{bottom:253.678667pt;}
.y115{bottom:255.012000pt;}
.y13a{bottom:255.508000pt;}
.yb2{bottom:260.345333pt;}
.y94{bottom:261.678667pt;}
.y160{bottom:261.710667pt;}
.yf6{bottom:262.477333pt;}
.y59{bottom:264.345333pt;}
.y7b{bottom:265.664000pt;}
.y150{bottom:267.012000pt;}
.y38{bottom:269.678667pt;}
.y114{bottom:271.012000pt;}
.y139{bottom:271.508000pt;}
.y12{bottom:275.044000pt;}
.yb1{bottom:276.345333pt;}
.y93{bottom:277.678667pt;}
.y15f{bottom:277.710667pt;}
.yf5{bottom:278.477333pt;}
.y58{bottom:280.345333pt;}
.y14f{bottom:283.012000pt;}
.y37{bottom:285.678667pt;}
.y113{bottom:287.012000pt;}
.y138{bottom:287.508000pt;}
.yb0{bottom:292.345333pt;}
.y92{bottom:293.678667pt;}
.y15e{bottom:293.710667pt;}
.yf4{bottom:294.477333pt;}
.y57{bottom:296.345333pt;}
.y14e{bottom:299.012000pt;}
.y36{bottom:301.678667pt;}
.y7a{bottom:302.477333pt;}
.y112{bottom:303.012000pt;}
.y11{bottom:307.044000pt;}
.yaf{bottom:308.345333pt;}
.y91{bottom:309.678667pt;}
.y15d{bottom:309.710667pt;}
.yf3{bottom:310.477333pt;}
.y137{bottom:311.508000pt;}
.y129{bottom:312.345333pt;}
.y14d{bottom:315.012000pt;}
.y35{bottom:317.678667pt;}
.y79{bottom:318.477333pt;}
.y111{bottom:319.012000pt;}
.y56{bottom:321.678667pt;}
.yae{bottom:324.345333pt;}
.y90{bottom:325.678667pt;}
.y15c{bottom:325.710667pt;}
.yf2{bottom:326.477333pt;}
.y128{bottom:328.345333pt;}
.y14c{bottom:331.012000pt;}
.y34{bottom:333.678667pt;}
.y78{bottom:334.477333pt;}
.y110{bottom:335.012000pt;}
.y55{bottom:337.678667pt;}
.yd4{bottom:341.678667pt;}
.y15b{bottom:341.710667pt;}
.yf1{bottom:342.477333pt;}
.y136{bottom:343.508000pt;}
.y127{bottom:344.345333pt;}
.y14b{bottom:347.012000pt;}
.y8f{bottom:348.345333pt;}
.y33{bottom:349.678667pt;}
.y77{bottom:350.477333pt;}
.y10f{bottom:351.012000pt;}
.y54{bottom:353.678667pt;}
.yc7{bottom:357.678667pt;}
.y10{bottom:357.710667pt;}
.yf0{bottom:358.477333pt;}
.y135{bottom:359.508000pt;}
.y126{bottom:360.345333pt;}
.y8e{bottom:364.345333pt;}
.y32{bottom:365.678667pt;}
.y76{bottom:366.477333pt;}
.yc6{bottom:373.678667pt;}
.yf{bottom:373.710667pt;}
.y10e{bottom:375.012000pt;}
.y134{bottom:375.508000pt;}
.y125{bottom:376.345333pt;}
.yad{bottom:377.678667pt;}
.y53{bottom:379.012000pt;}
.y8d{bottom:380.345333pt;}
.y31{bottom:381.678667pt;}
.y15a{bottom:381.710667pt;}
.yef{bottom:382.477333pt;}
.yc5{bottom:389.678667pt;}
.ye{bottom:389.710667pt;}
.y10d{bottom:391.012000pt;}
.y133{bottom:391.508000pt;}
.y124{bottom:392.345333pt;}
.yac{bottom:393.678667pt;}
.y52{bottom:395.012000pt;}
.y8c{bottom:396.345333pt;}
.y30{bottom:397.678667pt;}
.y159{bottom:397.710667pt;}
.y75{bottom:398.477333pt;}
.yc4{bottom:405.678667pt;}
.yd{bottom:405.710667pt;}
.y10c{bottom:407.012000pt;}
.y132{bottom:407.508000pt;}
.y123{bottom:408.345333pt;}
.yab{bottom:409.678667pt;}
.y51{bottom:411.012000pt;}
.y8b{bottom:412.345333pt;}
.y2f{bottom:413.678667pt;}
.y158{bottom:413.710667pt;}
.y74{bottom:414.477333pt;}
.yc3{bottom:421.678667pt;}
.yc{bottom:421.710667pt;}
.y131{bottom:423.508000pt;}
.y122{bottom:424.345333pt;}
.ya9{bottom:425.678667pt;}
.y50{bottom:427.012000pt;}
.y8a{bottom:428.345333pt;}
.y2e{bottom:429.678667pt;}
.y157{bottom:429.710667pt;}
.y73{bottom:430.477333pt;}
.y10b{bottom:431.012000pt;}
.yaa{bottom:431.545333pt;}
.yd3{bottom:437.678667pt;}
.yb{bottom:437.710667pt;}
.yee{bottom:438.477333pt;}
.y130{bottom:439.508000pt;}
.y121{bottom:440.345333pt;}
.ya8{bottom:441.678667pt;}
.y4f{bottom:443.012000pt;}
.y89{bottom:444.345333pt;}
.y2d{bottom:445.678667pt;}
.y72{bottom:446.477333pt;}
.y10a{bottom:447.012000pt;}
.yd2{bottom:453.678667pt;}
.ya{bottom:453.710667pt;}
.yed{bottom:454.477333pt;}
.y12f{bottom:455.508000pt;}
.y120{bottom:456.345333pt;}
.ya7{bottom:457.678667pt;}
.y4e{bottom:459.012000pt;}
.y2c{bottom:461.678667pt;}
.y71{bottom:462.477333pt;}
.y109{bottom:463.012000pt;}
.y88{bottom:468.345333pt;}
.yd1{bottom:469.678667pt;}
.y9{bottom:469.710667pt;}
.yec{bottom:470.477333pt;}
.y12e{bottom:471.508000pt;}
.y11f{bottom:472.345333pt;}
.ya6{bottom:473.678667pt;}
.y2b{bottom:477.678667pt;}
.y70{bottom:478.477333pt;}
.y108{bottom:479.012000pt;}
.y4d{bottom:484.345333pt;}
.yd0{bottom:485.678667pt;}
.y8{bottom:485.710667pt;}
.yeb{bottom:486.477333pt;}
.y12d{bottom:487.508000pt;}
.y11e{bottom:488.345333pt;}
.ya5{bottom:489.678667pt;}
.y2a{bottom:493.678667pt;}
.y6f{bottom:494.477333pt;}
.y107{bottom:495.012000pt;}
.y4c{bottom:500.345333pt;}
.ycf{bottom:501.678667pt;}
.y7{bottom:501.710667pt;}
.yea{bottom:502.477333pt;}
.y87{bottom:503.012000pt;}
.y12c{bottom:503.508000pt;}
.y11d{bottom:504.345333pt;}
.ya4{bottom:505.678667pt;}
.y29{bottom:509.678667pt;}
.y6e{bottom:510.477333pt;}
.y106{bottom:511.012000pt;}
.y4b{bottom:516.345333pt;}
.yc2{bottom:517.678667pt;}
.y6{bottom:517.710667pt;}
.ye9{bottom:518.477333pt;}
.y86{bottom:519.012000pt;}
.y11c{bottom:520.345333pt;}
.ya3{bottom:521.678667pt;}
.y28{bottom:525.678667pt;}
.y6d{bottom:526.477333pt;}
.y4a{bottom:532.345333pt;}
.yc1{bottom:533.678667pt;}
.ye8{bottom:534.477333pt;}
.y85{bottom:535.012000pt;}
.y11b{bottom:536.345333pt;}
.y27{bottom:541.678667pt;}
.y12a{bottom:541.682667pt;}
.y6c{bottom:542.477333pt;}
.y14a{bottom:543.989333pt;}
.ya2{bottom:545.678667pt;}
.yc0{bottom:549.678667pt;}
.ye7{bottom:550.477333pt;}
.y105{bottom:551.012000pt;}
.y11a{bottom:552.345333pt;}
.y49{bottom:556.345333pt;}
.y149{bottom:557.317333pt;}
.y26{bottom:557.678667pt;}
.y6b{bottom:558.477333pt;}
.ya1{bottom:561.678667pt;}
.ybf{bottom:565.678667pt;}
.y1b{bottom:565.697333pt;}
.ye6{bottom:566.477333pt;}
.y104{bottom:567.012000pt;}
.y148{bottom:570.645333pt;}
.y25{bottom:573.678667pt;}
.y6a{bottom:574.477333pt;}
.y119{bottom:576.345333pt;}
.ybe{bottom:581.678667pt;}
.ye5{bottom:582.477333pt;}
.y147{bottom:583.973333pt;}
.ya0{bottom:585.678667pt;}
.y24{bottom:589.678667pt;}
.y69{bottom:590.477333pt;}
.y103{bottom:591.012000pt;}
.y48{bottom:597.678667pt;}
.ye4{bottom:598.477333pt;}
.y5{bottom:601.732000pt;}
.y23{bottom:605.678667pt;}
.y68{bottom:606.477333pt;}
.y12b{bottom:606.666667pt;}
.y47{bottom:613.678667pt;}
.y146{bottom:614.242667pt;}
.ye3{bottom:614.477333pt;}
.y22{bottom:621.678667pt;}
.y67{bottom:622.477333pt;}
.y46{bottom:629.678667pt;}
.ye2{bottom:630.477333pt;}
.y21{bottom:637.678667pt;}
.y66{bottom:638.477333pt;}
.y45{bottom:645.678667pt;}
.ye1{bottom:646.477333pt;}
.y20{bottom:653.678667pt;}
.y65{bottom:654.477333pt;}
.y44{bottom:661.678667pt;}
.ye0{bottom:662.477333pt;}
.y64{bottom:670.477333pt;}
.y1f{bottom:677.678667pt;}
.y63{bottom:686.477333pt;}
.y1e{bottom:693.678667pt;}
.y145{bottom:705.402667pt;}
.y1d{bottom:709.678667pt;}
.y62{bottom:710.477333pt;}
.y0{bottom:730.000000pt;}
.y1c{bottom:740.909333pt;}
.y1{bottom:740.921333pt;}
.he{height:21.314560pt;}
.h8{height:22.666667pt;}
.h1{height:23.333333pt;}
.hd{height:26.643200pt;}
.h2{height:30.762667pt;}
.h3{height:30.890667pt;}
.h11{height:31.445333pt;}
.ha{height:32.685333pt;}
.hb{height:32.821333pt;}
.h7{height:34.608000pt;}
.h5{height:38.613333pt;}
.h6{height:48.066667pt;}
.h4{height:49.989333pt;}
.h10{height:146.000000pt;}
.hc{height:612.000000pt;}
.hf{height:667.333333pt;}
.h9{height:682.666667pt;}
.h0{height:816.377333pt;}
.w1{width:1.333333pt;}
.w3{width:46.666667pt;}
.w5{width:347.333333pt;}
.w4{width:392.666667pt;}
.w2{width:393.333333pt;}
.w0{width:529.133333pt;}
.x5{left:56.000000pt;}
.x6{left:65.099067pt;}
.x10{left:68.754533pt;}
.x7{left:70.406533pt;}
.x8{left:77.073333pt;}
.x2{left:80.000000pt;}
.xb{left:81.960000pt;}
.x3{left:85.273200pt;}
.x11{left:87.233333pt;}
.x4{left:91.940000pt;}
.x12{left:93.900000pt;}
.xd{left:96.820000pt;}
.xa{left:102.099867pt;}
.x13{left:181.781333pt;}
.xc{left:216.440000pt;}
.xe{left:345.213333pt;}
.xf{left:349.832000pt;}
.x9{left:400.748000pt;}
.x0{left:471.333333pt;}
.x1{left:476.672000pt;}
}
</style>
<script>
/*
 Copyright 2012 Mozilla Foundation 
 Copyright 2013 Lu Wang <coolwanglu@gmail.com>
 Apachine License Version 2.0 
*/
(function(){function b(a,b,e,f){var c=(a.className||"").split(/\s+/g);""===c[0]&&c.shift();var d=c.indexOf(b);0>d&&e&&c.push(b);0<=d&&f&&c.splice(d,1);a.className=c.join(" ");return 0<=d}if(!("classList"in document.createElement("div"))){var e={add:function(a){b(this.element,a,!0,!1)},contains:function(a){return b(this.element,a,!1,!1)},remove:function(a){b(this.element,a,!1,!0)},toggle:function(a){b(this.element,a,!0,!0)}};Object.defineProperty(HTMLElement.prototype,"classList",{get:function(){if(this._classList)return this._classList;
var a=Object.create(e,{element:{value:this,writable:!1,enumerable:!0}});Object.defineProperty(this,"_classList",{value:a,writable:!1,enumerable:!1});return a},enumerable:!0})}})();
</script>
<script>
(function(){/*
 pdf2htmlEX.js: Core UI functions for pdf2htmlEX 
 Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> and other contributors 
 https://github.com/coolwanglu/pdf2htmlEX/blob/master/share/LICENSE 
*/
var pdf2htmlEX=window.pdf2htmlEX=window.pdf2htmlEX||{},CSS_CLASS_NAMES={page_frame:"pf",page_content_box:"pc",page_data:"pi",background_image:"bi",link:"l",input_radio:"ir",__dummy__:"no comma"},DEFAULT_CONFIG={container_id:"page-container",sidebar_id:"sidebar",outline_id:"outline",loading_indicator_cls:"loading-indicator",preload_pages:3,render_timeout:100,scale_step:0.9,key_handler:!0,hashchange_handler:!0,view_history_handler:!0,__dummy__:"no comma"},EPS=1E-6;
function invert(a){var b=a[0]*a[3]-a[1]*a[2];return[a[3]/b,-a[1]/b,-a[2]/b,a[0]/b,(a[2]*a[5]-a[3]*a[4])/b,(a[1]*a[4]-a[0]*a[5])/b]}function transform(a,b){return[a[0]*b[0]+a[2]*b[1]+a[4],a[1]*b[0]+a[3]*b[1]+a[5]]}function get_page_number(a){return parseInt(a.getAttribute("data-page-no"),16)}function disable_dragstart(a){for(var b=0,c=a.length;b<c;++b)a[b].addEventListener("dragstart",function(){return!1},!1)}
function clone_and_extend_objs(a){for(var b={},c=0,e=arguments.length;c<e;++c){var h=arguments[c],d;for(d in h)h.hasOwnProperty(d)&&(b[d]=h[d])}return b}
function Page(a){if(a){this.shown=this.loaded=!1;this.page=a;this.num=get_page_number(a);this.original_height=a.clientHeight;this.original_width=a.clientWidth;var b=a.getElementsByClassName(CSS_CLASS_NAMES.page_content_box)[0];b&&(this.content_box=b,this.original_scale=this.cur_scale=this.original_height/b.clientHeight,this.page_data=JSON.parse(a.getElementsByClassName(CSS_CLASS_NAMES.page_data)[0].getAttribute("data-data")),this.ctm=this.page_data.ctm,this.ictm=invert(this.ctm),this.loaded=!0)}}
Page.prototype={hide:function(){this.loaded&&this.shown&&(this.content_box.classList.remove("opened"),this.shown=!1)},show:function(){this.loaded&&!this.shown&&(this.content_box.classList.add("opened"),this.shown=!0)},rescale:function(a){this.cur_scale=0===a?this.original_scale:a;this.loaded&&(a=this.content_box.style,a.msTransform=a.webkitTransform=a.transform="scale("+this.cur_scale.toFixed(3)+")");a=this.page.style;a.height=this.original_height*this.cur_scale+"px";a.width=this.original_width*this.cur_scale+
"px"},view_position:function(){var a=this.page,b=a.parentNode;return[b.scrollLeft-a.offsetLeft-a.clientLeft,b.scrollTop-a.offsetTop-a.clientTop]},height:function(){return this.page.clientHeight},width:function(){return this.page.clientWidth}};function Viewer(a){this.config=clone_and_extend_objs(DEFAULT_CONFIG,0<arguments.length?a:{});this.pages_loading=[];this.init_before_loading_content();var b=this;document.addEventListener("DOMContentLoaded",function(){b.init_after_loading_content()},!1)}
Viewer.prototype={scale:1,cur_page_idx:0,first_page_idx:0,init_before_loading_content:function(){this.pre_hide_pages()},initialize_radio_button:function(){for(var a=document.getElementsByClassName(CSS_CLASS_NAMES.input_radio),b=0;b<a.length;b++)a[b].addEventListener("click",function(){this.classList.toggle("checked")})},init_after_loading_content:function(){this.sidebar=document.getElementById(this.config.sidebar_id);this.outline=document.getElementById(this.config.outline_id);this.container=document.getElementById(this.config.container_id);
this.loading_indicator=document.getElementsByClassName(this.config.loading_indicator_cls)[0];for(var a=!0,b=this.outline.childNodes,c=0,e=b.length;c<e;++c)if("ul"===b[c].nodeName.toLowerCase()){a=!1;break}a||this.sidebar.classList.add("opened");this.find_pages();if(0!=this.pages.length){disable_dragstart(document.getElementsByClassName(CSS_CLASS_NAMES.background_image));this.config.key_handler&&this.register_key_handler();var h=this;this.config.hashchange_handler&&window.addEventListener("hashchange",
function(a){h.navigate_to_dest(document.location.hash.substring(1))},!1);this.config.view_history_handler&&window.addEventListener("popstate",function(a){a.state&&h.navigate_to_dest(a.state)},!1);this.container.addEventListener("scroll",function(){h.update_page_idx();h.schedule_render(!0)},!1);[this.container,this.outline].forEach(function(a){a.addEventListener("click",h.link_handler.bind(h),!1)});this.initialize_radio_button();this.render()}},find_pages:function(){for(var a=[],b={},c=this.container.childNodes,
e=0,h=c.length;e<h;++e){var d=c[e];d.nodeType===Node.ELEMENT_NODE&&d.classList.contains(CSS_CLASS_NAMES.page_frame)&&(d=new Page(d),a.push(d),b[d.num]=a.length-1)}this.pages=a;this.page_map=b},load_page:function(a,b,c){var e=this.pages;if(!(a>=e.length||(e=e[a],e.loaded||this.pages_loading[a]))){var e=e.page,h=e.getAttribute("data-page-url");if(h){this.pages_loading[a]=!0;var d=e.getElementsByClassName(this.config.loading_indicator_cls)[0];"undefined"===typeof d&&(d=this.loading_indicator.cloneNode(!0),
d.classList.add("active"),e.appendChild(d));var f=this,g=new XMLHttpRequest;g.open("GET",h,!0);g.onload=function(){if(200===g.status||0===g.status){var b=document.createElement("div");b.innerHTML=g.responseText;for(var d=null,b=b.childNodes,e=0,h=b.length;e<h;++e){var p=b[e];if(p.nodeType===Node.ELEMENT_NODE&&p.classList.contains(CSS_CLASS_NAMES.page_frame)){d=p;break}}b=f.pages[a];f.container.replaceChild(d,b.page);b=new Page(d);f.pages[a]=b;b.hide();b.rescale(f.scale);disable_dragstart(d.getElementsByClassName(CSS_CLASS_NAMES.background_image));
f.schedule_render(!1);c&&c(b)}delete f.pages_loading[a]};g.send(null)}void 0===b&&(b=this.config.preload_pages);0<--b&&(f=this,setTimeout(function(){f.load_page(a+1,b)},0))}},pre_hide_pages:function(){var a="@media screen{."+CSS_CLASS_NAMES.page_content_box+"{display:none;}}",b=document.createElement("style");b.styleSheet?b.styleSheet.cssText=a:b.appendChild(document.createTextNode(a));document.head.appendChild(b)},render:function(){for(var a=this.container,b=a.scrollTop,c=a.clientHeight,a=b-c,b=
b+c+c,c=this.pages,e=0,h=c.length;e<h;++e){var d=c[e],f=d.page,g=f.offsetTop+f.clientTop,f=g+f.clientHeight;g<=b&&f>=a?d.loaded?d.show():this.load_page(e):d.hide()}},update_page_idx:function(){var a=this.pages,b=a.length;if(!(2>b)){for(var c=this.container,e=c.scrollTop,c=e+c.clientHeight,h=-1,d=b,f=d-h;1<f;){var g=h+Math.floor(f/2),f=a[g].page;f.offsetTop+f.clientTop+f.clientHeight>=e?d=g:h=g;f=d-h}this.first_page_idx=d;for(var g=h=this.cur_page_idx,k=0;d<b;++d){var f=a[d].page,l=f.offsetTop+f.clientTop,
f=f.clientHeight;if(l>c)break;f=(Math.min(c,l+f)-Math.max(e,l))/f;if(d===h&&Math.abs(f-1)<=EPS){g=h;break}f>k&&(k=f,g=d)}this.cur_page_idx=g}},schedule_render:function(a){if(void 0!==this.render_timer){if(!a)return;clearTimeout(this.render_timer)}var b=this;this.render_timer=setTimeout(function(){delete b.render_timer;b.render()},this.config.render_timeout)},register_key_handler:function(){var a=this;window.addEventListener("DOMMouseScroll",function(b){if(b.ctrlKey){b.preventDefault();var c=a.container,
e=c.getBoundingClientRect(),c=[b.clientX-e.left-c.clientLeft,b.clientY-e.top-c.clientTop];a.rescale(Math.pow(a.config.scale_step,b.detail),!0,c)}},!1);window.addEventListener("keydown",function(b){var c=!1,e=b.ctrlKey||b.metaKey,h=b.altKey;switch(b.keyCode){case 61:case 107:case 187:e&&(a.rescale(1/a.config.scale_step,!0),c=!0);break;case 173:case 109:case 189:e&&(a.rescale(a.config.scale_step,!0),c=!0);break;case 48:e&&(a.rescale(0,!1),c=!0);break;case 33:h?a.scroll_to(a.cur_page_idx-1):a.container.scrollTop-=
a.container.clientHeight;c=!0;break;case 34:h?a.scroll_to(a.cur_page_idx+1):a.container.scrollTop+=a.container.clientHeight;c=!0;break;case 35:a.container.scrollTop=a.container.scrollHeight;c=!0;break;case 36:a.container.scrollTop=0,c=!0}c&&b.preventDefault()},!1)},rescale:function(a,b,c){var e=this.scale;this.scale=a=0===a?1:b?e*a:a;c||(c=[0,0]);b=this.container;c[0]+=b.scrollLeft;c[1]+=b.scrollTop;for(var h=this.pages,d=h.length,f=this.first_page_idx;f<d;++f){var g=h[f].page;if(g.offsetTop+g.clientTop>=
c[1])break}g=f-1;0>g&&(g=0);var g=h[g].page,k=g.clientWidth,f=g.clientHeight,l=g.offsetLeft+g.clientLeft,m=c[0]-l;0>m?m=0:m>k&&(m=k);k=g.offsetTop+g.clientTop;c=c[1]-k;0>c?c=0:c>f&&(c=f);for(f=0;f<d;++f)h[f].rescale(a);b.scrollLeft+=m/e*a+g.offsetLeft+g.clientLeft-m-l;b.scrollTop+=c/e*a+g.offsetTop+g.clientTop-c-k;this.schedule_render(!0)},fit_width:function(){var a=this.cur_page_idx;this.rescale(this.container.clientWidth/this.pages[a].width(),!0);this.scroll_to(a)},fit_height:function(){var a=this.cur_page_idx;
this.rescale(this.container.clientHeight/this.pages[a].height(),!0);this.scroll_to(a)},get_containing_page:function(a){for(;a;){if(a.nodeType===Node.ELEMENT_NODE&&a.classList.contains(CSS_CLASS_NAMES.page_frame)){a=get_page_number(a);var b=this.page_map;return a in b?this.pages[b[a]]:null}a=a.parentNode}return null},link_handler:function(a){var b=a.target,c=b.getAttribute("data-dest-detail");if(c){if(this.config.view_history_handler)try{var e=this.get_current_view_hash();window.history.replaceState(e,
"","#"+e);window.history.pushState(c,"","#"+c)}catch(h){}this.navigate_to_dest(c,this.get_containing_page(b));a.preventDefault()}},navigate_to_dest:function(a,b){try{var c=JSON.parse(a)}catch(e){return}if(c instanceof Array){var h=c[0],d=this.page_map;if(h in d){for(var f=d[h],h=this.pages[f],d=2,g=c.length;d<g;++d){var k=c[d];if(null!==k&&"number"!==typeof k)return}for(;6>c.length;)c.push(null);var g=b||this.pages[this.cur_page_idx],d=g.view_position(),d=transform(g.ictm,[d[0],g.height()-d[1]]),
g=this.scale,l=[0,0],m=!0,k=!1,n=this.scale;switch(c[1]){case "XYZ":l=[null===c[2]?d[0]:c[2]*n,null===c[3]?d[1]:c[3]*n];g=c[4];if(null===g||0===g)g=this.scale;k=!0;break;case "Fit":case "FitB":l=[0,0];k=!0;break;case "FitH":case "FitBH":l=[0,null===c[2]?d[1]:c[2]*n];k=!0;break;case "FitV":case "FitBV":l=[null===c[2]?d[0]:c[2]*n,0];k=!0;break;case "FitR":l=[c[2]*n,c[5]*n],m=!1,k=!0}if(k){this.rescale(g,!1);var p=this,c=function(a){l=transform(a.ctm,l);m&&(l[1]=a.height()-l[1]);p.scroll_to(f,l)};h.loaded?
c(h):(this.load_page(f,void 0,c),this.scroll_to(f))}}}},scroll_to:function(a,b){var c=this.pages;if(!(0>a||a>=c.length)){c=c[a].view_position();void 0===b&&(b=[0,0]);var e=this.container;e.scrollLeft+=b[0]-c[0];e.scrollTop+=b[1]-c[1]}},get_current_view_hash:function(){var a=[],b=this.pages[this.cur_page_idx];a.push(b.num);a.push("XYZ");var c=b.view_position(),c=transform(b.ictm,[c[0],b.height()-c[1]]);a.push(c[0]/this.scale);a.push(c[1]/this.scale);a.push(this.scale);return JSON.stringify(a)}};
pdf2htmlEX.Viewer=Viewer;})();
</script>
<script>
try{
pdf2htmlEX.defaultViewer = new pdf2htmlEX.Viewer({});
}catch(e){}
</script>
<title></title>
</head>
<body>
<div id="sidebar">
<div id="outline">
</div>
</div>
<div id="page-container">
<div id="pf1" class="pf w0 h0" data-page-no="1"><div class="pc pc1 w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x1 h2 y1 ff1 fs0 fc0 sc0 ls0 ws0">19</div><div class="t m0 x2 h3 y2 ff2 fs0 fc1 sc0 ls0 ws0">An I<span class="_ _0"></span>ntroduction toPharmacovigilance<span class="ff3">, S<span class="_ _1"></span>econd Edition. PatrickW<span class="_ _2"></span>aller </span></div><div class="t m0 x2 h3 y3 ff3 fs0 fc1 sc0 ls0 ws0">andMiraHarrison-W<span class="_ _2"></span>oolr<span class="_ _1"></span>ych. </div><div class="t m0 x2 h3 y4 ff3 fs0 fc1 sc0 ls0 ws0"> 2017 John W<span class="_ _2"></span>ile<span class="_ _1"></span>y &amp; Sons Ltd. Published 2017 by John W<span class="_ _0"></span>iley &amp; S<span class="_ _1"></span>ons Ltd.</div><div class="t m0 x2 h4 y5 ff1 fs1 fc0 sc0 ls0 ws0">2</div><div class="t m0 x2 h5 y6 ff4 fs2 fc1 sc0 ls1 ws1">The two most important concepts in pharmacovig<span class="_ _1"></span>ilance are opposites<span class="_ _1"></span>: </div><div class="t m0 x2 h5 y7 ff4 fs2 fc1 sc0 ls0 ws2">harm and safety<span class="_ _2"></span>. The usual term for harm related to a medicine is an </div><div class="t m0 x2 h5 y8 ff4 fs2 fc1 sc0 ls0 ws3">adverse drug reac<span class="_ _1"></span>tion (ADR). As phar<span class="_ _1"></span>macovigilance is f<span class="_ _1"></span>undamentally </div><div class="t m0 x2 h5 y9 ff4 fs2 fc1 sc0 ls0 ws4">about preventing and managing A<span class="_ _1"></span>DRs<span class="_ _1"></span>, this concept is considered first </div><div class="t m0 x2 h5 ya ff4 fs2 fc1 sc0 ls0 ws5">through a summar<span class="_ _1"></span>y of relevant definitions<span class="_ _1"></span>, classif<span class="_ _1"></span>ication systems that </div><div class="t m0 x2 h5 yb ff4 fs2 fc1 sc0 ls0 ws6">have been propo<span class="_ _1"></span>sed, their nature and mechanisms and predisp<span class="_ _1"></span>osing </div><div class="t m0 x2 h5 yc ff4 fs2 fc1 sc0 ls0 ws7">factors<span class="_ _1"></span>. Subse<span class="_ _1"></span>quently<span class="_ _2"></span>, the conc<span class="_ _0"></span>ept of safety is define<span class="_ _1"></span>d and discu<span class="_ _1"></span>ssed, </div><div class="t m0 x2 h5 yd ff4 fs2 fc1 sc0 ls0 ws8">particul<span class="_ _1"></span>arly in the con<span class="_ _0"></span>text of balancing harms with benef<span class="_ _1"></span>its<span class="_ _1"></span>. Finally<span class="_ _2"></span>, </div><div class="t m0 x2 h5 ye ff4 fs2 fc1 sc0 ls0 ws9">we consider the issue of causation  how we go about deciding whether </div><div class="t m0 x2 h5 yf ff4 fs2 fc1 sc0 ls0 wsa">or not a patient has experienced an ADR or whether a me<span class="_ _1"></span>dicinal prod<span class="ws0">-</span></div><div class="t m0 x2 h5 y10 ff4 fs2 fc1 sc0 ls0 ws0">uct really is resp<span class="_ _1"></span>onsible for an apparent saf<span class="_ _0"></span>ety problem.</div><div class="t m0 x2 h6 y11 ff1 fs3 fc0 sc0 ls0 ws0"> <span class="_ _3"></span>Adv<span class="_ _0"></span>erse Drug Reactions</div><div class="t m0 x2 h7 y12 ff5 fs4 fc2 sc0 ls0 ws0">Definitions</div><div class="t m0 x2 h5 y13 ff4 fs2 fc1 sc0 ls0 wsb">Standard, internationally agreed definitions of side ef<span class="_ _1"></span>fect<span class="_ _1"></span>, ADR and </div><div class="t m0 x2 h5 y14 ff4 fs2 fc1 sc0 ls0 ws0">adverse event can b<span class="_ _1"></span>e paraphras<span class="_ _1"></span>ed a<span class="_ _1"></span>s follows:</div><div class="t m0 x3 h5 y15 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">A <span class="_ _6"> </span><span class="ff7 wsc">side effect<span class="ff4"> is an </span>unintended effect of a medicine<span class="ff4">. Normally<span class="_ _2"></span>, it is </span></span></span></div><div class="t m0 x4 h5 y16 ff4 fs2 fc1 sc0 ls0 wsd">undesirable but it could be benef<span class="_ _1"></span>icial (e.g. an anxioly<span class="_ _1"></span>tic effec<span class="_ _1"></span>t from </div><div class="t m0 x4 h5 y17 ff4 fs2 fc1 sc0 ls0 ws0">a betablo<span class="_ _1"></span>cker prescrib<span class="_ _1"></span>ed for hyp<span class="_ _1"></span>ertension).</div><div class="t m0 x3 h5 y18 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">An <span class="ff7 wse">adverse drug reaction (ADR<span class="_ _1"></span>)<span class="ff4"> is an </span>unintended and noxious effect</span> </span></div><div class="t m0 x4 h5 y19 ff4 fs2 fc1 sc0 ls0 wsf">that is at<span class="_ _0"></span>tributable to a medicine when it ha<span class="_ _1"></span>s be<span class="_ _1"></span>en given w<span class="_ _1"></span>ithin the </div><div class="t m0 x4 h5 y1a ff4 fs2 fc1 sc0 ls0 ws0">normal range of dose<span class="_ _1"></span>s use<span class="_ _1"></span>d in humans.</div><div class="t m0 x2 h4 y1b ff1 fs1 fc0 sc0 ls0 ws0">Basic Conc<span class="_ _0"></span>epts</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf2" class="pf w0 h0" data-page-no="2"><div class="pc pc2 w0 h0"><img class="bi x5 y0 w1 h8" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAiCAIAAAD6eJ9FAAAACXBIWXMAABYlAAAWJQFJUiTwAAAADElEQVQI12NgGEkAAADuAAGm0YQWAAAAAElFTkSuQmCC"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">20</span></div><div class="t m0 x7 h5 y1d ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">An <span class="_ _8"></span><span class="ff7 ws10">adverse e<span class="_ _1"></span>vent (AE)<span class="ff4"> is an </span>unde<span class="_ _1"></span>sir<span class="_ _0"></span>able occurrence<span class="ff4"> that occurs in </span></span></span></div><div class="t m0 x8 h5 y1e ff4 fs2 fc1 sc0 ls0 ws11">the cont<span class="_ _0"></span>ext of drug treatment but whic<span class="_ _0"></span>h <span class="ff7">may or may not</span> be causally </div><div class="t m0 x8 h5 y1f ff4 fs2 fc1 sc0 ls0 ws0">related to a medicine.</div><div class="t m0 x8 h5 y20 ff4 fs2 fc1 sc0 ls0 ws12">The differenc<span class="_ _0"></span>e betwe<span class="_ _1"></span>en an ADR and an AE is c<span class="_ _1"></span>rucial and ye<span class="_ _1"></span>t these </div><div class="t m0 x6 h5 y21 ff4 fs2 fc1 sc0 ls0 ws13">terms are widely misuse<span class="_ _1"></span>d. In practice, determining whether a drug </div><div class="t m0 x6 h5 y22 ff4 fs2 fc1 sc0 ls0 ws14">is<span class="_ _9"> </span>responsible for a par<span class="_ _1"></span>ticular AE in an indiv<span class="_ _1"></span>idual patient is often </div><div class="t m0 x6 h5 y23 ff4 fs2 fc1 sc0 ls0 ws15"> <span class="_ _a"></span>difficult and a judgement ha<span class="_ _1"></span>s to be made (for an explanation of the </div><div class="t m0 x6 h5 y24 ff4 fs2 fc1 sc0 ls0 ws11">principles on which this judgement is ba<span class="_ _1"></span>sed s<span class="_ _1"></span>ee C<span class="_ _1"></span>ausality Assessment </div><div class="t m0 x6 h5 y25 ff4 fs2 fc1 sc0 ls0 ws16">in Individual Ca<span class="_ _1"></span>ses). When the judgement is that the drug is a po<span class="_ _1"></span>ssible </div><div class="t m0 x6 h5 y26 ff4 fs2 fc1 sc0 ls0 ws17">cause, this should be calle<span class="_ _1"></span>d a <span class="ff7">suspecte<span class="_ _1"></span>d ADR</span>. Rep<span class="_ _1"></span>ort<span class="_ _1"></span>s of such suspi<span class="ws0">-</span></div><div class="t m0 x6 h5 y27 ff4 fs2 fc1 sc0 ls0 ws18">cions form the basis of sp<span class="_ _1"></span>ontaneou<span class="_ _1"></span>s ADR repor<span class="_ _1"></span>ting schemes and the </div><div class="t m0 x6 h5 y28 ff4 fs2 fc1 sc0 ls0 ws19">key p<span class="_ _1"></span>oint about such data is that they are a <span class="ff7 ws0">su<span class="_ _0"></span>bset<span class="ff4 ws19"> of all the AEs o<span class="_ _1"></span>ccur<span class="_ _0"></span><span class="ws0">-</span></span></span></div><div class="t m0 x6 h5 y29 ff4 fs2 fc1 sc0 ls0 ws1a">ring during dr<span class="_ _1"></span>ug treatment which someone (generally a health profes<span class="_ _1"></span><span class="ws0">-</span></div><div class="t m0 x6 h5 y2a ff4 fs2 fc1 sc0 ls0 ws1b">sional who has se<span class="_ _1"></span>en the patient) has identified a<span class="_ _1"></span>s possibly b<span class="_ _1"></span>eing </div><div class="t m0 x6 h5 y2b ff4 fs2 fc1 sc0 ls0 ws1c">drugrelated. It is the c<span class="_ _0"></span>linician<span class="_ _0"></span><span class="_ _2"></span>s experience and professional judge<span class="ws0">-</span></div><div class="t m0 x6 h5 y2c ff4 fs2 fc1 sc0 ls0 ws1d">ment that ena<span class="_ _0"></span>bles him or her to suspe<span class="_ _1"></span>ct a drug a<span class="_ _1"></span>s the cause but<span class="_ _1"></span>, of </div><div class="t m0 x6 h5 y2d ff4 fs2 fc1 sc0 ls0 ws0">course, that suspicion may not be correct<span class="_ _1"></span>.</div><div class="t m0 x8 h5 y2e ff4 fs2 fc1 sc0 ls0 ws1e">Proper use of the term AE should imply that a more systematic data </div><div class="t m0 x6 h5 y2f ff4 fs2 fc1 sc0 ls0 ws1f">collection process ha<span class="_ _1"></span>s be<span class="_ _1"></span>en use<span class="_ _1"></span>d so that events w<span class="_ _1"></span>ill be included, </div><div class="t m0 x6 h5 y30 ff4 fs2 fc1 sc0 ls0 ws1">regardless of whether anyone believe<span class="_ _1"></span>s they might be c<span class="_ _1"></span>aused by a dr<span class="_ _1"></span>ug<span class="_ _1"></span>. </div><div class="t m0 x6 h5 y31 ff4 fs2 fc1 sc0 ls0 ws20">In most clinical trial<span class="_ _1"></span>s it is a standard practice to document all AE<span class="_ _1"></span>s and </div><div class="t m0 x6 h5 y32 ff4 fs2 fc1 sc0 ls0 ws21">the best way of determining whether a dr<span class="_ _1"></span>ug is responsible for a par<span class="ws0">-</span></div><div class="t m0 x6 h5 y33 ff4 fs2 fc1 sc0 ls0 ws22">ticular ty<span class="_ _1"></span>pe of e<span class="_ _1"></span>vent from such data is by comparison with a control </div><div class="t m0 x6 h5 y34 ff4 fs2 fc1 sc0 ls0 ws23">group. F<span class="_ _0"></span>or example, if 10% of patien<span class="_ _0"></span>ts expose<span class="_ _1"></span>d to an active drug expe<span class="ws0">-</span></div><div class="t m0 x6 h5 y35 ff4 fs2 fc1 sc0 ls0 ws23">rienced head<span class="_ _1"></span>ache compared to 2% on place<span class="_ _0"></span>bo, then this is an estimate </div><div class="t m0 x6 h5 y36 ff4 fs2 fc1 sc0 ls0 ws10">that headache attributable to t<span class="_ _0"></span>he drug occurs in 8% (i.e. 10% minus </div><div class="t m0 x6 h5 y37 ff4 fs2 fc1 sc0 ls0 ws24">2%) of patients using it. In such tr<span class="_ _1"></span>ials it is als<span class="_ _1"></span>o common to ask investi<span class="ws0">-</span></div><div class="t m0 x6 h5 y38 ff4 fs2 fc1 sc0 ls0 ws1d">gators whether they belie<span class="_ _1"></span>ve that individual events are related to the </div><div class="t m0 x6 h5 y39 ff4 fs2 fc1 sc0 ls0 ws25">drug<span class="_ _1"></span>. This is effe<span class="_ _1"></span>ctively another way of collecting suspe<span class="_ _1"></span>cted A<span class="_ _1"></span>DRs<span class="_ _1"></span>, </div><div class="t m0 x6 h5 y3a ff4 fs2 fc1 sc0 ls0 ws3">although such data are likely t<span class="_ _0"></span>o be more complete if the patien<span class="_ _0"></span>t is in a </div><div class="t m0 x6 h5 y3b ff4 fs2 fc1 sc0 ls0 ws26">clinical trial rather than being treated in ordinar<span class="_ _1"></span>y practice. It is impor<span class="_ _2"></span><span class="ws0">-</span></div><div class="t m0 x6 h5 y3c ff4 fs2 fc1 sc0 ls0 wse">tant to realise that relying on clinical judgement is a methodologically </div><div class="t m0 x6 h5 y3d ff4 fs2 fc1 sc0 ls0 ws27">weaker approach. Providing that t<span class="_ _0"></span>he estimated 8% difference is not </div><div class="t m0 x6 h5 y3e ff4 fs2 fc1 sc0 ls0 ws28">base<span class="_ _1"></span>d on ver<span class="_ _1"></span>y small numbers<span class="_ _1"></span>, then it would b<span class="_ _1"></span>e more persua<span class="_ _1"></span>sive ev<span class="_ _1"></span>i<span class="ws0">-</span></div><div class="t m0 x6 h5 y3f ff4 fs2 fc1 sc0 ls0 ws0">dence that t<span class="_ _0"></span>he drug cause<span class="_ _1"></span>s headache.</div><div class="t m0 x8 h5 y40 ff4 fs2 fc1 sc0 ls0 ws0">Thus, the three terms should be applied in the following contexts:</div><div class="t m0 x7 h5 y41 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ls2 ws29">Use<span class="_ _1"></span> <span class="ff7 ls0 ws0">ADR<span class="ff4 ws2a"> to me<span class="_ _1"></span>an that it is now generally acc<span class="_ _0"></span>epted that drug x may </span></span></span></div><div class="t m0 x8 h5 y42 ff4 fs2 fc1 sc0 ls0 ws2b">cause effe<span class="_ _1"></span>ct y rather than in re<span class="_ _0"></span>lation to individual cas<span class="_ _1"></span>es<span class="_ _1"></span>. Qu<span class="_ _1"></span>alif<span class="_ _1"></span>y the </div><div class="t m0 x8 h5 y43 ff4 fs2 fc1 sc0 ls0 ws0">term with possible if there is doubt<span class="_ _1"></span>.</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf3" class="pf w0 h0" data-page-no="3"><div class="pc pc3 w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">21</span></div><div class="t m0 x3 h5 y1d ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ls2 ws29">Use<span class="_ _1"></span> <span class="_ _c"> </span><span class="ff7 ls0 ws2c">suspected A<span class="_ _1"></span>DR<span class="ff4"> when a health professional or investigator </span></span></span></div><div class="t m0 x4 h5 y1e ff4 fs2 fc1 sc0 ls0 ws2d"> <span class="_ _3"></span>indicat<span class="_ _0"></span>es that a drug <span class="ff7 ls3 ws2e">may</span> have be<span class="_ _1"></span>en responsible for an e<span class="_ _1"></span>vent in an </div><div class="t m0 x4 h5 y1f ff4 fs2 fc1 sc0 ls0 ws22">individual ca<span class="_ _1"></span>se. A valid c<span class="_ _1"></span>ase submitte<span class="_ _1"></span>d as a spontane<span class="_ _1"></span>ous rep<span class="_ _1"></span>ort to </div><div class="t m0 x4 h5 y44 ff4 fs2 fc1 sc0 ls0 ws2f">acompany or regulator<span class="_ _1"></span>y authority (see Chapter5) i<span class="_ _1"></span>s<span class="_ _1"></span>, by definition, </div><div class="t m0 x4 h5 y45 ff4 fs2 fc1 sc0 ls0 ws0">a suspe<span class="_ _1"></span>cted ADR<span class="_ _d"></span>.</div><div class="t m0 x3 h5 y46 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ls2 ws29">Use<span class="_ _1"></span> <span class="_ _8"></span><span class="ff7 ls4 ws24">AE</span><span class="ls0 ws30"> only in the con<span class="_ _0"></span>tex<span class="_ _0"></span>t of systematic data collection when no </span></span></div><div class="t m0 x4 h5 y47 ff4 fs2 fc1 sc0 ls0 ws31">element of judgemen<span class="_ _0"></span>t is involved in determining whether a ca<span class="_ _1"></span>se is </div><div class="t m0 x4 h5 y48 ff4 fs2 fc1 sc0 ls0 ws0">counted.</div><div class="t m0 x2 h7 y49 ff5 fs4 fc2 sc0 ls0 ws0">Classification Sy<span class="_ _2"></span>stems</div><div class="t m0 x2 h5 y4a ff4 fs2 fc1 sc0 ls5 ws32">Since the 1970s, ADR<span class="_ _1"></span>s have traditionally been cla<span class="_ _1"></span>ssifie<span class="_ _1"></span>d into two </div><div class="t m0 x2 h5 y4b ff4 fs2 fc1 sc0 ls5 ws33">broad categories<span class="_ _1"></span>: T<span class="_ _2"></span>ypes A and B. The usual characteri<span class="_ _1"></span>stics of </div><div class="t m0 x2 h5 y4c ff4 fs2 fc1 sc0 ls5 ws34">these<span class="_ _8"></span>dif<span class="_ _1"></span>ferent types of reac<span class="_ _1"></span>tions are contrasted, followed by some </div><div class="t m0 x2 h5 y4d ff4 fs2 fc1 sc0 ls5 ws5">examples:</div><div class="t m0 x2 h5 y4e ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="ff7 fc1 ls6 ws35">Ty<span class="_ _8"></span>p<span class="_ _d"></span>e<span class="_ _d"></span> A<span class="_ _d"></span></span><span class="fc1"> (Augmented) reactions are generally<span class="_ _1"></span>:</span></div><div class="t m0 xa h5 y4f ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ls7 ws36">Do<span class="_ _1"></span>se<span class="_ _1"></span>relate<span class="_ _1"></span>d</span></div><div class="t m0 xa h5 y50 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Predictable from dr<span class="_ _1"></span>ug pharmacolog<span class="_ _1"></span>y</span></div><div class="t m0 xa h5 y51 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Common</span></div><div class="t m0 xa h5 y52 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Reversible</span></div><div class="t m0 xa h5 y53 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Manageable with dose adjustment<span class="_ _1"></span>.</span></div><div class="t m0 x2 h5 y54 ff4 fs2 fc1 sc0 ls0 ws37">Classic examples of T<span class="_ _2"></span>ype A reac<span class="_ _1"></span>tions are bleeding w<span class="_ _1"></span>ith warf<span class="_ _1"></span>arin, </div><div class="t m0 x2 h5 y55 ff4 fs2 fc1 sc0 ls0 ws38">hypog<span class="_ _1"></span>lycaemia with oral antidiabetic agent<span class="_ _1"></span>s and headache with </div><div class="t m0 x2 h5 y56 ff4 fs2 fc1 sc0 ls0 ws0">nitrates.</div><div class="t m0 x2 h5 y57 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="ff7 fc1 ls6 ws35">Ty<span class="_ _8"></span>p<span class="_ _d"></span>e<span class="_ _d"></span> B<span class="_ _d"></span></span><span class="fc1"> (Bi<span class="_ _1"></span>zarre) reactions are generally<span class="_ _1"></span>:</span></div><div class="t m0 xa h5 y58 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Not doserelated</span></div><div class="t m0 xa h5 y59 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Unpr<span class="_ _0"></span>edictable</span></div><div class="t m0 xa h5 y5a ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Uncommon</span></div><div class="t m0 xa h5 y5b ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Seriou<span class="_ _1"></span>s/irreversible</span></div><div class="t m0 xa h5 y5c ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Indicative that the drug needs to b<span class="_ _1"></span>e stopped.</span></div><div class="t m0 x2 h5 y5d ff4 fs2 fc1 sc0 ls0 ws0">Classic examples of T<span class="_ _2"></span>ype B reac<span class="_ _1"></span>tions are anaphylaxis with penicillins<span class="_ _1"></span>, </div><div class="t m0 x2 h5 y5e ff4 fs2 fc1 sc0 ls0 ws0">hepatitis with halothane and agranuloc<span class="_ _1"></span>y<span class="_ _1"></span>tosis w<span class="_ _1"></span>ith clozapine.</div><div class="t m0 x4 h5 y5f ff4 fs2 fc1 sc0 ls0 ws39">Additional categories of ADRs have also b<span class="_ _1"></span>een sugge<span class="_ _1"></span>sted, as </div><div class="t m0 x2 h5 y60 ff4 fs2 fc1 sc0 ls0 ws0">follows:</div><div class="t m0 x3 h5 y41 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">T<span class="_ _2"></span>ype C (Chronic), e.g. adrenal suppression with corticosteroids<span class="_ _1"></span>.</span></div><div class="t m0 x3 h5 y42 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">T<span class="_ _2"></span>ype D (Delayed), e.g<span class="_ _1"></span>. t<span class="_ _1"></span>ardive dyskinesia with neuroleptic<span class="_ _1"></span>s<span class="_ _1"></span>.</span></div><div class="t m0 x3 h5 y43 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ls8">T<span class="_ _2"></span>ype E (End of use), e.g<span class="_ _d"></span>. withdrawal reactions with benzo<span class="_ _1"></span>di<span class="_ _1"></span>az<span class="_ _1"></span>ep<span class="_ _1"></span>ine<span class="_ _1"></span>s<span class="_ _1"></span>.</span></div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf4" class="pf w0 h0" data-page-no="4"><div class="pc pc4 w0 h0"><img class="bi x5 y61 w2 h9" alt="" src="data:image/png;base64,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"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">22</span></div><div class="t m0 x6 h7 y62 ff5 fs4 fc2 sc0 ls0 ws0">Do<span class="_ _2"></span>TS Classification</div><div class="t m0 x6 h5 y63 ff4 fs2 fc1 sc0 ls0 ws3a">In 2003, a system of classif<span class="_ _1"></span>ication was prop<span class="_ _1"></span>ose<span class="_ _1"></span>d by Aronson and </div><div class="t m0 x6 h5 y64 ff4 fs2 fc1 sc0 ls0 ws3b">F<span class="_ _2"></span>er<span class="_ _1"></span>ner bas<span class="_ _1"></span>ed on <span class="ff7">doserel<span class="_ _1"></span>atedness<span class="_ _1"></span>, time course</span> and <span class="ff7 ws0">susceptibility;</span> this is </div><div class="t m0 x6 h5 y65 ff4 fs2 fc1 sc0 ls0 ws3c">known a<span class="_ _1"></span>s Do<span class="_ _2"></span>TS. The main ways in which ADRs can b<span class="_ _1"></span>e classif<span class="_ _1"></span>ied </div><div class="t m0 x6 h5 y66 ff4 fs2 fc1 sc0 ls0 ws0">within each of these three categorie<span class="_ _1"></span>s is given in T<span class="_ _2"></span>able2.1.</div><div class="t m0 x8 h5 y67 ff4 fs2 fc1 sc0 ls0 ws5">In terms of doserelatedness<span class="_ _1"></span>, toxic means that reactions occur a<span class="_ _1"></span>s a </div><div class="t m0 x6 h5 y68 ff4 fs2 fc1 sc0 ls0 ws3d">result of drug le<span class="_ _1"></span>vels being too hig<span class="_ _1"></span>h, <span class="_ _2"></span>collateral<span class="_ _0"></span> means that reactions </div><div class="t m0 x6 h5 y69 ff4 fs2 fc1 sc0 ls0 ws3e">occur at drug le<span class="_ _1"></span>vels that are in the usual thera<span class="_ _0"></span>peutic range and </div><div class="t m0 x6 h5 y6a ff4 fs2 fc1 sc0 ls0 ws3f"> <span class="_ _3"></span>hypersu<span class="_ _1"></span>sceptibility<span class="_ _1"></span> means that reactions can o<span class="_ _1"></span>ccur e<span class="_ _1"></span>ven at very low<span class="_ _0"></span>, </div><div class="t m0 x6 h5 y6b ff4 fs2 fc1 sc0 ls0 ws40">subtherapeutic doses<span class="_ _1"></span>. The terms <span class="_ _2"></span>early<span class="_ _1"></span><span class="_ _e"></span>, int<span class="_ _0"></span>ermedi<span class="_ _1"></span>ate and lat<span class="_ _0"></span>e have </div><div class="t m0 x6 h5 y6c ff4 fs2 fc1 sc0 ls0 ws41">not be<span class="_ _1"></span>en precisely def<span class="_ _1"></span>ined; the main difference betwe<span class="_ _1"></span>en late and </div><div class="t m0 x6 h5 y6d ff4 fs2 fc1 sc0 ls0 ws6"><span class="_ _2"></span>delayed reactions is that the la<span class="_ _0"></span>tter can occur long after treatment is </div><div class="t m0 x6 h5 y6e ff4 fs2 fc1 sc0 ls0 ws42">stopped (e.g<span class="_ _1"></span>. cancer<span class="_ _2"></span>, which can occur years after exposure to a causal </div><div class="t m0 x6 h5 y6f ff4 fs2 fc1 sc0 ls0 ws43">agent). A<span class="_ _d"></span>withdrawal reaction means one that is spe<span class="_ _1"></span>cific<span class="_ _1"></span>ally precipi<span class="ws0">-</span></div><div class="t m0 x6 h5 y70 ff4 fs2 fc1 sc0 ls0 ws0">tated by stopping the drug<span class="_ _1"></span>.</div><div class="t m0 x8 h5 y71 ff4 fs2 fc1 sc0 ls0 wsd">If suitable estimates of risk are available, it may be possible to draw </div><div class="t m0 x6 h5 y72 ff4 fs2 fc1 sc0 ls0 ws44">threedimensional Do<span class="_ _2"></span>TS diagrams of the probability of an ADR occur<span class="ws0">-</span></div><div class="t m0 x6 h5 y73 ff4 fs2 fc1 sc0 ls0 ws45">ring in subgroups over time and a<span class="_ _1"></span>s a function of do<span class="_ _1"></span>se. When this is </div><div class="t m0 x6 h5 y74 ff4 fs2 fc1 sc0 ls0 ws29">not possible, qualit<span class="_ _1"></span>ative classification may still be usef<span class="_ _1"></span>ul, as show<span class="_ _1"></span>n by </div><div class="t m0 x6 h5 y75 ff4 fs2 fc1 sc0 ls0 ws0">the following examples.</div><div class="t m0 x6 h7 y76 ff5 fs4 fc3 sc0 ls0 ws0">Do<span class="_ _2"></span>TS Classification: Examples</div><div class="t m0 x6 h5 y77 ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="ff7 fc1 ws46">O<span class="_ _1"></span>steoporo<span class="_ _1"></span>sis due to corticosteroid<span class="_ _1"></span>s:<span class="ff4"> this reac<span class="_ _1"></span>tion occurs at </span></span></div><div class="t m0 xb h5 y78 ff4 fs2 fc1 sc0 ls0 ws47"> <span class="_ _f"></span>therapeutic doses<span class="_ _1"></span>, u<span class="_ _1"></span>sually after some months of treatment. </div><div class="t m0 xb h5 y79 ff4 fs2 fc1 sc0 ls0 ws7">F<span class="_ _2"></span>emale<span class="_ _1"></span>s<span class="_ _d"></span>and older people are at the greatest risk<span class="_ _1"></span>. Hence, it would </div><div class="t m0 xb h5 y7a ff4 fs2 fc1 sc0 ls0 ws0">be  <span class="_ _10"></span>classifie<span class="_ _1"></span>d as<span class="_ _1"></span>:</div><div class="t m0 x6 ha y7b ff1 fs6 fc0 sc0 ls0 ws0">T<span class="_ _2"></span>able2.1 <span class="_ _11"> </span><span class="ff9 fc1">Summary ofdoserelatedness, time course andsusceptibility (Do<span class="_ _2"></span>TS) </span></div><div class="t m0 x6 ha y7c ff9 fs6 fc1 sc0 ls0 ws0">categories.</div><div class="t m0 x7 h2 y7d ff1 fs0 fc1 sc0 ls0 ws0">Dose<span class="_ _12"> </span>Time<span class="_ _13"> </span>Susceptibility</div><div class="t m0 x7 hb y7e ff4 fs6 fc1 sc0 ls0 ws0">T<span class="_ _14"></span>oxic<span class="_ _15"> </span>Independent<span class="_ _16"> </span>Age</div><div class="t m0 x7 hb y7f ff4 fs6 fc1 sc0 ls0 ws0">Collateral<span class="_ _17"> </span>Dep<span class="_ _1"></span>endent:<span class="_ _18"> </span>Gender</div><div class="t m0 x7 hb y80 ff4 fs6 fc1 sc0 ls0 ws0">Hypersusceptibility<span class="_ _19"> </span>rapid administration<span class="_ _1a"> </span>Ethnic origin</div><div class="t m0 xc hb y81 ff4 fs6 fc1 sc0 ls0 ws0">first dose<span class="_ _1b"> </span>Genetic</div><div class="t m0 xc hb y82 ff4 fs6 fc1 sc0 ls0 ws0">early<span class="_ _2"></span>, intermedi<span class="_ _1"></span>ate, late<span class="_ _19"> </span><span class="ls9 ws48">Disease</span></div><div class="t m0 xc hb y83 ff4 fs6 fc1 sc0 ls0 ws0">delayed</div><div class="t m0 xc hb y84 ff4 fs6 fc1 sc0 ls0 ws0">withdrawal</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf5" class="pf w0 h0" data-page-no="5"><div class="pc pc5 w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">23</span></div><div class="t m0 xa h5 y1d ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Dose: collateral effec<span class="_ _1"></span>t</span></div><div class="t m0 xa h5 y1e ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">T<span class="_ _14"></span>ime: l<span class="_ _1"></span>ate</span></div><div class="t m0 xa h5 y1f ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Susceptibility<span class="_ _1"></span>: age, sex<span class="_ _1"></span>.</span></div><div class="t m0 x2 h5 y20 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="ff7 fc1 ws49">Anaphylaxi<span class="_ _1"></span>s due to penicill<span class="_ _0"></span>in:<span class="ff4"> this reac<span class="_ _1"></span>tion can occur w<span class="_ _1"></span>ith ver<span class="_ _1"></span>y </span></span></div><div class="t m0 xd h5 y21 ff4 fs2 fc1 sc0 ls0 ws4a">small doses and w<span class="_ _1"></span>ithin minutes of taking the first dose of a course, </div><div class="t m0 xd h5 y22 ff4 fs2 fc1 sc0 ls0 ws4b">but true anaphylaxis only o<span class="_ _1"></span>ccurs when the drug (or a closely re<span class="_ _0"></span>lated </div><div class="t m0 xd h5 y23 ff4 fs2 fc1 sc0 ls0 ws0">agent) has be<span class="_ _1"></span>en use<span class="_ _1"></span>d prev<span class="_ _1"></span>iously<span class="_ _2"></span>. Hence, it would be classif<span class="_ _1"></span>ied a<span class="_ _1"></span>s:</div><div class="t m0 xa h5 y24 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Dose: hy<span class="_ _1"></span>persusceptibility</span></div><div class="t m0 xa h5 y25 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">T<span class="_ _14"></span>ime: f<span class="_ _1"></span>irst dose</span></div><div class="t m0 xa h5 y26 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">Susceptibility<span class="_ _1"></span>: requires pre<span class="_ _1"></span>vious sensiti<span class="_ _1"></span>sation.</span></div><div class="t m0 x4 h5 y85 ff4 fs2 fc1 sc0 ls0 ws4c">The Do<span class="_ _14"></span>TS approach is usef<span class="_ _1"></span>ul be<span class="_ _1"></span>cause it addresses the limitations of </div><div class="t m0 x2 h5 y86 ff4 fs2 fc1 sc0 ls0 ws36">the T<span class="_ _14"></span>yp<span class="_ _1"></span>e A/B scheme into which man<span class="_ _0"></span>y ADRs do not cle<span class="_ _1"></span>arly fit and in </div><div class="t m0 x2 h5 y87 ff4 fs2 fc1 sc0 ls0 ws0">providing pointers as to how spe<span class="_ _1"></span>cific A<span class="_ _1"></span>DRs c<span class="_ _1"></span>an be avoided.</div><div class="t m0 x2 h7 y88 ff5 fs4 fc2 sc0 ls0 ws0">Nature andMechanisms ofADRs</div><div class="t m0 x2 h5 y89 ff4 fs2 fc1 sc0 ls0 ws4d">The adverse effect<span class="_ _1"></span>s of medicine<span class="_ _1"></span>s usually mimic dise<span class="_ _1"></span>ase<span class="_ _1"></span>s or syndromes </div><div class="t m0 x2 h5 y8a ff4 fs2 fc1 sc0 ls0 ws4e">that occur naturally and ha<span class="_ _0"></span>ve a variety of nondr<span class="_ _1"></span>ug potential causes </div><div class="t m0 x2 h5 y8b ff4 fs2 fc1 sc0 ls0 ws3a">(e.g. hepatitis or aplastic anaemi<span class="_ _1"></span>a). As a general r<span class="_ _1"></span>ule, considering </div><div class="t m0 x2 h5 y8c ff4 fs2 fc1 sc0 ls0 ws4f">other potential causes is an impor<span class="_ _1"></span>tant part of the a<span class="_ _1"></span>ssessment of a </div><div class="t m0 x2 h5 y8d ff4 fs2 fc1 sc0 ls0 ws50">potential adverse effe<span class="_ _1"></span>ct (se<span class="_ _1"></span>e Causality Asse<span class="_ _1"></span>ssment). However<span class="_ _14"></span>, there </div><div class="t m0 x2 h5 y8e ff4 fs2 fc1 sc0 ls0 ws51">are a few unique sy<span class="_ _1"></span>ndromes that, as far a<span class="_ _1"></span>s we yet know<span class="_ _0"></span>, seem to be </div><div class="t m0 x2 h5 y8f ff4 fs2 fc1 sc0 ls0 ws0">caused only by sp<span class="_ _1"></span>ec<span class="_ _1"></span>ific drug<span class="_ _1"></span>s<span class="_ _1"></span>. F<span class="_ _0"></span>our examples of this are:</div><div class="t m0 x2 h5 y90 ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="fc1 ws52">V<span class="_ _2"></span>aginal cancer in young women cause<span class="_ _1"></span>d by maternal exposure to </span></div><div class="t m0 xd h5 y91 ff4 fs2 fc1 sc0 ls0 ws0">diethylstilboe<span class="_ _1"></span>strol</div><div class="t m0 x2 h5 y92 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="fc1 ls1 ws53">Oc<span class="_ _1"></span>ulomucocutane<span class="_ _1"></span>ous syndrome caus<span class="_ _1"></span>ed by practolol (se<span class="_ _1"></span>e Chapter<span class="_ _14"></span>1)</span></div><div class="t m0 x2 h5 y93 ff4 fs2 fc0 sc0 ls0 ws0">3) <span class="_ _9"> </span><span class="fc1 ws54">Eosinophili<span class="_ _1"></span>amyalgia sy<span class="_ _1"></span>ndrome caused by s<span class="_ _1"></span>ome <span class="ws0">tr<span class="_ _1"></span>yptophan </span></span></div><div class="t m0 xd h5 y94 ff4 fs2 fc1 sc0 ls0 ws0">products</div><div class="t m0 x2 h5 y95 ff4 fs2 fc0 sc0 ls0 ws0">4) <span class="_ _9"> </span><span class="fc1 ws55">Fibrosing colonopat<span class="_ _0"></span>hy induced by large doses of highstrength </span></div><div class="t m0 xd h5 y96 ff4 fs2 fc1 sc0 ls0 ws0">pancreatic enzy<span class="_ _1"></span>mes in children with c<span class="_ _1"></span>ystic fibrosis<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y3c ff4 fs2 fc1 sc0 ls0 ws0">In broad terms<span class="_ _1"></span>, there are a<span class="_ _0"></span>t least four me<span class="_ _1"></span>chanisms for ADRs<span class="_ _1"></span>:</div><div class="t m0 x2 h5 y97 ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="fc1 ws56">Exaggerated therape<span class="_ _1"></span>utic response at the target site (e.g. blee<span class="_ _1"></span>ding </span></div><div class="t m0 xd h5 y98 ff4 fs2 fc1 sc0 ls0 ws0">with warf<span class="_ _1"></span>arin)</div><div class="t m0 x2 h5 y99 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="fc1 ws57">De<span class="_ _1"></span>sired pharmacolog<span class="_ _1"></span>ical effe<span class="_ _1"></span>ct at another site (<span class="_ _2"></span>e.g<span class="_ _1"></span>. he<span class="_ _1"></span>adache with </span></div><div class="t m0 xd h5 y9a ff4 fs2 fc1 sc0 ls0 ws0">glycer<span class="_ _1"></span>yltrinitrate)</div><div class="t m0 x2 h5 y9b ff4 fs2 fc0 sc0 ls0 ws0">3) <span class="_ _9"> </span><span class="fc1 ws5">Additional (secondar<span class="_ _d"></span>y) pharmacological actions (e.g<span class="_ _1"></span>. prolongation </span></div><div class="t m0 xd h5 y9c ff4 fs2 fc1 sc0 ls0 ws0">of the QT in<span class="_ _0"></span>ter<span class="_ _1"></span>val on the electro<span class="_ _1"></span>cardiogrammany drug<span class="_ _1"></span>s)</div><div class="t m0 x2 h5 y9d ff4 fs2 fc0 sc0 ls0 ws0">4) <span class="_ _9"> </span><span class="fc1 ws58">T<span class="_ _2"></span>riggering an immunolog<span class="_ _1"></span>ical resp<span class="_ _1"></span>onse (e.g. anaphylaxis due to </span></div><div class="t m0 xd h5 y9e ff4 fs2 fc1 sc0 ls0 ws0">many drugs).</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf6" class="pf w0 h0" data-page-no="6"><div class="pc pc6 w0 h0"><img class="bi x5 y9f w3 hc" alt="" src="data:image/png;base64,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"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">24</span></div><div class="t m0 x8 h5 y1d ff4 fs2 fc1 sc0 ls0 ws59">Particularly at the time they are first identifie<span class="_ _1"></span>d, the mechanism </div><div class="t m0 x6 h5 y1e ff4 fs2 fc1 sc0 ls0 ws52">of<span class="_ _8"></span>many ADRs is unknow<span class="_ _1"></span>n or incompletely understood. Some have </div><div class="t m0 x6 h5 y1f ff4 fs2 fc1 sc0 ls0 ws5a">a<span class="_ _6"> </span>pharmacokinetic ba<span class="_ _1"></span>sis e.g<span class="_ _1"></span>. impaired hep<span class="_ _1"></span>atic metabolism due to a </div><div class="t m0 x6 h5 y44 ff4 fs2 fc1 sc0 ls0 ws0">genetic poly<span class="_ _1"></span>morphism or the effe<span class="_ _1"></span>ct of another medic<span class="_ _1"></span>ation takencon-</div><div class="t m0 x6 h5 y45 ff4 fs2 fc1 sc0 ls0 ws5b">currently<span class="_ _2"></span>, leading to increas<span class="_ _1"></span>ed pla<span class="_ _1"></span>sma concentra<span class="_ _0"></span>tions. Understanding </div><div class="t m0 x6 h5 y46 ff4 fs2 fc1 sc0 ls0 ws5c">genetic predisp<span class="_ _1"></span>ositions is likely to be an impor<span class="_ _1"></span>tant factor in determin<span class="ws0">-</span></div><div class="t m0 x6 h5 y47 ff4 fs2 fc1 sc0 ls0 ws0">ing how we might prevent ADRs in the f<span class="_ _1"></span>uture (see Chapter9).</div><div class="t m0 x6 h7 ya0 ff5 fs4 fc2 sc0 ls0 ws0">Predisposing F<span class="_ _2"></span>ac<span class="_ _1"></span>tors forADRs</div><div class="t m0 x6 h5 ya1 ff4 fs2 fc1 sc0 ls0 ws5d">The main clinical factors that increase the chance tha<span class="_ _0"></span>t patients will </div><div class="t m0 x6 h5 ya2 ff4 fs2 fc1 sc0 ls0 ws0">experience an adverse reaction are as follows<span class="_ _1"></span>:</div><div class="t m0 x7 h5 ya3 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 lsa wsf">Age<span class="_ _1"></span><span class="ff4 ls0 ws0">the elderly and neonates are at greatest risk<span class="_ _1"></span>.</span></span></div><div class="t m0 x7 h5 ya4 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Gender<span class="ff4">women are generally at higher risk<span class="_ _1"></span>.</span></span></div><div class="t m0 x7 h5 ya5 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws5e">Ethnic origin<span class="ff4"><span class="_ _11"> </span><span class="_ _11"> </span>can affe<span class="_ _1"></span>ct drug me<span class="_ _1"></span>tabolism b<span class="_ _1"></span>ec<span class="_ _1"></span>ause of genetic </span></span></div><div class="t m0 x8 h5 ya6 ff4 fs2 fc1 sc0 ls0 ws0">predisp<span class="_ _1"></span>osition.</div><div class="t m0 x7 h5 ya7 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws5f">Im<span class="_ _0"></span>paired e<span class="_ _1"></span>xcretor<span class="_ _1"></span>y mechanisms<span class="ff4"><span class="_ _11"> </span><span class="_ _1c"> </span>reduced hep<span class="_ _1"></span>atic and/or renal </span></span></div><div class="t m0 x8 h5 ya8 ff4 fs2 fc1 sc0 ls0 ws0">function.</div><div class="t m0 x7 h5 ya9 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Specific dise<span class="_ _1"></span>ase<span class="_ _1"></span>s<span class="ff4">e.g<span class="_ _1"></span>. asthma and b<span class="_ _1"></span>etablo<span class="_ _1"></span>ckers</span></span></div><div class="t m0 xe hd yaa ff4 fs7 fc1 sc0 ls0 ws0">1</div><div class="t m0 xf h5 ya9 ff4 fs2 fc1 sc0 ls0 ws0">.</div><div class="t m0 x7 h5 yab ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Polypharmacy<span class="ff4 ws60"> <span class="_ _1"></span>use of multiple dr<span class="_ _1"></span>ugs simultaneou<span class="_ _1"></span>sly<span class="_ _2"></span>, increasing </span></span></div><div class="t m0 x8 h5 yac ff4 fs2 fc1 sc0 ls0 ws0">the potential for drug interactions (see next section).</div><div class="t m0 x7 h5 yad ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">An<span class="_ _0"></span>y prev<span class="_ _1"></span>ious histor<span class="_ _1"></span>y of an A<span class="_ _1"></span>DR<span class="ff4">.</span></span></div><div class="t m0 x6 h7 y8f ff5 fs4 fc2 sc0 ls0 ws0">Drug Interactions</div><div class="t m0 x6 h5 yae ff4 fs2 fc1 sc0 ls0 ws13">Drug interactions occur when the presence of one drug af<span class="_ _1"></span>fect<span class="_ _1"></span>s the </div><div class="t m0 x6 h5 yaf ff4 fs2 fc1 sc0 ls0 ws61">activity of another<span class="_ _14"></span>. This o<span class="_ _1"></span>ccurs either bec<span class="_ _1"></span>ause both drug<span class="_ _1"></span>s act through </div><div class="t m0 x6 h5 yb0 ff4 fs2 fc1 sc0 ls0 ws62">the same path<span class="_ _0"></span>way(s)<span class="_ _9"> </span><span class="_ _1d"> </span>these are called <span class="ff7 ws0">phar<span class="_ _1"></span>macodynamic</span> interac<span class="_ _0"></span><span class="ws0">-</span></div><div class="t m0 x6 h5 yb1 ff4 fs2 fc1 sc0 ls0 ws63">tions<span class="_ _1"></span>or through effe<span class="_ _1"></span>cts on abs<span class="_ _1"></span>orption, distr<span class="_ _1"></span>ibution, metabolism or </div><div class="t m0 x6 h5 yb2 ff4 fs2 fc1 sc0 ls0 ws0">ex<span class="_ _0"></span>cretion<span class="_ _c"> </span><span class="_ _1e"> </span><span class="ff7">pharmacokinetic</span><span class="ws64"> interactions. The result may be an </span></div><div class="t m0 x6 h5 yb3 ff4 fs2 fc1 sc0 ls0 ws65">adverse reaction or mo<span class="_ _1"></span>dified ef<span class="_ _1"></span>fectivene<span class="_ _1"></span>ss<span class="_ _1"></span>. Some sp<span class="_ _1"></span>ecif<span class="_ _1"></span>ic examples </div><div class="t m0 x6 h5 yb4 ff4 fs2 fc1 sc0 ls0 ws0">are given as follows<span class="_ _1"></span>:</div><div class="t m0 x7 h5 yb5 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Pharmacodynamic<span class="ff4 ws32"><span class="_ _9"> </span><span class="_ _1d"> </span>concomitant use of two drug<span class="_ _1"></span>s with similar </span></span></div><div class="t m0 x8 h5 yb6 ff4 fs2 fc1 sc0 ls0 ws66">effect<span class="_ _1"></span>s<span class="_ _1"></span>. F<span class="_ _0"></span>or example, an angiotensin con<span class="_ _0"></span>verting enzy<span class="_ _1"></span>me (ACE) </div><div class="t m0 x8 h5 yb7 ff4 fs2 fc1 sc0 ls0 ws67">inhibitor plus a pota<span class="_ _1"></span>ssiumsparing diuretic c<span class="_ _1"></span>an result in hyper<span class="ws0">-</span></div><div class="t m0 x8 h5 yb8 ff4 fs2 fc1 sc0 ls0 ws0">kalaemia and cardiac ar<span class="_ _1"></span>rhythmias<span class="_ _1"></span>.</div><div class="t m0 x6 he yb9 ff4 fs8 fc1 sc0 ls0 ws0">1</div><div class="t m0 x10 h3 yba ff4 fs0 fc1 sc0 ls3 ws0"> <span class="_ _1c"> </span>This is a very imp<span class="_ _1"></span>ortant example because the ef<span class="_ _1"></span>fect of be<span class="_ _1"></span>tablockers in patients with </div><div class="t m0 x6 h3 ybb ff4 fs0 fc1 sc0 ls3 ws0">asthma is to constrict the air<span class="_ _1"></span>ways and to counteract some of the treatments tha<span class="_ _0"></span>t the </div><div class="t m0 x6 h3 ybc ff4 fs0 fc1 sc0 ls3 ws0">patient may be taking (e.g. bet<span class="_ _1"></span>aagonists). Giving a b<span class="_ _1"></span>etablo<span class="_ _1"></span>cker to an asthmatic patien<span class="_ _0"></span>t </div><div class="t m0 x6 h3 ybd ff4 fs0 fc1 sc0 ls3 ws0">can prove to be fatal.</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf7" class="pf w0 h0" data-page-no="7"><div class="pc pc7 w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">25</span></div><div class="t m0 x3 h5 y1d ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Absorption<span class="ff4 ws68"><span class="_ _1c"> </span><span class="_ _11"> </span>orlistat<span class="_ _1"></span>, a drug us<span class="_ _1"></span>ed to treat obesity<span class="_ _0"></span>, impairs the </span></span></div><div class="t m0 x4 h5 y1e ff4 fs2 fc1 sc0 ls0 ws69">absorption of some me<span class="_ _1"></span>dicines (e.g<span class="_ _1"></span>. anticonvulsants) and its use in </div><div class="t m0 x4 h5 y1f ff4 fs2 fc1 sc0 ls0 ws0">this conte<span class="_ _0"></span>xt could lead to c<span class="_ _0"></span>onvulsions<span class="_ _1"></span>.</div><div class="t m0 x3 h5 y44 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Di<span class="_ _1"></span>stribution<span class="ff4 ws6a"><span class="_ _1d"> </span><span class="_ _9"> </span>proteinbound drug<span class="_ _1"></span>s (e.g. phenytoin, aspir<span class="_ _1"></span>in) can </span></span></div><div class="t m0 x4 h5 y45 ff4 fs2 fc1 sc0 ls0 ws6b">displace each other<span class="_ _14"></span>, resulting in an increa<span class="_ _1"></span>se<span class="_ _1"></span>d unbound (i.e. active) </div><div class="t m0 x4 h5 y46 ff4 fs2 fc1 sc0 ls0 ws0">fraction of dr<span class="_ _1"></span>ug in plasma<span class="_ _1"></span>.</div><div class="t m0 x3 h5 y47 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 lsb ws6c">Metaboli<span class="_ _1"></span>sm<span class="ff4 ls0 ws49"><span class="_ _1d"> </span><span class="_ _1d"> </span>many medicines (e.g<span class="_ _1"></span>. cimetidine and omepra<span class="_ _1"></span>zole), </span></span></div><div class="t m0 x4 h5 y48 ff4 fs2 fc1 sc0 ls0 ws6d">drugs that reduce gastr<span class="_ _1"></span>ic acid by different mechanisms<span class="_ _1"></span>, inhibit the </div><div class="t m0 x4 h5 ybe ff4 fs2 fc1 sc0 ls0 ws6e">metabolism of w<span class="_ _1"></span>arfar<span class="_ _1"></span>in and thereby increase its anticoagul<span class="_ _1"></span>ant </div><div class="t m0 x4 h5 ybf ff4 fs2 fc1 sc0 ls0 ws0">effect<span class="_ _1"></span>, leading to ble<span class="_ _1"></span>eding reac<span class="_ _1"></span>tions<span class="_ _1"></span>.</div><div class="t m0 x3 h5 yc0 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">E<span class="_ _1"></span>xcretion<span class="ff4 ws6f"><span class="_ _6"> </span><span class="_ _8"></span>amio<span class="_ _1"></span>darone, an antiarrhythmic drug<span class="_ _1"></span>, reduces excre<span class="ws0">-</span></span></span></div><div class="t m0 x4 h5 yc1 ff4 fs2 fc1 sc0 ls0 ws70">tion of, and therefore t<span class="_ _0"></span>he dosage requirements for<span class="_ _14"></span>, digoxina drug </div><div class="t m0 x4 h5 yc2 ff4 fs2 fc1 sc0 ls0 ws0">widely prescrib<span class="_ _1"></span>ed to patients w<span class="_ _1"></span>ith cardiac disea<span class="_ _1"></span>se.</div><div class="t m0 x4 h5 y2a ff4 fs2 fc1 sc0 ls0 ws71">Many drugs are metaboli<span class="_ _1"></span>sed by he<span class="_ _1"></span>patic cy<span class="_ _1"></span>tochrome P450 (C<span class="_ _1"></span>YP450) </div><div class="t m0 x2 h5 y2b ff4 fs2 fc1 sc0 ls0 ws42">enzyme<span class="_ _1"></span>s<span class="_ _1"></span>, the activity of which may be induced or inhibited by a w<span class="_ _1"></span>ide </div><div class="t m0 x2 h5 y2c ff4 fs2 fc1 sc0 ls0 ws72">variety of dr<span class="_ _1"></span>ugs<span class="_ _1"></span>. There are several subg<span class="_ _1"></span>roups of C<span class="_ _1"></span>YP450 enzy<span class="_ _1"></span>mes and </div><div class="t m0 x2 h5 y2d ff4 fs2 fc1 sc0 ls0 ws0">their activity can als<span class="_ _1"></span>o be affe<span class="_ _1"></span>cted by<span class="_ _1"></span>:</div><div class="t m0 x3 h5 yc3 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws73">Herbal medici<span class="_ _0"></span>nes<span class="ff4"><span class="_ _0"></span>e.g<span class="_ _1"></span>. St John<span class="_ _2"></span><span class="_ _2"></span>s wort is an enz<span class="_ _1"></span>yme inducer and can </span></span></div><div class="t m0 x4 h5 yc4 ff4 fs2 fc1 sc0 ls0 ws0">reduce the effectiveness of v<span class="_ _1"></span>arious dr<span class="_ _1"></span>ugs including ciclosp<span class="_ _1"></span>orin.</div><div class="t m0 x3 h5 yc5 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws74">Diet<span class="_ _1"></span>ar<span class="_ _1"></span>y products<span class="ff4"><span class="_ _d"></span><span class="_ _d"></span>e.g. g<span class="_ _1"></span>rapefr<span class="_ _1"></span>uit juice is an enzyme inhibitor and </span></span></div><div class="t m0 x4 h5 yc6 ff4 fs2 fc1 sc0 ls0 wse">increas<span class="_ _1"></span>es plasma concentrations of some calcium channel blockers, </div><div class="t m0 x4 h5 yc7 ff4 fs2 fc1 sc0 ls0 ws0">drugs that are used to treat hyp<span class="_ _1"></span>ertension and angina<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y34 ff4 fs2 fc1 sc0 ls0 ws75">Drugs c<span class="_ _1"></span>an also interact with <span class="ff7 ws0">alcohol</span><span class="_ _d"></span><span class="_ _d"></span>for exam<span class="_ _0"></span>ple, metronidazole </div><div class="t m0 x2 h5 y35 ff4 fs2 fc1 sc0 ls0 ws76">(an antibiotic<span class="_ _0"></span>) blocks p<span class="_ _1"></span>art of the metab<span class="_ _1"></span>olic pathway f<span class="_ _0"></span>or alcohol </div><div class="t m0 x2 h5 y36 ff4 fs2 fc1 sc0 ls0 ws77">and<span class="_ _1d"> </span>concomitant use, which is not recommended, leads to intense </div><div class="t m0 x2 h5 y37 ff4 fs2 fc1 sc0 ls0 ws0">vas<span class="_ _1"></span>odilatation.</div><div class="t m0 x2 h6 y3a ff1 fs3 fc0 sc0 ls0 ws0"> <span class="_ _3"></span>The C<span class="_ _0"></span>oncept ofSafety</div><div class="t m0 x2 h7 y3c ff5 fs4 fc2 sc0 ls0 ws0">Definition</div><div class="t m0 x2 h5 yc8 ff4 fs2 fc1 sc0 ls0 ws78">Safety can b<span class="_ _1"></span>e defined a<span class="_ _1"></span>s <span class="ff7">relative absence of harm<span class="_ _1"></span>.</span> When using the </div><div class="t m0 x2 h5 yc9 ff4 fs2 fc1 sc0 ls0 ws79">word <span class="_ _2"></span>safety<span class="_ _1"></span> we of<span class="_ _1"></span>ten mean something else. For e<span class="_ _0"></span>xample, safety data </div><div class="t m0 x2 h5 yca ff4 fs2 fc1 sc0 ls0 ws7a">often means collec<span class="_ _1"></span>tion of report<span class="_ _1"></span>s of harm. Safety de<span class="_ _1"></span>partments in the </div><div class="t m0 x2 h5 ycb ff4 fs2 fc1 sc0 ls0 ws7b">pharmaceutical industr<span class="_ _d"></span>y are generally focused much more on harm </div><div class="t m0 x2 h5 ycc ff4 fs2 fc1 sc0 ls0 ws0">than safety<span class="_ _2"></span>. And yet how safe something is a ke<span class="_ _1"></span>y question for the user </div><div class="t m0 x2 h5 ycd ff4 fs2 fc1 sc0 ls0 ws7c">and one that pharmacovigilance is gradually b<span class="_ _1"></span>ecoming more targeted </div><div class="t m0 x2 h5 yce ff4 fs2 fc1 sc0 ls0 ws7d">at. T<span class="_ _14"></span>o establish safety<span class="_ _2"></span>, it is not enough to sit around and hope that </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf8" class="pf w0 h0" data-page-no="8"><div class="pc pc8 w0 h0"><img class="bi x5 y0 w1 h8" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAiCAIAAAD6eJ9FAAAACXBIWXMAABYlAAAWJQFJUiTwAAAADElEQVQI12NgGEkAAADuAAGm0YQWAAAAAElFTkSuQmCC"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">26</span></div><div class="t m0 x6 h5 y1d ff4 fs2 fc1 sc0 ls0 ws7e">nothing much ha<span class="_ _0"></span>ppens<span class="_ _1"></span>. Active processes are require<span class="_ _1"></span>d to generate data </div><div class="t m0 x6 h5 y1e ff4 fs2 fc1 sc0 ls0 ws7f">in large numbers of users<span class="_ _d"></span><span class="_ _d"></span>this is one of the main challenges facing </div><div class="t m0 x6 h5 y1f ff4 fs2 fc1 sc0 ls0 ws0">pe<span class="_ _1"></span>ople working in the field.</div><div class="t m0 x8 h5 y44 ff4 fs2 fc1 sc0 ls0 ws61">In practice, there is no such thing as absolute safety bec<span class="_ _1"></span>ause, even if </div><div class="t m0 x6 h5 y45 ff4 fs2 fc1 sc0 ls0 wsa">something is completely harmless<span class="_ _1"></span>, it is impossible to demonstrate that </div><div class="t m0 x6 h5 y46 ff4 fs2 fc1 sc0 ls0 ws80">with complete certainty<span class="_ _14"></span>. For exam<span class="_ _0"></span>ple, if a drug were given to 999 <span class="_ _1f"></span>999 </div><div class="t m0 x6 h5 y47 ff4 fs2 fc1 sc0 ls0 ws2f">pe<span class="_ _1"></span>ople without any problem occurring<span class="_ _1"></span>, it would b<span class="_ _1"></span>e ver<span class="_ _1"></span>y unlikely that </div><div class="t m0 x6 h5 y48 ff4 fs2 fc1 sc0 ls0 ws81">the millionth person to use it would be harme<span class="_ _1"></span>d, but it is not impo<span class="_ _1"></span>ssi<span class="ws0">-</span></div><div class="t m0 x6 h5 ybe ff4 fs2 fc1 sc0 ls0 ws82">ble. In any case, we know that all pharmacologic<span class="_ _1"></span>ally active substances </div><div class="t m0 x6 h5 ybf ff4 fs2 fc1 sc0 ls0 ws83">have the potential to ca<span class="_ _0"></span>use harm. When we say that a drug is <span class="_ _2"></span>safe<span class="_ _e"></span>, we </div><div class="t m0 x6 h5 yc0 ff4 fs2 fc1 sc0 ls0 ws6">mean that there is a low probability of harm which, <span class="ff7">i<span class="_ _0"></span>n the conte<span class="_ _1"></span>xt of </span></div><div class="t m0 x6 h5 yc1 ff7 fs2 fc1 sc0 ls0 ws18">the disea<span class="_ _1"></span>se being treated and the e<span class="_ _1"></span>xpe<span class="_ _1"></span>cted benef<span class="_ _1"></span>its of the drug<span class="ff4">, can be </span></div><div class="t m0 x6 h5 yc2 ff4 fs2 fc1 sc0 ls0 ws57">considered acceptable. Diseas<span class="_ _1"></span>e conte<span class="_ _0"></span>xt is important be<span class="_ _1"></span>cause patients </div><div class="t m0 x6 h5 ycf ff4 fs2 fc1 sc0 ls0 ws34">with more serious illness<span class="_ _1"></span>es are much more like<span class="_ _0"></span>ly to be prepared to </div><div class="t m0 x6 h5 yd0 ff4 fs2 fc1 sc0 ls0 ws84">accept potentially harmful treatments than those who have minor or </div><div class="t m0 x6 h5 yd1 ff4 fs2 fc1 sc0 ls0 ws28">selflimiting illnesses<span class="_ _1"></span>. <span class="_ _1f"></span>Acceptability<span class="_ _1"></span> is a subje<span class="_ _1"></span>ctive judgement which </div><div class="t m0 x6 h5 yd2 ff4 fs2 fc1 sc0 ls0 ws85">ultimately is made by com<span class="_ _2"></span>p<span class="_ _1"></span>aring b<span class="_ _1"></span>oth the positive and the negative </div><div class="t m0 x6 h5 yd3 ff4 fs2 fc1 sc0 ls0 ws4b">consequences of one course of action (e.g. a dr<span class="_ _1"></span>ug) with another (which </div><div class="t m0 x6 h5 yc3 ff4 fs2 fc1 sc0 ls0 ws15">could be any form of treatment or no tr<span class="_ _0"></span>eatment). W<span class="_ _14"></span>e will return to </div><div class="t m0 x6 h5 yc4 ff4 fs2 fc1 sc0 ls0 ws0">this point in more detail in the sec<span class="_ _1"></span>tion on riskbenefit balance.</div><div class="t m0 x8 h5 yc5 ff4 fs2 fc1 sc0 ls1 ws7e">Safety is a moving b<span class="_ _1"></span>all<span class="_ _2"></span><span class="_ _0"></span>there is a need to reev<span class="_ _1"></span>aluate it as experience </div><div class="t m0 x6 h5 yc6 ff4 fs2 fc1 sc0 ls1 ws86">accumulates. T<span class="_ _2"></span>reatments previou<span class="_ _1"></span>sly considered acceptably safe ma<span class="_ _0"></span>y </div><div class="t m0 x6 h5 yc7 ff4 fs2 fc1 sc0 ls1 ws22">be<span class="_ _1"></span>come unsafe in t<span class="_ _0"></span>he light of new e<span class="_ _1"></span>vidence or the discover<span class="_ _1"></span>y of safer </div><div class="t m0 x6 h5 yd4 ff4 fs2 fc1 sc0 ls1 ws87">alternatives. An example of the latter was the antihistamine terfena<span class="ls0 ws0">-</span></div><div class="t m0 x6 h5 y90 ff4 fs2 fc1 sc0 ls1 ws88">dine which was w<span class="_ _1"></span>idely used in the treatment of hay fever until the early </div><div class="t m0 x6 h5 y91 ff4 fs2 fc1 sc0 ls1 ws23">1990s. It was then dis<span class="_ _1"></span>covered that it could, very rarely<span class="_ _2"></span>, cause ser<span class="_ _1"></span>ious or </div><div class="t m0 x6 h5 y92 ff4 fs2 fc1 sc0 ls1 ws89">fatal ventricular arrhythmia<span class="_ _1"></span>s through the mechanism of prolonging </div><div class="t m0 x6 h5 y93 ff4 fs2 fc1 sc0 ls1 ws8a">the QT in<span class="_ _0"></span>ter<span class="_ _1"></span>val. T<span class="_ _14"></span>erfenadine is a prodrug (i.e. precurs<span class="_ _1"></span>or of the active </div><div class="t m0 x6 h5 y94 ff4 fs2 fc1 sc0 ls1 ws8b">substance) which is normally completely metabolise<span class="_ _1"></span>d on the firstpa<span class="_ _1"></span>ss </div><div class="t m0 x6 h5 y95 ff4 fs2 fc1 sc0 ls1 ws3b">through the liver<span class="_ _14"></span>. It is the paren<span class="_ _0"></span>t drug terfenadine that prolongs the QT </div><div class="t m0 x6 h5 y96 ff4 fs2 fc1 sc0 ls1 ws8c">interv<span class="_ _1"></span>al (when its met<span class="_ _1"></span>abolism is inhibited) but the met<span class="_ _1"></span>abolite is </div><div class="t m0 x6 h5 yd5 ff4 fs2 fc1 sc0 ls1 ws8d">responsible for the benefic<span class="_ _1"></span>ial effec<span class="_ _1"></span>ts<span class="_ _1"></span>. Thus, the met<span class="_ _1"></span>abolite, known a<span class="_ _1"></span>s </div><div class="t m0 x6 h5 yd6 ff4 fs2 fc1 sc0 ls1 ws26">fex<span class="_ _0"></span>ofenadine, was de<span class="_ _1"></span>veloped for this indic<span class="_ _1"></span>ation and rapidly ac<span class="_ _0"></span>cepted to </div><div class="t m0 x6 h5 yc8 ff4 fs2 fc1 sc0 ls1 ws0">be a safer alternative, following which terfenadine bec<span class="_ _1"></span>ame obsolete.</div><div class="t m0 x6 h7 y60 ff5 fs4 fc2 sc0 ls0 ws0">Measuring Risk</div><div class="t m0 x6 h5 yd7 ff4 fs2 fc1 sc0 ls0 ws57">T<span class="_ _14"></span>o assess how safe something is we ne<span class="_ _1"></span>ed to identif<span class="_ _1"></span>y and mea<span class="_ _1"></span>sure the </div><div class="t m0 x6 h5 yd8 ff4 fs2 fc1 sc0 ls0 ws6b">risk<span class="_ _1"></span>s of harm asso<span class="_ _1"></span>ciated w<span class="_ _1"></span>ith it. <span class="ff7 lsc ws8e">Ri<span class="_ _1"></span>sk<span class="_ _1"></span></span> is the probability of an adverse </div><div class="t m0 x6 h5 yd9 ff4 fs2 fc1 sc0 ls0 ws0">outcome. I<span class="_ _2"></span>t may be expresse<span class="_ _1"></span>d in the following terms:</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf9" class="pf w0 h0" data-page-no="9"><div class="pc pc9 w0 h0"><img class="bi x2 yda w4 hf" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAk0AAAPpCAIAAACHYo5DAAAACXBIWXMAABYlAAAWJQFJUiTwAAAL8ElEQVR42u3YsQ0DIRBFQdaiKtLr54qhH1KqQlq3cIEtCzwTE/3kaYnMLABworVWtQIAR4qIUsrLEAAcTOcA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQD4nMhMKwDgngMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAODX6tWnFQDYzrjbk2eRmcYC4FT+LQHQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAEDnAEDnAEDnAEDnAEDnAEDnANA5ANA5ANA5ANA5ANA5ANA5AHQOAHQOAHQOAHQOAHQOAHQOAHQOAJ0DAJ0DAJ0DAJ0DgG+rV59WAGA7427uOQD+XWSmFQA4lXsOAJ0DAJ0DAJ0DAJ0DAJ0DAJ0DQOcAQOcAQOcAQOcAQOcAQOcAQOcA0DkA0DkA0DkA0DkA0DkA0DkA0DkAdA4AdA4AdA4AdA4AdA4AdA4AdA4AnQMAnQMAnQMAnQMAnQMAnQNA5wBA5wBA5wBA5wBA5wBA5wBA5wDQOQDQOQDQOQDQOQDQOQDQOQDQOQB0DgB0DgB0DgB0DgB0DgB0DgB0DgCdAwCdAwCdAwCdAwCdAwCdAwCdA0DnAGBf9erTCgBsZ9ztybM3vdAfwpf0TZcAAAAASUVORK5CYII="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">27</span></div><div class="t m0 x3 h5 y1d ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws8f">Absol<span class="_ _0"></span>ute ri<span class="_ _1"></span>sk<span class="ff4 ws0">  <span class="ffa"></span><span class="ws8f"> an absolute risk must have a numera<span class="_ _0"></span>tor and a </span></span></span></div><div class="t m0 x4 h5 y1e ff4 fs2 fc1 sc0 ls0 ws1c">denominator but it ma<span class="_ _0"></span>y be a propor<span class="_ _1"></span>tion (e.g. 1 in 100) or a rate </div><div class="t m0 x4 h5 y1f ff4 fs2 fc1 sc0 ls0 ws90">which includes time (e.g. 1 in 100 per ye<span class="_ _1"></span>ar). The null value (i.e. no </div><div class="t m0 x4 h5 y44 ff4 fs2 fc1 sc0 ls0 ws0">increas<span class="_ _1"></span>ed ri<span class="_ _1"></span>sk) is zero.</div><div class="t m0 x3 h5 y45 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws91">Relative ri<span class="_ _1"></span>sk<span class="ff4 ws0"> <span class="ffa"></span><span class="ws91"> a r<span class="_ _0"></span>elative risk is a ratio and makes com<span class="_ _0"></span>parison w<span class="_ _1"></span>ith a </span></span></span></div><div class="t m0 x4 h5 y46 ff4 fs2 fc1 sc0 ls0 ws90">spe<span class="_ _1"></span>cifie<span class="_ _1"></span>d alternative (e.g. a twofold increase compared to no treat<span class="ws0">-</span></div><div class="t m0 x4 h5 y47 ff4 fs2 fc1 sc0 ls0 ws0">ment is a relative risk of 2). T<span class="_ _0"></span>he null value is one.</div><div class="t m0 x4 h5 y24 ff4 fs2 fc1 sc0 ls0 wsc">Absolute risk provides more usef<span class="_ _1"></span>ul information than relative risk </div><div class="t m0 x2 h5 y25 ff4 fs2 fc1 sc0 ls0 ws92">but the latter is often easier to measure. Interpreting a relative risk is </div><div class="t m0 x2 h5 y26 ff4 fs2 fc1 sc0 ls0 ws93">difficult w<span class="_ _1"></span>ithout knowledge of the <span class="ff7 ws0">b<span class="_ _1"></span>aseline</span> rate (i.e. the background </div><div class="t m0 x2 h5 y27 ff4 fs2 fc1 sc0 ls0 ws4c">probability of the effect occur<span class="_ _1"></span>ring in the absence of any int<span class="_ _0"></span>er<span class="_ _1"></span>vention). </div><div class="t m0 x2 h5 y28 ff4 fs2 fc1 sc0 ls0 ws94">Se<span class="_ _1"></span>veral times a ver<span class="_ _1"></span>y small number i<span class="_ _1"></span>s still a small number<span class="_ _14"></span>, wherea<span class="_ _1"></span>s a </div><div class="t m0 x2 h5 y29 ff4 fs2 fc1 sc0 ls0 ws32">small increas<span class="_ _1"></span>e in the relative <span class="_ _0"></span>risk of something common could be </div><div class="t m0 x2 h5 y2a ff4 fs2 fc1 sc0 ls0 wsb">important<span class="_ _1"></span>. This is illustrated by the comparison made in T<span class="_ _14"></span>able<span class="_ _8"></span>2.2, </div><div class="t m0 x2 h5 y2b ff4 fs2 fc1 sc0 ls0 ws2e">showing that many mor<span class="_ _0"></span>e extra cases will o<span class="_ _1"></span>ccur in the situation where </div><div class="t m0 x2 h5 y2c ff4 fs2 fc1 sc0 ls0 ws0">the baseline risk is hig<span class="_ _1"></span>h.</div><div class="t m0 x4 h5 y2d ff4 fs2 fc1 sc0 ls0 ws90">The fundamental problem with measur<span class="_ _1"></span>ing safety is that it is much </div><div class="t m0 x2 h5 y2e ff4 fs2 fc1 sc0 ls0 ws95">more difficult to determine that an effec<span class="_ _1"></span>t is absent than to measure </div><div class="t m0 x2 h5 y2f ff4 fs2 fc1 sc0 ls0 ws96">one that is present. W<span class="_ _14"></span>e may be hoping or expe<span class="_ _1"></span>cting to obser<span class="_ _d"></span>ve no </div><div class="t m0 x2 h5 y30 ff4 fs2 fc1 sc0 ls5 ws97">effect but if nothing go<span class="_ _1"></span>es wrong<span class="_ _1"></span>, do<span class="_ _1"></span>es that mean ever<span class="_ _d"></span>ything is </div><div class="t m0 x2 h5 y31 ff4 fs2 fc1 sc0 ls5 ws5">allright?</div><div class="t m0 x4 h5 y32 ff4 fs2 fc1 sc0 ls0 ws0">The <span class="_ _d"></span><span class="ff7 ws98">rule of three<span class="ff4"> is a simple and usef<span class="_ _1"></span>ul tool when zero ca<span class="_ _1"></span>ses have </span></span></div><div class="t m0 x2 h5 y33 ff4 fs2 fc1 sc0 ls0 ws99">be<span class="_ _1"></span>en obser<span class="_ _1"></span>ve<span class="_ _1"></span>d in a define<span class="_ _1"></span>d population (NB it c<span class="_ _1"></span>annot be use<span class="_ _1"></span>d if any </div><div class="t m0 x2 h5 y34 ff4 fs2 fc1 sc0 ls0 ws9a">cas<span class="_ _1"></span>es have occurred). Simply dividing the si<span class="_ _1"></span>ze of population by 3 </div><div class="t m0 x2 h5 y35 ff4 fs2 fc1 sc0 ls0 ws3d">appro<span class="_ _0"></span>ximates an upper 95% confidence limit. In practice, this is the </div><div class="t m0 x2 h5 y36 ff4 fs2 fc1 sc0 ls0 ws9b">highest value that<span class="_ _1"></span>, statistically<span class="_ _2"></span>, is re<span class="_ _1"></span>asonably likely to represent the </div><div class="t m0 x2 h5 y37 ff4 fs2 fc1 sc0 ls0 ws9c">truth. F<span class="_ _0"></span>or example, if 900 patien<span class="_ _0"></span>ts use a ne<span class="_ _1"></span>w antibiotic and 0 allergic </div><div class="t m0 x2 h5 y38 ff4 fs2 fc1 sc0 ls0 ws2a">reactions occur<span class="_ _2"></span>, then it is statistically unlikely that such reactions will </div><div class="t m0 x2 h5 y39 ff4 fs2 fc1 sc0 ls0 ws0">occur more frequently than 1 in 300 patients (i.e. 1 in 900/3).</div><div class="t m0 x4 h5 y3a ff4 fs2 fc1 sc0 lsd ws20">The rule of three works ver<span class="_ _1"></span>y well provide<span class="_ _1"></span>d the size of the population is<span class="_ _1"></span> </div><div class="t m0 x2 h5 y3b ff4 fs2 fc1 sc0 lsd ws0">at least 30 and thus<span class="_ _1"></span>, in the cont<span class="_ _0"></span>ext of drug safety<span class="_ _2"></span>, it usually is applicable.</div><div class="t m0 x2 ha ydb ff1 fs6 fc0 sc0 ls0 ws0">T<span class="_ _2"></span>able2.2 <span class="_ _11"> </span><span class="ff9 fc1">Comparison between the number of extra cases produced by diff<span class="_ _0"></span>ering </span></div><div class="t m0 x2 ha ydc ff9 fs6 fc1 sc0 ls0 ws0">relative risks acc<span class="_ _0"></span>ording to the level of baseline risk.</div><div class="t m0 x3 h2 ydd ff1 fs0 fc1 sc0 ls0 ws0">Baseline risk<span class="_ _20"> </span>Relative risk<span class="_ _21"> </span>Extra cases per million</div><div class="t m0 x3 hb yde ff4 fs6 fc1 sc0 ls0 ws0">1 in 100 (common)<span class="_ _22"> </span>1.1 (small increase)<span class="_ _23"> </span>1000</div><div class="t m0 x3 hb ydf ff4 fs6 fc1 sc0 ls0 ws0">1 in 1 <span class="_ _14"></span>000 <span class="_ _14"></span>000 (very rare)<span class="_ _24"> </span>10 (large increase)<span class="_ _25"> </span>10</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfa" class="pf w0 h0" data-page-no="a"><div class="pc pca w0 h0"><img class="bi x5 y0 w1 h8" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAiCAIAAAD6eJ9FAAAACXBIWXMAABYlAAAWJQFJUiTwAAAADElEQVQI12NgGEkAAADuAAGm0YQWAAAAAElFTkSuQmCC"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">28</span></div><div class="t m0 x6 h7 y62 ff5 fs4 fc2 sc0 ls0 ws0">Safety inPractice</div><div class="t m0 x6 h5 y63 ff4 fs2 fc1 sc0 ls0 ws0">There ar<span class="_ _0"></span>e two basic components to safety<span class="_ _1"></span>:</div><div class="t m0 x7 h5 ye0 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws9d">Intrinsic safety<span class="ff4 ws0"> <span class="_ _8"></span><span class="ffa"></span><span class="ws9d"> s<span class="_ _1"></span>ome drugs are intrinsically and obv<span class="_ _1"></span>iously safer </span></span></span></div><div class="t m0 x8 h5 ye1 ff4 fs2 fc1 sc0 ls0 ws9e">than others at t<span class="_ _0"></span>herapeutic dose<span class="_ _1"></span>s<span class="_ _1"></span>. F<span class="_ _0"></span>or example, t<span class="_ _0"></span>he adverse reactions </div><div class="t m0 x8 h5 ye2 ff4 fs2 fc1 sc0 ls0 ws0">produced by paracetamol compared w<span class="_ _1"></span>ith cy<span class="_ _1"></span>totoxic drugs<span class="_ _1"></span>.</div><div class="t m0 x7 h5 ye3 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 ws5c">Userdependent safety<span class="ff4 ws0"> <span class="_ _0"></span><span class="ffa"><span class="ff4 ws5c"> the safety of a drug can als<span class="_ _1"></span>o depend on how </span></span></span></span></div><div class="t m0 x8 h5 ye4 ff4 fs2 fc1 sc0 ls0 ws9f">it is use<span class="_ _1"></span>d. F<span class="_ _0"></span>or example, monit<span class="_ _0"></span>oring white bloo<span class="_ _1"></span>d cell coun<span class="_ _0"></span>t in users </div><div class="t m0 x8 h5 ye5 ff4 fs2 fc1 sc0 ls0 wsa0">of clozapine can complete<span class="_ _0"></span>ly prevent reduction in white bloo<span class="_ _1"></span>d cells </div><div class="t m0 x8 h5 ye6 ff4 fs2 fc1 sc0 ls0 wsa1">to a level that would potentially have fatal consequences. Using </div><div class="t m0 x8 h5 ye7 ff4 fs2 fc1 sc0 ls0 ws3f">thedrug w<span class="_ _1"></span>ithout such monitoring is therefore c<span class="_ _0"></span>learly less safe than </div><div class="t m0 x8 h5 ye8 ff4 fs2 fc1 sc0 ls0 ws84">following the recommended procedure. Another example of safety </div><div class="t m0 x8 h5 ye9 ff4 fs2 fc1 sc0 ls0 wsa2">being userde<span class="_ _1"></span>pendent would be g<span class="_ _1"></span>iving p<span class="_ _1"></span>enicillin to someone who is </div><div class="t m0 x8 h5 yea ff4 fs2 fc1 sc0 ls0 ws0">allergic to it, p<span class="_ _1"></span>erhaps bec<span class="_ _1"></span>ause that information has been ig<span class="_ _1"></span>nored or </div><div class="t m0 x8 h5 yeb ff4 fs2 fc1 sc0 ls0 wsa3">is not available. In such a case, the safeg<span class="_ _1"></span>uard (i.e. means of minimis<span class="ws0">-</span></div><div class="t m0 x8 h5 yec ff4 fs2 fc1 sc0 ls0 ws4">ing the risk) is avoidance of a specif<span class="_ _1"></span>ic drug in a par<span class="_ _1"></span>ticular individu<span class="_ _1"></span>al. </div><div class="t m0 x8 h5 yed ff4 fs2 fc1 sc0 ls0 ws22">Using an appr<span class="_ _0"></span>opriate dose of medic<span class="_ _1"></span>ine is an example of practising </div><div class="t m0 x8 h5 yee ff4 fs2 fc1 sc0 ls0 ws0">risk minimisation that applies to most thera<span class="_ _0"></span>peutic situations<span class="_ _1"></span>.</div><div class="t m0 x8 h5 y74 ff4 fs2 fc1 sc0 ls0 ws27">The amount of saf<span class="_ _0"></span>ety knowledge avail<span class="_ _1"></span>able for a drug depends on </div><div class="t m0 x6 h5 y75 ff4 fs2 fc1 sc0 ls0 ws8a">how much it has been studie<span class="_ _1"></span>d and use<span class="_ _1"></span>d. Broadly<span class="_ _2"></span>, there are four cat<span class="_ _0"></span>e<span class="ws0">-</span></div><div class="t m0 x6 h5 yef ff4 fs2 fc1 sc0 ls0 ws0">gories of safety in resp<span class="_ _1"></span>ect of the amount of knowle<span class="_ _1"></span>dge available:</div><div class="t m0 x6 h5 yf0 ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="ff7 fc1">W<span class="_ _2"></span>elle<span class="_ _1"></span>stablished<span class="ff4">  <span class="ffa"></span><span class="wsa4"> drugs that have been widely use<span class="_ _1"></span>d for many </span></span></span></div><div class="t m0 xb h5 yf1 ff4 fs2 fc1 sc0 ls0 ws98">(~<span class="_ _d"></span>20+) ye<span class="_ _1"></span>ars for which it is unlikely tha<span class="_ _0"></span>t <span class="ff7">completely u<span class="_ _0"></span>nidentified<span class="ff4 ws0"> </span></span></div><div class="t m0 xb h5 yf2 ff4 fs2 fc1 sc0 ls0 ws0">safety issues will emerge.</div><div class="t m0 x6 h5 yf3 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="ff7 fc1 ws6f">E<span class="_ _1"></span>stablished <span class="ff4"> drug<span class="_ _1"></span>s for which there is a substantial body of e<span class="_ _1"></span>vi<span class="ws0">-</span></span></span></div><div class="t m0 xb h5 yf4 ff4 fs2 fc1 sc0 ls0 ws0">dence of safety in clinical use but not enough to meet le<span class="_ _1"></span>vel 1.</div><div class="t m0 x6 h5 yf5 ff4 fs2 fc0 sc0 ls0 ws0">3) <span class="_ _9"> </span><span class="ff7 fc1">P<span class="_ _1"></span>rovi<span class="_ _1"></span>sional<span class="ff4"> <span class="ffa"></span><span class="ws8b"> all newly authorise<span class="_ _1"></span>d drug<span class="_ _1"></span>s until they have been us<span class="_ _1"></span>ed </span></span></span></div><div class="t m0 xb h5 yf6 ff4 fs2 fc1 sc0 ls0 wsa5">fairly extensive<span class="_ _0"></span>ly in ordinar<span class="_ _1"></span>y practice over a perio<span class="_ _1"></span>d of at least </div><div class="t m0 xb h5 yf7 ff4 fs2 fc1 sc0 ls0 ws10">5<span class="_ _8"></span>years<span class="_ _1"></span>. Dur<span class="_ _1"></span>ing this perio<span class="_ _1"></span>d such drugs are nor<span class="_ _1"></span>mally under <span class="ff7 ws0">addi-</span></div><div class="t m0 xb h5 yf8 ff7 fs2 fc1 sc0 ls0 ws80">tional monitoring<span class="ff4"> (see Glossar<span class="_ _1"></span>y) and their safety in ordinar<span class="_ _1"></span>y prac<span class="ws0">-</span></span></div><div class="t m0 xb h5 yf9 ff4 fs2 fc1 sc0 ls0 ws0">tice needs to b<span class="_ _1"></span>e studied proactively<span class="_ _2"></span>.</div><div class="t m0 x6 h5 yfa ff4 fs2 fc0 sc0 ls0 ws0">4) <span class="_ _9"> </span><span class="ff7 fc1 ls3 ws2e">Limite<span class="_ _1"></span>d</span><span class="fc1">  <span class="ffa"></span><span class="wsa6"> all in<span class="_ _0"></span>vestigational drug<span class="_ _1"></span>s and the following situations </span></span></div><div class="t m0 xb h5 yfb ff4 fs2 fc1 sc0 ls0 ws0">where the drug might be authorise<span class="_ _1"></span>d on limited safety information:</div><div class="t m0 x11 h5 yfc ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ws1e">Small populations eligible for treatment (<span class="_ _0"></span>e.g<span class="_ _1"></span>. rare disea<span class="_ _1"></span>ses<span class="_ _1"></span>, treat<span class="ws0">-</span></span></div><div class="t m0 x12 h5 yfd ff4 fs2 fc1 sc0 ls0 wsa7">ments for which are known as <span class="ff7">or<span class="_ _1"></span>phan drugs</span>). An example is </div><div class="t m0 x12 h5 yfe ff4 fs2 fc1 sc0 ls0 ws81">Gaucher<span class="_ _2"></span>s dise<span class="_ _1"></span>ase, a ly<span class="_ _1"></span>sosomal storage dis<span class="_ _1"></span>order<span class="_ _14"></span>, which is usually </div><div class="t m0 x12 h5 yff ff4 fs2 fc1 sc0 ls0 ws0">treated with a recombinant glucocerebrosidase.</div><div class="t m0 x11 h5 y100 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ws96">Drugs w<span class="_ _1"></span>ith important benef<span class="_ _1"></span>its or where there is great clinical </span></div><div class="t m0 x12 h5 y101 ff4 fs2 fc1 sc0 ls0 wsa8">nee<span class="_ _1"></span>d (i.e. situations where potentially large risks might be </div><div class="t m0 x12 h5 y102 ff4 fs2 fc1 sc0 ls0 ws0"> <span class="_ _3"></span>acceptable, such as in adv<span class="_ _1"></span>anced cancer).</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfb" class="pf w0 h0" data-page-no="b"><div class="pc pcb w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">29</span></div><div class="t m0 x4 h5 y1d ff4 fs2 fc1 sc0 ls0 ws18">A logical pr<span class="_ _1"></span>inciple following from this categori<span class="_ _1"></span>sation is that <span class="ff7 lsb ws6c">all</span> use </div><div class="t m0 x2 h5 y1e ff4 fs2 fc1 sc0 ls0 ws5">of drugs in c<span class="_ _1"></span>ategor<span class="_ _1"></span>y 4 should be ass<span class="_ _1"></span>ociated w<span class="_ _1"></span>ith systematic collection </div><div class="t m0 x2 h5 y1f ff4 fs2 fc1 sc0 ls0 ws0">of safety information.</div><div class="t m0 x4 h5 y44 ff4 fs2 fc1 sc0 ls0 wsa9">It is im<span class="_ _0"></span>por<span class="_ _1"></span>tant to recognise that drugs in the wellestablishe<span class="_ _1"></span>d </div><div class="t m0 x2 h5 y45 ff4 fs2 fc1 sc0 ls0 ws18"> <span class="_ _3"></span>categor<span class="_ _1"></span>y are not necessarily safer than those in lower categorie<span class="_ _1"></span>s (and </div><div class="t m0 x2 h5 y46 ff4 fs2 fc1 sc0 ls0 ws0">so on), only that more information is a<span class="_ _0"></span>vailable about their safety<span class="_ _2"></span>.</div><div class="t m0 x2 h7 y103 ff5 fs4 fc2 sc0 ls0 ws0">RiskBenefit Balance</div><div class="t m0 x2 h5 y104 ff4 fs2 fc1 sc0 ls0 ws8e">As absolute safety is an unattainable goal, the aim is to use medic<span class="_ _1"></span>ines </div><div class="t m0 x2 h5 y105 ff4 fs2 fc1 sc0 ls0 ws8d">with an <span class="ff7">acceptable level of safet<span class="_ _1"></span>y</span>. V<span class="_ _2"></span>arious factors ne<span class="_ _1"></span>ed to b<span class="_ _1"></span>e consid<span class="ws0">-</span></div><div class="t m0 x2 h5 y85 ff4 fs2 fc1 sc0 ls0 ws0">ered in judging whether safety is or i<span class="_ _1"></span>s not acceptable:</div><div class="t m0 x3 h5 y106 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">The level of <span class="ff7">absolute</span> risk(s) and the potential health consequences<span class="_ _1"></span>.</span></div><div class="t m0 x3 h5 y107 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">The benefit(s) expecte<span class="_ _1"></span>d, also me<span class="_ _1"></span>asured in abs<span class="_ _1"></span>olute terms.</span></div><div class="t m0 x3 h5 y108 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">The seriousness of the dise<span class="_ _1"></span>ase for which treatment is given.</span></div><div class="t m0 x3 h5 y109 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1">The risks and benef<span class="_ _1"></span>its of alternative approaches<span class="_ _1"></span>.</span></div><div class="t m0 x3 h5 y10a ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff4 fs2 fc1 ws10">The perspe<span class="_ _1"></span>ctive and circumstances of the individual who i<span class="_ _1"></span>s to be </span></div><div class="t m0 x4 h5 y10b ff4 fs2 fc1 sc0 ls3 ws2e">expo<span class="_ _1"></span>se<span class="_ _1"></span>d<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y10c ff4 fs2 fc1 sc0 ls0 wsaa">In practice, therefor<span class="_ _0"></span>e, whether safety is acceptable cannot be </div><div class="t m0 x2 h5 y10d ff4 fs2 fc1 sc0 ls0 ws73">divorced from effic<span class="_ _1"></span>ac<span class="_ _1"></span>y and expecte<span class="_ _1"></span>d benefit<span class="_ _1"></span>s<span class="_ _1"></span>. The harms and benefit<span class="_ _1"></span>s </div><div class="t m0 x2 h5 y10e ff4 fs2 fc1 sc0 ls0 ws0">of a medicine are balance<span class="_ _1"></span>d at two levels<span class="_ _1"></span>:</div><div class="t m0 x2 h5 y10f ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="ff7 fc1 ws2e">Population le<span class="_ _1"></span>vel<span class="ff4">this i<span class="_ _1"></span>s a regulator<span class="_ _1"></span>y and rese<span class="_ _1"></span>archbase<span class="_ _1"></span>d task and </span></span></div><div class="t m0 xd h5 y110 ff4 fs2 fc1 sc0 ls0 wsab">a question of whether<span class="_ _14"></span>, overall, the b<span class="_ _1"></span>enefits that will accrue f<span class="_ _1"></span>rom </div><div class="t m0 xd h5 y111 ff4 fs2 fc1 sc0 ls0 ws0">availability of a medicine will exceed the expec<span class="_ _1"></span>ted harms<span class="_ _1"></span>.</div><div class="t m0 x2 h5 y112 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="ff7 fc1 wsac">Individual level<span class="ff4">this is made by the clinician in consultation with </span></span></div><div class="t m0 xd h5 y113 ff4 fs2 fc1 sc0 ls0 ws61">the patient and takes int<span class="_ _0"></span>o account factors such as the patien<span class="_ _0"></span>t<span class="_ _2"></span>s pre<span class="ws0">-</span></div><div class="t m0 xd h5 y114 ff4 fs2 fc1 sc0 ls0 wsad">vious treatment, dis<span class="_ _1"></span>eas<span class="_ _1"></span>e se<span class="_ _1"></span>verity and the patient<span class="_ _14"></span>s c<span class="_ _1"></span>ircumstances </div><div class="t m0 xd h5 y115 ff4 fs2 fc1 sc0 ls0 ws0">and preferenc<span class="_ _0"></span>es<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y116 ff4 fs2 fc1 sc0 lse ws8b">The process of balancing harms and b<span class="_ _1"></span>enefits i<span class="_ _1"></span>s a judgemental one </div><div class="t m0 x2 h5 y117 ff4 fs2 fc1 sc0 lse wsae">and an element of judgemen<span class="_ _0"></span>t is always likely to remain, despite </div><div class="t m0 x2 h5 y118 ff4 fs2 fc1 sc0 lse ws15">promising attem<span class="_ _0"></span>pts that have been made to develop mathematical </div><div class="t m0 x2 h5 y97 ff4 fs2 fc1 sc0 lse wsaf">tools to aid the process at the population level. The term risk <span class="_ _10"></span>b<span class="_ _1"></span>enefit </div><div class="t m0 x2 h5 y98 ff4 fs2 fc1 sc0 lse wsb0">ratio has often be<span class="_ _1"></span>en use<span class="_ _1"></span>d but is b<span class="_ _1"></span>est avoided. A ratio implies one </div><div class="t m0 x2 h5 y99 ff4 fs2 fc1 sc0 lse wsb1">number divide<span class="_ _1"></span>d by another and even if two simple numbers were </div><div class="t m0 x2 h5 y9a ff4 fs2 fc1 sc0 lse ws61">available to summarise risk<span class="_ _1"></span>s and benef<span class="_ _1"></span>its<span class="_ _1"></span>, what would a ratio of, say<span class="_ _14"></span>, </div><div class="t m0 x2 h5 y9b ff4 fs2 fc1 sc0 lse ws2e">1.5 mean? Conceptually it is preferable to use an additive process in </div><div class="t m0 x2 h5 y9c ff7 fs2 fc1 sc0 lse wsb2">ri<span class="_ _1"></span>sk<span class="_ _0"></span>benefit a<span class="_ _1"></span>ssessment<span class="ff4"> and the resulting balance b<span class="_ _1"></span>ecomes analo<span class="ls0 ws0">-</span></span></div><div class="t m0 x2 h5 y9d ff4 fs2 fc1 sc0 lse wsae">gous to a financial bal<span class="_ _1"></span>ance, which is either positive or negative. </div><div class="t m0 x2 h5 y9e ff4 fs2 fc1 sc0 lsf ws97">Ideally<span class="_ _2"></span>, a balance shee<span class="_ _1"></span>t<span class="_ _c"> </span>would be constructed and the debits </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfc" class="pf w0 h0" data-page-no="c"><div class="pc pcc w0 h0"><img class="bi x5 y0 w1 h8" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAiCAIAAAD6eJ9FAAAACXBIWXMAABYlAAAWJQFJUiTwAAAADElEQVQI12NgGEkAAADuAAGm0YQWAAAAAElFTkSuQmCC"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">30</span></div><div class="t m0 x6 h5 y1d ff4 fs2 fc1 sc0 lse wsb3">(i<span class="_ _1"></span>.e<span class="_ _1"></span>.<span class="_ _1e"> </span>th<span class="_ _1"></span>e<span class="_ _1"></span> ADR<span class="_ _1"></span>s) would be  <span class="_ _4"></span>subtracte<span class="_ _1"></span>d from the credits (i.e. the </div><div class="t m0 x6 h5 y1e ff4 fs2 fc1 sc0 lse ws68">expected b<span class="_ _1"></span>enefit<span class="_ _1"></span>s), it is to be hop<span class="_ _1"></span>ed leaving a p<span class="_ _1"></span>ositive balance. </div><div class="t m0 x6 h5 y1f ff4 fs2 fc1 sc0 lse ws9">The<span class="_ _2"></span>problems are that the credits and debits are not usually me<span class="_ _1"></span>asur<span class="ls0 ws0">-</span></div><div class="t m0 x6 h5 y44 ff4 fs2 fc1 sc0 lse ws83">able in the same way and ther<span class="_ _0"></span>e is often uncertainty about the size of </div><div class="t m0 x6 h5 y45 ff4 fs2 fc1 sc0 lse ws58">some of the entries<span class="_ _1"></span>. Never<span class="_ _1"></span>theless<span class="_ _1"></span>, such an analogy i<span class="_ _1"></span>s helpful in </div><div class="t m0 x6 h5 y46 ff4 fs2 fc1 sc0 lse ws79">assessing whe<span class="_ _1"></span>ther to achieve these  <span class="_ _3"></span>benefits it is re<span class="_ _1"></span>asonable (or not) </div><div class="t m0 x6 h5 y47 ff4 fs2 fc1 sc0 lse ws0">to accept these risks of harm.</div><div class="t m0 x6 h7 y119 ff5 fs4 fc2 sc0 ls0 ws0">Lack ofBenefit</div><div class="t m0 x6 h5 y11a ff4 fs2 fc1 sc0 ls0 ws2a">The efficac<span class="_ _1"></span>y and effe<span class="_ _1"></span>ctiveness of dr<span class="_ _1"></span>ugs is not considered in any detail </div><div class="t m0 x6 h5 y11b ff4 fs2 fc1 sc0 ls0 wsb4">in this book b<span class="_ _1"></span>e<span class="_ _1"></span>cause pharmacovig<span class="_ _1"></span>ilance is primarily ab<span class="_ _1"></span>out clinical </div><div class="t m0 x6 h5 y11c ff4 fs2 fc1 sc0 ls0 ws75">safety of medicine<span class="_ _1"></span>s. Howe<span class="_ _1"></span>ver<span class="_ _2"></span>, the ex<span class="_ _0"></span>pe<span class="_ _1"></span>cted b<span class="_ _1"></span>enefits of a dr<span class="_ _1"></span>ug are an </div><div class="t m0 x6 h5 y11d ff4 fs2 fc1 sc0 ls0 wsb5">important fac<span class="_ _1"></span>tor when considering whether safety is acceptable, and </div><div class="t m0 x6 h5 y11e ff4 fs2 fc1 sc0 ls0 wsb6">the overall balance of risks and b<span class="_ _1"></span>enefit<span class="_ _1"></span>s for at least one indication </div><div class="t m0 x6 h5 y11f ff4 fs2 fc1 sc0 ls0 wsb7">must be considered po<span class="_ _1"></span>sitive if a drug is to remain on the market. </div><div class="t m0 x6 h5 y120 ff4 fs2 fc1 sc0 ls0 wsa0">Conversely<span class="_ _14"></span>, when a dr<span class="_ _1"></span>ug is initially launched there must be e<span class="_ _1"></span>vidence </div><div class="t m0 x6 h5 y121 ff4 fs2 fc1 sc0 ls0 ws3">of effic<span class="_ _1"></span>ac<span class="_ _1"></span>y and potential benefit<span class="_ _1"></span>, but this do<span class="_ _1"></span>es not mean that the drug </div><div class="t m0 x6 h5 y122 ff4 fs2 fc1 sc0 ls0 ws90">will be b<span class="_ _1"></span>enefici<span class="_ _1"></span>al to all patients (many drugs do not work in surpris<span class="_ _1"></span><span class="ws0">-</span></div><div class="t m0 x6 h5 y123 ff4 fs2 fc1 sc0 ls0 ws1">ingly high propor<span class="_ _1"></span>tions of patients) or that its real world level of effec<span class="ws0">-</span></div><div class="t m0 x6 h5 y124 ff4 fs2 fc1 sc0 ls0 ws5c">tiveness will b<span class="_ _1"></span>e suffic<span class="_ _1"></span>ient for the risk<span class="_ _2"></span>b<span class="_ _1"></span>enefit bal<span class="_ _1"></span>ance to be considered </div><div class="t m0 x6 h5 y125 ff4 fs2 fc1 sc0 ls0 ws0">positive, or remain constant over time.</div><div class="t m0 x8 h5 y126 ff4 fs2 fc1 sc0 lse ws9b">The development of resistance to antibiotics is a good example </div><div class="t m0 x6 h5 y127 ff4 fs2 fc1 sc0 lse wsb8">ofdiminishing effec<span class="_ _1"></span>tiveness<span class="_ _1"></span>. If there is no longer any ex<span class="_ _0"></span>pec<span class="_ _1"></span>tation of </div><div class="t m0 x6 h5 y128 ff4 fs2 fc1 sc0 lse wsb9"> <span class="_ _10"></span>b<span class="_ _1"></span>enefit<span class="_ _1"></span>, then there can be no le<span class="_ _1"></span>vel of safety that will lead to a positive </div><div class="t m0 x6 h5 y129 ff4 fs2 fc1 sc0 lse wsba">riskbenefit balance. At t<span class="_ _0"></span>he individual le<span class="_ _1"></span>vel, lack of effic<span class="_ _1"></span>ac<span class="_ _1"></span>y can </div><div class="t m0 x6 h5 y57 ff4 fs2 fc1 sc0 lse wsbb">sometimes b<span class="_ _1"></span>e regarded a<span class="_ _1"></span>s having serious safety implications (and </div><div class="t m0 x6 h5 y58 ff4 fs2 fc1 sc0 lse ws8e">therefore poten<span class="_ _0"></span>tially repor<span class="_ _1"></span>table as a susp<span class="_ _1"></span>ec<span class="_ _1"></span>ted ADR), for example if </div><div class="t m0 x6 h5 y59 ff4 fs2 fc1 sc0 lse wsbc">contraceptive pr<span class="_ _0"></span>oduct<span class="_ _1"></span>s or de<span class="_ _1"></span>vices fail, resulting in unintended </div><div class="t m0 x6 h5 y5a ff4 fs2 fc1 sc0 lse ws61">pregnancies<span class="_ _1"></span>.</div><div class="t m0 x6 h6 yd6 ff1 fs3 fc0 sc0 ls0 wsbd"> Causation<span class="_ _14"></span>WastheDrug <span class="_ _11"> </span>Responsible?</div><div class="t m0 x6 h5 yc9 ff4 fs2 fc1 sc0 ls1 ws5c">De<span class="_ _1"></span>ciding whether a drug is resp<span class="_ _1"></span>onsible for an AE is ver<span class="_ _1"></span>y of<span class="_ _1"></span>ten the most </div><div class="t m0 x6 h5 yca ff4 fs2 fc1 sc0 ls1 wsab">important question f<span class="_ _1"></span>acing scientist<span class="_ _1"></span>s working in the field of pharma<span class="ls0 ws0">-</span></div><div class="t m0 x6 h5 ycb ff4 fs2 fc1 sc0 ls1 ws78">covigilance. Y<span class="_ _14"></span>et<span class="_ _1"></span>, it is rarely complete<span class="_ _0"></span>ly straightforw<span class="_ _1"></span>ard, whether the </div><div class="t m0 x6 h5 ycc ff4 fs2 fc1 sc0 ls1 wsb"> <span class="_ _a"></span>mat<span class="_ _0"></span>ter is being considered at the level of an individual p<span class="_ _1"></span>atient or in </div><div class="t m0 x6 h5 ycd ff4 fs2 fc1 sc0 ls1 wsbe">terms of study data for various p<span class="_ _1"></span>opulations. A<span class="_ _1"></span>s in the cas<span class="_ _1"></span>e of risk </div><div class="t m0 x6 h5 yce ff4 fs2 fc1 sc0 ls1 wsbf">benefit a<span class="_ _1"></span>ssessment<span class="_ _1"></span>, a judgement is often necessar<span class="_ _d"></span>y and there ar<span class="_ _0"></span>e </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfd" class="pf w0 h0" data-page-no="d"><div class="pc pcd w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">31</span></div><div class="t m0 x2 h5 y1d ff4 fs2 fc1 sc0 ls1 wsc0">some  <span class="_ _10"></span>principles to be applie<span class="_ _1"></span>d. There ar<span class="_ _0"></span>e some similaritie<span class="_ _1"></span>s in approach </div><div class="t m0 x2 h5 y1e ff4 fs2 fc1 sc0 ls1 wsc1">betwe<span class="_ _1"></span>en the two levels mentioned, although the<span class="_ _1"></span>y are considered </div><div class="t m0 x2 h5 y1f ff4 fs2 fc1 sc0 ls1 wsc2"> separately <span class="_ _1c"> </span>here.</div><div class="t m0 x2 h7 y45 ff5 fs4 fc2 sc0 ls0 ws0">Causality Assessment inIndividual Cases</div><div class="t m0 x2 h5 y22 ff4 fs2 fc1 sc0 ls0 wsc3">Many causality algorithms and categorisation systems have been </div><div class="t m0 x2 h5 y23 ff4 fs2 fc1 sc0 ls0 ws6d"> <span class="_ _3"></span>proposed but none ha<span class="_ _1"></span>s gained universal acceptance, and the value of </div><div class="t m0 x2 h5 y24 ff4 fs2 fc1 sc0 ls0 ws7c">assessing this for e<span class="_ _1"></span>ach individual repor<span class="_ _1"></span>t of a susp<span class="_ _1"></span>ecte<span class="_ _1"></span>d ADR has b<span class="_ _1"></span>een </div><div class="t m0 x2 h5 y25 ff4 fs2 fc1 sc0 ls0 wsc4">questioned. It may be more efficient to reser<span class="_ _1"></span>ve such asse<span class="_ _1"></span>ssment for a </div><div class="t m0 x2 h5 y26 ff4 fs2 fc1 sc0 ls0 wsc5">series of c<span class="_ _1"></span>ase<span class="_ _1"></span>s which might represent a new and/or impor<span class="_ _1"></span>tant safety </div><div class="t m0 x2 h5 y27 ff4 fs2 fc1 sc0 ls0 ws73">issue. Systematic assessment of causality in individual ca<span class="_ _1"></span>ses o<span class="_ _1"></span>ccurring </div><div class="t m0 x2 h5 y28 ff4 fs2 fc1 sc0 ls0 wsb5">in clinical trials i<span class="_ _1"></span>s generally a weaker approach to assessing causality </div><div class="t m0 x2 h5 y29 ff4 fs2 fc1 sc0 ls0 wsc6">than comparison of numerical counts<span class="_ _1"></span>. However<span class="_ _2"></span>, in postmarketing </div><div class="t m0 x2 h5 y2a ff4 fs2 fc1 sc0 ls0 wsc7">sur<span class="_ _1"></span>veillance, and espe<span class="_ _1"></span>cially in pres<span class="_ _1"></span>criptione<span class="_ _1"></span>vent monitoring (PEM) </div><div class="t m0 x2 h5 y2b ff4 fs2 fc1 sc0 ls0 wsc0">studies (see Chapter3), causality a<span class="_ _1"></span>ssessment of individual A<span class="_ _1"></span>Es can b<span class="_ _1"></span>e </div><div class="t m0 x2 h5 y2c ff4 fs2 fc1 sc0 ls0 ws28">important in determining which may be related to the medicine and </div><div class="t m0 x2 h5 y2d ff4 fs2 fc1 sc0 ls0 ws0">which represent background clinical events<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y2e ff4 fs2 fc1 sc0 ls0 wsc8">When individual ca<span class="_ _1"></span>se causality a<span class="_ _1"></span>ssessment is to be p<span class="_ _1"></span>erforme<span class="_ _1"></span>d, there </div><div class="t m0 x2 h5 y2f ff4 fs2 fc1 sc0 ls0 wsb9">are usually four categories into which a case might b<span class="_ _1"></span>e placed following </div><div class="t m0 x2 h5 y30 ff4 fs2 fc1 sc0 ls0 ws0">analysis of all available clinical information:</div><div class="t m0 x2 h5 yc6 ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="ff7 fc1">P<span class="_ _1"></span>robable<span class="ff4 ws1c"><span class="_ _6"> </span><span class="_ _1d"> </span>the balance of information a<span class="_ _0"></span>vailable suppor<span class="_ _1"></span>ts causa<span class="ws0">-</span></span></span></div><div class="t m0 xd h5 yc7 ff4 fs2 fc1 sc0 ls0 wsb5">tion. Usually<span class="_ _2"></span>, ev<span class="_ _1"></span>idence of a positive rechallenge (reo<span class="_ _1"></span>ccurrence of </div><div class="t m0 xd h5 yd4 ff4 fs2 fc1 sc0 ls0 ws57">the AE on readministration of the same dose of the suspe<span class="_ _1"></span>ct medi<span class="ws0">-</span></div><div class="t m0 xd h5 y90 ff4 fs2 fc1 sc0 ls0 ws0">cine) is require<span class="_ _1"></span>d for this category<span class="_ _0"></span>.</div><div class="t m0 x2 h5 y91 ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="ff7 fc1">Possible<span class="ff4 ws49"><span class="_ _6"> </span><span class="_ _1d"> </span>some of the available information is in favour of and </span></span></div><div class="t m0 xd h5 y92 ff4 fs2 fc1 sc0 ls0 wsc9">some against causation. F<span class="_ _0"></span>or this categor<span class="_ _1"></span>y<span class="_ _2"></span>, usually e<span class="_ _1"></span>vidence of a </div><div class="t m0 xd h5 y93 ff4 fs2 fc1 sc0 ls0 ws8">positive dechallenge (res<span class="_ _1"></span>olution of the AE symptoms after stop<span class="ws0">-</span></div><div class="t m0 xd h5 y94 ff4 fs2 fc1 sc0 ls0 ws0">ping the suspe<span class="_ _1"></span>ct medicine) i<span class="_ _1"></span>s required.</div><div class="t m0 x2 h5 y95 ff4 fs2 fc0 sc0 ls0 ws0">3) <span class="_ _9"> </span><span class="ff7 fc1 ls7 ws36">Unlikely</span><span class="fc1 ws4d"><span class="_ _2"></span>the balance of information available is against causation. </span></div><div class="t m0 xd h5 y96 ff4 fs2 fc1 sc0 ls0 ws51">F<span class="_ _2"></span>or example, it is more likely that ot<span class="_ _0"></span>her factors (e.g. the patient<span class="_ _2"></span>s </div><div class="t m0 xd h5 yd5 ff4 fs2 fc1 sc0 ls0 ws0">condition) have caused the AE<span class="_ _1"></span>.</div><div class="t m0 x2 h5 yd6 ff4 fs2 fc0 sc0 ls0 ws0">4) <span class="_ _9"> </span><span class="ff7 fc1">Unasse<span class="_ _1"></span>ssable<span class="ff4 ws3a"><span class="_ _9"> </span><span class="_ _1c"> </span>a rea<span class="_ _1"></span>sonable judgement cannot be made, of<span class="_ _1"></span>ten </span></span></div><div class="t m0 xd h5 yc8 ff4 fs2 fc1 sc0 ls0 ws0">be<span class="_ _1"></span>cause key infor<span class="_ _1"></span>mation is missing<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y3f ff4 fs2 fc1 sc0 ls0 ws0">In making such judgements there are four br<span class="_ _0"></span>oad areas to consider<span class="_ _1"></span>:</div><div class="t m0 x2 h5 ycb ff4 fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="ff7 fc1 ws22">T<span class="_ _14"></span>emporal relationships<span class="ff4"><span class="_ _1"></span><span class="_ _d"></span>what was the time relationship betwe<span class="_ _1"></span>en </span></span></div><div class="t m0 xd h5 ycc ff4 fs2 fc1 sc0 ls0 wsca">starting treatment and the onset of the event<span class="_ _1"></span>. If treatment was </div><div class="t m0 xd h5 ycd ff4 fs2 fc1 sc0 ls0 ws9b">stopped (<span class="_ _2"></span>de<span class="_ _1"></span>challenge) or restarted (rechallenge), did the e<span class="_ _1"></span>vent </div><div class="t m0 xd h5 yce ff4 fs2 fc1 sc0 ls0 ws0">abate and/or recur?</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pfe" class="pf w0 h0" data-page-no="e"><div class="pc pce w0 h0"><img class="bi x5 y0 w1 h8" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAiCAIAAAD6eJ9FAAAACXBIWXMAABYlAAAWJQFJUiTwAAAADElEQVQI12NgGEkAAADuAAGm0YQWAAAAAElFTkSuQmCC"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">32</span></div><div class="t m0 x6 h5 y1d ff4 fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="ff7 fc1 wscb">Alternative cau<span class="_ _1"></span>ses<span class="ff4"><span class="_ _11"> </span><span class="_ _1c"> </span>are there concomitant diseases and other </span></span></div><div class="t m0 xb h5 y1e ff4 fs2 fc1 sc0 ls0 ws0">medications or nondrug expo<span class="_ _1"></span>sures that could e<span class="_ _0"></span>xplain the event?</div><div class="t m0 x6 h5 y1f ff4 fs2 fc0 sc0 ls0 ws0">3) <span class="_ _9"> </span><span class="ff7 fc1 ws7e">Nature of the event<span class="ff4"><span class="_ _0"></span><span class="_ _2"></span>some clinical e<span class="_ _1"></span>vents are often cause<span class="_ _1"></span>d by drug<span class="_ _1"></span>s </span></span></div><div class="t m0 xb h5 y44 ff4 fs2 fc1 sc0 ls0 wscc">and immediately suggest a relationship (<span class="_ _2"></span>e.g<span class="_ _1"></span>. cert<span class="_ _1"></span>ain typ<span class="_ _1"></span>es of skin </div><div class="t m0 xb h5 y45 ff4 fs2 fc1 sc0 ls0 ws0">reactions such as toxic epidermal nec<span class="_ _1"></span>rolysis; s<span class="_ _1"></span>ee Chapter7).</div><div class="t m0 x6 h5 y46 ff4 fs2 fc0 sc0 ls0 ws0">4) <span class="_ _9"> </span><span class="ff7 fc1 lsb ws6c">Pl<span class="_ _1"></span>au<span class="_ _1"></span>sibility<span class="_ _1"></span></span><span class="fc1 ws12"><span class="_ _1"></span><span class="_ _1"></span>is the reaction already re<span class="_ _1"></span>cognise<span class="_ _1"></span>d with this drug (or </span></div><div class="t m0 xb h5 y47 ff4 fs2 fc1 sc0 ls0 wsa0">similar drug<span class="_ _1"></span>s) or can a biologic<span class="_ _1"></span>al mechanism b<span class="_ _1"></span>e po<span class="_ _1"></span>stulated base<span class="_ _1"></span>d </div><div class="t m0 xb h5 y48 ff4 fs2 fc1 sc0 ls0 ws0">on the pharmacology of the drug?</div><div class="t m0 x8 h5 y25 ff4 fs2 fc1 sc0 ls0 wscd">In terms of temporal asso<span class="_ _1"></span>ciation, sometimes c<span class="_ _1"></span>ausation can be defi<span class="ws0">-</span></div><div class="t m0 x6 h5 y26 ff4 fs2 fc1 sc0 ls0 wsce">nitely ex<span class="_ _2"></span>clude<span class="_ _1"></span>d; for example, ADRs cannot star<span class="_ _1"></span>t before the drug is </div><div class="t m0 x6 h5 y27 ff4 fs2 fc1 sc0 ls0 wsb7">given (although drug<span class="_ _1"></span>s can worsen existing dis<span class="_ _1"></span>eas<span class="_ _1"></span>es). On the other </div><div class="t m0 x6 h5 y28 ff4 fs2 fc1 sc0 ls0 wscf">hand, a positive re<span class="_ _1"></span>challenge in the absence of alternative causes is </div><div class="t m0 x6 h5 y29 ff4 fs2 fc1 sc0 ls0 ws3f"> <span class="_ _3"></span>generally considered to be strong e<span class="_ _1"></span>vidence for causation. While most </div><div class="t m0 x6 h5 y2a ff4 fs2 fc1 sc0 ls0 wsd0">ADRs st<span class="_ _1"></span>art early on in treatment this is not invariably true, a<span class="_ _1"></span>s ref<span class="_ _1"></span>lecte<span class="_ _1"></span>d </div><div class="t m0 x6 h5 y2b ff4 fs2 fc1 sc0 ls0 wsd1">in the time course element of t<span class="_ _0"></span>he Do<span class="_ _2"></span>TS classification already </div><div class="t m0 x6 h5 y2c ff4 fs2 fc1 sc0 ls0 ws0">discuss<span class="_ _1"></span>ed.</div><div class="t m0 x8 h5 y2d ff4 fs2 fc1 sc0 ls0 wsd2">Merely because an alternative cause c<span class="_ _1"></span>an be identifie<span class="_ _1"></span>d does not me<span class="_ _1"></span>an </div><div class="t m0 x6 h5 y2e ff4 fs2 fc1 sc0 ls0 wsd3">that it was responsible. Possible other causes are often calle<span class="_ _1"></span>d </div><div class="t m0 x6 h5 y2f ff4 fs2 fc1 sc0 ls0 wsd4"><span class="_ _14"></span> <span class="_ _26"></span>confounding factors and when they are present, c<span class="_ _1"></span>ases are said to </div><div class="t m0 x6 h5 y30 ff4 fs2 fc1 sc0 ls0 ws8d">be<span class="_ _d"></span><span class="_ _2"></span>confounded<span class="_ _e"></span>. This is rather loose use of the word (see Figure 2.1) </div><div class="t m0 x6 h5 y31 ff4 fs2 fc1 sc0 ls0 ws0">and best avoided.</div><div class="t m0 x8 h5 y32 ff4 fs2 fc1 sc0 ls0 ws3">The issues of nature of t<span class="_ _0"></span>he event and plausibility nee<span class="_ _1"></span>d to be consid<span class="ws0">-</span></div><div class="t m0 x6 h5 y33 ff4 fs2 fc1 sc0 ls0 wsf">ered with some c<span class="_ _1"></span>autionthe<span class="_ _1"></span>se factors may add to the arguments for </div><div class="t m0 x6 h5 y34 ff4 fs2 fc1 sc0 ls0 wsd5">causation, but a clinical event that is not normally known to b<span class="_ _1"></span>e drug</div><div class="t m0 x6 h5 y35 ff4 fs2 fc1 sc0 ls0 ws7e">related or the absence of an<span class="_ _0"></span>y information supporting plausibility is not </div><div class="t m0 x6 h5 y36 ff4 fs2 fc1 sc0 ls0 wsd6">strong evidence against it<span class="_ _1"></span>. Absence of e<span class="_ _1"></span>vidence is not the same as </div><div class="t m0 x6 h5 y37 ff4 fs2 fc1 sc0 ls0 ws0"> <span class="_ _3"></span>e<span class="_ _1"></span>v<span class="_ _1"></span>idence of absence.</div><div class="t m0 x6 h7 y39 ff5 fs4 fc2 sc0 ls0 ws0">Assessing Causality fromClinical <span class="_ _2"></span>T<span class="_ _2"></span>rial Data</div><div class="t m0 x6 h5 y96 ff4 fs2 fc1 sc0 ls0 ws80">One of the main reasons why data from randomise<span class="_ _1"></span>d controlled trials </div><div class="t m0 x6 h5 yd5 ff4 fs2 fc1 sc0 ls0 wsd7">are considered to be the gold standard is that, in principle, ob<span class="_ _1"></span>ser<span class="_ _1"></span>ve<span class="_ _1"></span>d </div><div class="t m0 x6 h5 yd6 ff4 fs2 fc1 sc0 ls0 wsd8">differences betwe<span class="_ _1"></span>en randomise<span class="_ _1"></span>d groups should be attributable to the </div><div class="t m0 x6 h5 yc8 ff4 fs2 fc1 sc0 ls0 wsb8">different treatmen<span class="_ _0"></span>ts (i.e. causal). O<span class="_ _1"></span>ther explanations ar<span class="_ _0"></span>e still possible, </div><div class="t m0 x6 h5 yc9 ff4 fs2 fc1 sc0 ls0 wsd9">for example differ<span class="_ _0"></span>ences could simply be due to chance or ca<span class="_ _0"></span>use<span class="_ _1"></span>d by </div><div class="t m0 x6 h5 yca ff4 fs2 fc1 sc0 ls0 wsda">various bi<span class="_ _1"></span>ase<span class="_ _1"></span>s, p<span class="_ _1"></span>articul<span class="_ _1"></span>arly in relation t<span class="_ _0"></span>o what is being measure<span class="_ _1"></span>d. </div><div class="t m0 x6 h5 ycb ff4 fs2 fc1 sc0 ls0 ws26">Problems with the randomisation ma<span class="_ _0"></span>y also o<span class="_ _1"></span>ccur<span class="_ _2"></span>such as that it ma<span class="_ _0"></span>y </div><div class="t m0 x6 h5 ycc ff4 fs2 fc1 sc0 ls0 ws1a">not have been car<span class="_ _1"></span>rie<span class="_ _1"></span>d out properly<span class="_ _2"></span>. Some<span class="_ _1"></span>times<span class="_ _1"></span>, as a result of bad luck<span class="_ _d"></span>, </div><div class="t m0 x6 h5 ycd ff4 fs2 fc1 sc0 ls0 ws3c">randomisation may not ha<span class="_ _0"></span>ve worked to produce groups that were </div><div class="t m0 x6 h5 yce ff4 fs2 fc1 sc0 ls0 wsdb">adequately balanced at bas<span class="_ _1"></span>eline in terms of important factors that may </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pff" class="pf w0 h0" data-page-no="f"><div class="pc pcf w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">33</span></div><div class="t m0 x2 h5 y1d ff4 fs2 fc1 sc0 ls0 ws3d">predict the outcome of inter<span class="_ _0"></span>est<span class="_ _1"></span>. While all these alternative explana<span class="ws0">-</span></div><div class="t m0 x2 h5 y1e ff4 fs2 fc1 sc0 ls0 wsa2">tions nee<span class="_ _1"></span>d to be considered, when a difference that looks impor<span class="_ _1"></span>tant is </div><div class="t m0 x2 h5 y1f ff4 fs2 fc1 sc0 ls0 ws35">obser<span class="_ _1"></span>ve<span class="_ _1"></span>d in a randomise<span class="_ _1"></span>d trial, c<span class="_ _1"></span>ausation is the most likely e<span class="_ _0"></span>xplana<span class="ws0">-</span></div><div class="t m0 x2 h5 y44 ff4 fs2 fc1 sc0 ls0 ws6d">tion. If the trial has ade<span class="_ _1"></span>quate statistical power (and the obs<span class="_ _1"></span>er<span class="_ _1"></span>ved dif<span class="_ _1"></span><span class="ws0">-</span></div><div class="t m0 x2 h5 y45 ff4 fs2 fc1 sc0 ls0 ws7d">ference is statistically significant), the groups were wellbalanced at </div><div class="t m0 x2 h5 y46 ff4 fs2 fc1 sc0 ls0 wsdc">baseline and the mea<span class="_ _1"></span>surements are objective or blinde<span class="_ _1"></span>d, then no great </div><div class="t m0 x2 h5 y47 ff4 fs2 fc1 sc0 ls0 wsdd">element of judgemen<span class="_ _0"></span>t is required to accept that such a difference </div><div class="t m0 x2 h5 y48 ff4 fs2 fc1 sc0 ls0 ws0">betwe<span class="_ _1"></span>en treatments is likely to be real.</div><div class="t m0 x2 h7 y26 ff5 fs4 fc2 sc0 ls0 ws0">Causality inNonRandomised Studies<span class="_ _2"></span>TheProblems of </div><div class="t m0 x2 h7 y12a ff5 fs4 fc2 sc0 ls0 ws0">BiasandConf<span class="_ _0"></span>ounding</div><div class="t m0 x2 h5 yc2 ff4 fs2 fc1 sc0 ls0 ws22">F<span class="_ _2"></span>or study data that are not randomised, a<span class="_ _1"></span>ssessing c<span class="_ _1"></span>ausation requires </div><div class="t m0 x2 h5 ycf ff4 fs2 fc1 sc0 ls0 ws27">much more judgemen<span class="_ _0"></span>t and is often a source of debate. When such </div><div class="t m0 x2 h5 yd0 ff4 fs2 fc1 sc0 ls0 wsde">studies find a difference, this is known a<span class="_ _1"></span>s an <span class="ff7 ws0">asso<span class="_ _1"></span>ciation</span>. In terms of </div><div class="t m0 x2 h5 yd1 ff4 fs2 fc1 sc0 ls0 wsc">chance, the issues are muc<span class="_ _0"></span>h the same as for randomised tr<span class="_ _1"></span>ials<span class="_ _1"></span>, but </div><div class="t m0 x2 h5 yd2 ff4 fs2 fc1 sc0 ls0 ws6d">there are man<span class="_ _0"></span>y more type<span class="_ _1"></span>s of biase<span class="_ _1"></span>s that ma<span class="_ _0"></span>y be relev<span class="_ _1"></span>ant. In the real </div><div class="t m0 x2 h5 yd3 ff4 fs2 fc1 sc0 ls0 wsdf">world, people tend to do things for a reas<span class="_ _1"></span>on and patients who are </div><div class="t m0 x2 h5 yc3 ff4 fs2 fc1 sc0 ls0 ws12">given par<span class="_ _1"></span>ticular treatments may be selec<span class="_ _1"></span>ted according to factors that </div><div class="t m0 x2 h5 yc4 ff4 fs2 fc1 sc0 ls0 wse0">are relevant to the outc<span class="_ _0"></span>ome of interest. F<span class="_ _0"></span>or example, patien<span class="_ _0"></span>ts using </div><div class="t m0 x2 h5 yc5 ff4 fs2 fc1 sc0 ls0 wse1">coxibs (see Chapter<span class="_ _2"></span>1) are often selecte<span class="_ _1"></span>d on the basis of b<span class="_ _1"></span>eing at higher </div><div class="t m0 x2 h5 yc6 ff4 fs2 fc1 sc0 ls0 wsb4">baseline ri<span class="_ _1"></span>sk of gastrointestinal blee<span class="_ _1"></span>ding than patients using tradi<span class="ws0">-</span></div><div class="t m0 x2 h5 yc7 ff4 fs2 fc1 sc0 ls0 ws51">tional antiinflammator<span class="_ _1"></span>y dr<span class="_ _1"></span>ugs<span class="_ _1"></span>. Nonrandomise<span class="_ _1"></span>d comparative stud<span class="ws0">-</span></div><div class="t m0 x2 h5 yd4 ff4 fs2 fc1 sc0 ls0 ws88">ies that did not address this bias would therefore be likely to (wrongly) </div><div class="t m0 x2 h5 y90 ff4 fs2 fc1 sc0 ls0 ws1a">obser<span class="_ _1"></span>ve the opp<span class="_ _1"></span>osite of what is found in trials<span class="_ _1"></span>. A fur<span class="_ _1"></span>ther potential bias </div><div class="t m0 x2 h5 y91 ff4 fs2 fc1 sc0 ls0 ws1a">is that losses to followup are more like<span class="_ _0"></span>ly than in trials and the reas<span class="_ _1"></span>ons </div><div class="t m0 x2 h5 y92 ff4 fs2 fc1 sc0 ls0 ws43">why people are lost f<span class="_ _1"></span>rom studies may not be random. F<span class="_ _0"></span>or example, </div><div class="t m0 x2 h5 y93 ff4 fs2 fc1 sc0 ls0 wse2">patients could be lost from followup be<span class="_ _1"></span>cause the<span class="_ _1"></span>y have died from </div><div class="t m0 x2 h5 y94 ff4 fs2 fc1 sc0 ls0 ws0">anADR<span class="_ _1"></span>.</div><div class="t m0 x4 h5 y95 ff4 fs2 fc1 sc0 ls0 ws7c">Aside from the greater problem of bias<span class="_ _1"></span>, there is also the problem of </div><div class="t m0 x2 h5 y96 ff7 fs2 fc1 sc0 ls0 ws0">confoundin<span class="_ _0"></span>g<span class="ff4 ws8e"> in nonrandomised studies<span class="_ _1"></span>. A confounder has a tr<span class="_ _1"></span>iangu<span class="ws0">-</span></span></div><div class="t m0 x2 h5 yd5 ff4 fs2 fc1 sc0 ls0 wse">lar relationship with an ex<span class="_ _0"></span>posure (usually a dr<span class="_ _1"></span>ug) and outcome (AE of </div><div class="t m0 x2 h5 yd6 ff4 fs2 fc1 sc0 ls0 ws87">interest;  Figure<span class="_ _8"></span>2.1). When it is present<span class="_ _1"></span>, the risk of the outcome is </div><div class="t m0 x2 h5 yc8 ff4 fs2 fc1 sc0 ls0 ws28">affecte<span class="_ _1"></span>d and whether or not it is present also v<span class="_ _1"></span>aries according to the </div><div class="t m0 x2 h5 yc9 ff4 fs2 fc1 sc0 ls0 wsa3">exposure status. Age is a go<span class="_ _1"></span>od example of a perennial confounder<span class="_ _2"></span>in </div><div class="t m0 x2 h5 yca ff4 fs2 fc1 sc0 ls0 ws16">ver<span class="_ _1"></span>y simple terms, older p<span class="_ _1"></span>eople tend to use more dr<span class="_ _1"></span>ugs and have more </div><div class="t m0 x2 h5 ycb ff4 fs2 fc1 sc0 ls0 wse3">adverse outcomes. Therefore there is a need to be sure that any </div><div class="t m0 x2 h5 ycc ff4 fs2 fc1 sc0 ls0 wse4">obser<span class="_ _1"></span>ve<span class="_ _1"></span>d ass<span class="_ _1"></span>ociation is not simply a consequence of that. A ran<span class="ws0">-</span></div><div class="t m0 x2 h5 ycd ff4 fs2 fc1 sc0 ls0 ws8d">domised study w<span class="_ _1"></span>ill, unless it is small, tend to balance the groups for </div><div class="t m0 x2 h5 yce ff4 fs2 fc1 sc0 ls0 ws72">age<span class="_ _2"></span>or indee<span class="_ _1"></span>d any confounder<span class="_ _2"></span>largely circumven<span class="_ _0"></span>ting this problem. </div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf10" class="pf w0 h0" data-page-no="10"><div class="pc pc10 w0 h0"><img class="bi x5 y12b w5 h10" alt="" src="data:image/png;base64,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"/><div class="t m0 x6 h2 y1c ff8 fs0 fc0 sc0 ls0 ws0">An Introduction to Pharmacovigilance<span class="_ _7"></span><span class="ff1">34</span></div><div class="t m0 x6 h5 y12c ff4 fs2 fc1 sc0 ls0 ws24">In principle, confounding can be de<span class="_ _1"></span>alt with, either in the study design </div><div class="t m0 x6 h5 y12d ff4 fs2 fc1 sc0 ls0 wse5">(e.g. by matching patients or groups so that relevant factors are bal<span class="ws0">-</span></div><div class="t m0 x6 h5 y12e ff4 fs2 fc1 sc0 ls0 wse6">anced) or in the analysis by statistical adjustment<span class="_ _1"></span>. However<span class="_ _2"></span>, to do so </div><div class="t m0 x6 h5 y12f ff4 fs2 fc1 sc0 ls0 ws98">requires that all potential confounders are iden<span class="_ _0"></span>tified and ade<span class="_ _1"></span>quately </div><div class="t m0 x6 h5 y130 ff4 fs2 fc1 sc0 ls0 ws1d">measure<span class="_ _1"></span>d. Smoking is another common confounder and knowledge </div><div class="t m0 x6 h5 y131 ff4 fs2 fc1 sc0 ls0 wsa3">of smoking status in terms of (say) current, ex or nonsmoker is fairly </div><div class="t m0 x6 h5 y132 ff4 fs2 fc1 sc0 ls0 ws19">crude g<span class="_ _1"></span>iven that ther<span class="_ _0"></span>e may be a close relationship between the prec<span class="_ _1"></span>ise </div><div class="t m0 x6 h5 y133 ff4 fs2 fc1 sc0 ls0 ws23">amount smoked and the risk of the outcome. T<span class="_ _2"></span>he p<span class="_ _1"></span>ossibility that con<span class="ws0">-</span></div><div class="t m0 x6 h5 y134 ff4 fs2 fc1 sc0 ls0 ws6b">founding has not be<span class="_ _1"></span>en fully address<span class="_ _1"></span>ed is c<span class="_ _1"></span>alled <span class="ff7">re<span class="_ _1"></span>sidual confoundi<span class="_ _0"></span>ng<span class="ff4 ws0"> </span></span></div><div class="t m0 x6 h5 y135 ff4 fs2 fc1 sc0 ls0 ws92">and this is often a po<span class="_ _1"></span>ssible alternative explanation t<span class="_ _0"></span>o causation when </div><div class="t m0 x6 h5 y136 ff4 fs2 fc1 sc0 ls0 ws0">data come from nonrandomised studies<span class="_ _1"></span>.</div><div class="t m0 x6 h7 y137 ff5 fs4 fc2 sc0 ls0 ws0">Using theBradf<span class="_ _0"></span>ord  Hill Criteria toAssess C<span class="_ _0"></span>ausality</div><div class="t m0 x6 h5 y138 ff4 fs2 fc1 sc0 ls0 ws1d">When chance, bias and confounding are consider<span class="_ _0"></span>ed unlikely<span class="_ _2"></span>, causa<span class="ws0">-</span></div><div class="t m0 x6 h5 y139 ff4 fs2 fc1 sc0 ls0 wse7">tion is possible but still c<span class="_ _1"></span>annot be a<span class="_ _1"></span>ssumed a<span class="_ _1"></span>s an explanation for an </div><div class="t m0 x6 h5 y13a ff4 fs2 fc1 sc0 ls0 wsa">asso<span class="_ _1"></span>ciation bas<span class="_ _1"></span>ed on nonrandomis<span class="_ _1"></span>ed data<span class="_ _1"></span>. Of<span class="_ _1"></span>ten, there are a series of </div><div class="t m0 x6 h5 y13b ff4 fs2 fc1 sc0 ls0 wse8">studies or various ty<span class="_ _1"></span>pe<span class="_ _1"></span>s of data that bear on this question. In this con<span class="ws0">-</span></div><div class="t m0 x6 h5 y13c ff4 fs2 fc1 sc0 ls0 ws82">text, nine criteria f<span class="_ _1"></span>irst descr<span class="_ _1"></span>ibe<span class="_ _1"></span>d by Bradford Hill in the 1960s are still </div><div class="t m0 x6 h5 y13d ff4 fs2 fc1 sc0 ls0 ws0">use<span class="_ _1"></span>d. Five of t<span class="_ _0"></span>hese can b<span class="_ _1"></span>e summarise<span class="_ _1"></span>d as follows<span class="_ _1"></span>:</div><div class="t m0 x7 h5 y13e ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Strength<span class="ff4 ws85"><span class="_ _8"></span><span class="_ _8"></span>the stronger an ass<span class="_ _1"></span>ociation is<span class="_ _1"></span>, the less likely it is to be </span></span></div><div class="t m0 x8 h5 y13f ff4 fs2 fc1 sc0 ls0 ws0">explained by other factors<span class="_ _1"></span>.</div><div class="t m0 x7 h5 y140 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Consistenc<span class="_ _1"></span>y<span class="ff4 ws65"><span class="_ _6"> </span><span class="_ _1d"> </span>repe<span class="_ _1"></span>ated obser<span class="_ _1"></span>v<span class="_ _1"></span>ation of an assoc<span class="_ _1"></span>iation in different </span></span></div><div class="t m0 x8 h5 y141 ff4 fs2 fc1 sc0 ls0 ws0">studies and under different conditions support causation.</div><div class="t m0 x7 h5 y142 ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">Specificity<span class="ff4 ws8"><span class="_ _8"></span><span class="_ _8"></span>a few ADR<span class="_ _1"></span>s are completely unique syndromes (some </span></span></div><div class="t m0 x8 h5 y143 ff4 fs2 fc1 sc0 ls0 wse9">examples were given earlier) and their specif<span class="_ _1"></span>icity means that </div><div class="t m0 x8 h5 y144 ff4 fs2 fc1 sc0 ls0 ws0"> <span class="_ _3"></span>c<span class="_ _1"></span>ausation is hardly in doubt.</div><div class="t m0 x13 h11 y145 ffb fs0 fc1 sc0 ls0 ws0">Conf<span class="_ _2"></span>ounder (e.g<span class="ls10 ws9f">. </span>age)</div><div class="t m0 x10 h11 y146 ffb fs0 fc1 sc0 ls0 ws0">Exposure (e<span class="_ _0"></span>.g<span class="ls10 ws9f">. </span>drug)<span class="_ _27"> </span>Outcome (e.g<span class="_ _0"></span><span class="ls10 ws9f">. <span class="_ _2"></span><span class="ls0 ws0">ADR)</span></span></div><div class="t m0 x6 ha y147 ff1 fs6 fc0 sc0 ls0 ws0">Figur<span class="_ _0"></span>e2.1 <span class="_ _11"> </span><span class="ff9 fc1">The triangular relationship between a conf<span class="_ _2"></span>ounder, an exposur<span class="_ _0"></span>e and </span></div><div class="t m0 x6 ha y148 ff9 fs6 fc1 sc0 ls0 ws0">an outcome. By influencing both the pr<span class="_ _0"></span>obability of being exposed and the </div><div class="t m0 x6 ha y149 ff9 fs6 fc1 sc0 ls0 ws0">probability of the outcome occurring, a c<span class="_ _0"></span>onfounder distorts the relationship of </div><div class="t m0 x6 ha y14a ff9 fs6 fc1 sc0 ls0 ws0">interest (i.e<span class="_ _0"></span>. between the exposure and outcome).</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf11" class="pf w0 h0" data-page-no="11"><div class="pc pc11 w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x9 h2 y1 ff8 fs0 fc0 sc0 ls0 ws0">Basic Concepts<span class="_ _b"> </span><span class="ff1">35</span></div><div class="t m0 x3 h5 y1d ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1">T<span class="_ _14"></span>empora<span class="_ _0"></span>lity<span class="ff4">  <span class="ffa"></span><span class="wsea"> exposure to the suspe<span class="_ _1"></span>ct me<span class="_ _1"></span>dicine must precede </span></span></span></div><div class="t m0 x4 h5 y1e ff4 fs2 fc1 sc0 ls0 ws0"> <span class="_ _3"></span>outcomes in a consistent manner<span class="_ _14"></span>.</div><div class="t m0 x3 h5 y1f ff6 fs5 fc0 sc0 ls0 ws0"> <span class="_ _4"></span><span class="_ _5"> </span><span class="ff7 fs2 fc1 wseb">Biological g<span class="_ _1"></span>radient<span class="ff4 ws0"> <span class="_ _1"></span><span class="ffa"></span><span class="wseb"> is there evidence of dos<span class="_ _1"></span>e or durationrelat<span class="_ _0"></span>ed </span></span></span></div><div class="t m0 x4 h5 y44 ff4 fs2 fc1 sc0 ls1 wsb8">risk<span class="_ _1"></span>?</div><div class="t m0 x4 h5 y21 ff4 fs2 fc1 sc0 ls0 ws2f">The final four criteria are <span class="ff7">plausibility<span class="_ _2"></span>, coherence<span class="_ _1"></span>, supportive e<span class="_ _1"></span>xper<span class="_ _1"></span>i<span class="ws0">-</span></span></div><div class="t m0 x2 h5 y22 ff7 fs2 fc1 sc0 ls0 ws72">mental ev<span class="_ _1"></span>idence<span class="ff4"> and </span><span class="ws0">analogy</span><span class="ff4">. These are related by a theme of whether </span></div><div class="t m0 x2 h5 y23 ff4 fs2 fc1 sc0 ls0 wsdb">the assoc<span class="_ _1"></span>iation fits w<span class="_ _1"></span>ith existing scientific knowle<span class="_ _1"></span>dge and beliefs<span class="_ _1"></span>. If so, </div><div class="t m0 x2 h5 y24 ff4 fs2 fc1 sc0 ls0 wsec">then causation is more likely but newly identified ass<span class="_ _1"></span>ociations may </div><div class="t m0 x2 h5 y25 ff4 fs2 fc1 sc0 ls0 ws5">not fit<span class="_ _1"></span>, so absence of any (<span class="_ _0"></span>or all) of these criteri<span class="_ _1"></span>a does not pre<span class="_ _1"></span>clude an </div><div class="t m0 x2 h5 y26 ff4 fs2 fc1 sc0 ls0 ws0">asso<span class="_ _1"></span>ciation being c<span class="_ _1"></span>ausal.</div><div class="t m0 x4 h5 y27 ff4 fs2 fc1 sc0 ls0 wsed">In general terms, the more criter<span class="_ _1"></span>ia that are met, the more likely an </div><div class="t m0 x2 h5 y28 ff4 fs2 fc1 sc0 ls0 wsee">asso<span class="_ _1"></span>ciation is to be c<span class="_ _1"></span>ausal. However<span class="_ _14"></span>, there is no simple formula for </div><div class="t m0 x2 h5 y29 ff4 fs2 fc1 sc0 ls0 wsef">adding up these criteri<span class="_ _1"></span>a and coming to a definitive answer<span class="_ _14"></span>. Professional </div><div class="t m0 x2 h5 y2a ff4 fs2 fc1 sc0 ls0 wsf0">judgement is required for such asse<span class="_ _1"></span>ssments and Bradford Hill<span class="_ _14"></span>s  <span class="_ _e"></span>criter<span class="_ _1"></span>ia </div><div class="t m0 x2 h5 y2b ff4 fs2 fc1 sc0 ls0 wse8">are merely a c<span class="_ _0"></span>onceptual framework for making such a judgement. It is </div><div class="t m0 x2 h5 y2c ff4 fs2 fc1 sc0 ls0 ws53">worth noting that some of the criteria (e.g. temporality<span class="_ _2"></span>, do<span class="_ _1"></span>seresp<span class="_ _1"></span>onse, </div><div class="t m0 x2 h5 y2d ff4 fs2 fc1 sc0 ls0 ws4b">plausibility) are analogous to what was desc<span class="_ _1"></span>ribe<span class="_ _1"></span>d for the assessment of </div><div class="t m0 x2 h5 y2e ff4 fs2 fc1 sc0 ls0 ws0">causality in individual c<span class="_ _1"></span>ase<span class="_ _1"></span>s.</div><div class="t m0 x2 h6 y53 ff1 fs3 fc0 sc0 ls0 wsbd"> Conclusions</div><div class="t m0 x2 h5 y14b ff4 fs2 fc1 sc0 ls0 wscd">This chapt<span class="_ _0"></span>er has considered the most fund<span class="_ _1"></span>amental concepts in phar<span class="_ _0"></span><span class="ws0">-</span></div><div class="t m0 x2 h5 y14c ff4 fs2 fc1 sc0 ls0 wsf1">macovigilance: what is an adverse effe<span class="_ _1"></span>ct of a medic<span class="_ _1"></span>ine, how do we </div><div class="t m0 x2 h5 y14d ff4 fs2 fc1 sc0 ls0 ws28">know that it really is an adverse reaction, what is safety and on what </div><div class="t m0 x2 h5 y14e ff4 fs2 fc1 sc0 ls0 ws1d">basis do we consider a treatment to be safe? W<span class="_ _14"></span>e have discuss<span class="_ _1"></span>ed the </div><div class="t m0 x2 h5 y14f ff4 fs2 fc1 sc0 ls0 wsf2">concept of measuring r<span class="_ _1"></span>isk and the differences between relative and </div><div class="t m0 x2 h5 y150 ff4 fs2 fc1 sc0 ls0 ws83">absolute risk<span class="_ _1"></span>. The concept of the balance of risk and benefit i<span class="_ _1"></span>s impor<span class="_ _0"></span><span class="ws0">-</span></div><div class="t m0 x2 h5 y151 ff4 fs2 fc1 sc0 ls0 ws42">tant bec<span class="_ _1"></span>ause a key go<span class="_ _1"></span>al of the pharmacovigilance process is to ensure </div><div class="t m0 x2 h5 y152 ff4 fs2 fc1 sc0 ls0 ws58">that the risks of drug treatments are outweighe<span class="_ _1"></span>d by the benefit<span class="_ _1"></span>s<span class="_ _1"></span>. </div><div class="t m0 x2 h5 y153 ff4 fs2 fc1 sc0 ls0 ws28">Finally<span class="_ _14"></span>, we have covered the concepts behind causality asse<span class="_ _1"></span>ssment, a </div><div class="t m0 x2 h5 y154 ff4 fs2 fc1 sc0 ls0 ws29">basic and v<span class="_ _1"></span>ital tool in pharmacovig<span class="_ _1"></span>ilance practice. The nex<span class="_ _0"></span>t step is to </div><div class="t m0 x2 h5 y155 ff4 fs2 fc1 sc0 ls0 ws4b">consider in more detail the various kind<span class="_ _1"></span>s of data that help us to answer </div><div class="t m0 x2 h5 y156 ff4 fs2 fc1 sc0 ls0 ws0">such questions in relation to specific me<span class="_ _1"></span>dicines and safety issue<span class="_ _1"></span>s<span class="_ _1"></span>.</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
<div id="pf12" class="pf w0 h0" data-page-no="12"><div class="pc pc12 w0 h0"><img class="bi x0 y0 w1 h1" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAjCAIAAAAxJEzgAAAACXBIWXMAABYlAAAWJQFJUiTwAAAAE0lEQVQI12P8////nz9/GEYUAACdHAXziKsAfAAAAABJRU5ErkJggg=="/><div class="t m0 x1 h2 y1 ffc fs0 fc0 sc0 ls0 ws0">37</div><div class="t m0 x2 h3 y2 ffd fs0 fc1 sc0 ls0 ws0">An I<span class="_ _0"></span>ntroduction toPharmacovigilance<span class="ffe">, S<span class="_ _1"></span>econd Edition. PatrickW<span class="_ _2"></span>aller </span></div><div class="t m0 x2 h3 y3 ffe fs0 fc1 sc0 ls0 ws0">andMiraHarrison-W<span class="_ _2"></span>oolr<span class="_ _1"></span>ych. </div><div class="t m0 x2 h3 y4 ffe fs0 fc1 sc0 ls0 ws0"> 2017 John W<span class="_ _2"></span>ile<span class="_ _1"></span>y &amp; Sons Ltd. Published 2017 by John W<span class="_ _0"></span>iley &amp; S<span class="_ _1"></span>ons Ltd.</div><div class="t m0 x2 h4 y5 ffc fs1 fc0 sc0 ls0 ws0">3</div><div class="t m0 x2 h5 y6 fff fs2 fc1 sc0 ls0 wsf3">The safety of medicines is under e<span class="_ _1"></span>valuation throughout the drug </div><div class="t m0 x2 h5 y7 fff fs2 fc1 sc0 ls0 wsf4">development c<span class="_ _1"></span>ycle. This process starts b<span class="_ _1"></span>efore humans are ex<span class="_ _0"></span>pose<span class="_ _1"></span>d, </div><div class="t m0 x2 h5 y8 fff fs2 fc1 sc0 ls0 wsc6">and contin<span class="_ _0"></span>ues during the clinical de<span class="_ _1"></span>velopment and postmarketing </div><div class="t m0 x2 h5 y9 fff fs2 fc1 sc0 ls0 ws4a">phases<span class="_ _1"></span>. Broadly<span class="_ _0"></span>, the safety of a medicine is tested in four pha<span class="_ _1"></span>ses<span class="_ _1"></span>, each </div><div class="t m0 x2 h5 ya fff fs2 fc1 sc0 ls0 ws0">of which produces different types of d<span class="_ _1"></span>ata:</div><div class="t m0 x2 h5 y157 fff fs2 fc0 sc0 ls0 ws0">1) <span class="_ _9"> </span><span class="fc1">Preclinical (animal) studies</span></div><div class="t m0 x2 h5 y158 fff fs2 fc0 sc0 ls0 ws0">2) <span class="_ _9"> </span><span class="fc1">Healthy human volunt<span class="_ _0"></span>eer studies (Phase I)</span></div><div class="t m0 x2 h5 y159 fff fs2 fc0 sc0 ls0 ws0">3) <span class="_ _9"> </span><span class="fc1">Clinic<span class="_ _1"></span>al trials (Phas<span class="_ _1"></span>es II and III)</span></div><div class="t m0 x2 h5 y15a fff fs2 fc0 sc0 ls0 ws0">4) <span class="_ _9"> </span><span class="fc1">Postmarketing sur<span class="_ _1"></span>veillance (Phase IV<span class="_ _d"></span>)</span></div><div class="t m0 x4 h5 y10 fff fs2 fc1 sc0 ls0 ws71">Although there is a natural sequence defined by the above order<span class="_ _14"></span>, the </div><div class="t m0 x2 h5 y15b fff fs2 fc1 sc0 ls0 ws93">phases are not entirely distinct<span class="_ _1"></span>. Sometime<span class="_ _1"></span>s, ne<span class="_ _1"></span>w preclinical studies </div><div class="t m0 x2 h5 y15c fff fs2 fc1 sc0 ls0 wsa0">are undertaken for authorised pro<span class="_ _1"></span>ducts and, a<span class="_ _1"></span>s we saw in Chapter1, </div><div class="t m0 x2 h5 y15d fff fs2 fc1 sc0 ls0 wsf5">clinical trials are increa<span class="_ _1"></span>singly b<span class="_ _1"></span>ecoming import<span class="_ _1"></span>ant postmarketing<span class="_ _1"></span>. </div><div class="t m0 x2 h5 y15e fff fs2 fc1 sc0 ls0 ws4">Systematic r<span class="_ _0"></span>ev<span class="_ _1"></span>iew<span class="_ _1"></span>s and metaanalysis are impor<span class="_ _1"></span>tant tools for bring<span class="_ _1"></span>ing </div><div class="t m0 x2 h5 y15f fff fs2 fc1 sc0 ls0 ws2a">together data from multiple studies. Although the<span class="_ _1"></span>y have usually be<span class="_ _1"></span>en </div><div class="t m0 x2 h5 y160 fff fs2 fc1 sc0 ls0 ws35">applied in the assessment of eff<span class="_ _1"></span>icac<span class="_ _1"></span>y<span class="_ _2"></span>, their us<span class="_ _1"></span>e for safety purpo<span class="_ _1"></span>ses is </div><div class="t m0 x2 h5 y161 fff fs2 fc1 sc0 ls0 ws0">increasing<span class="_ _1"></span>.</div><div class="t m0 x2 h6 y16 ffc fs3 fc0 sc0 ls0 wsbd"> Pr<span class="_ _0"></span>eclinical <span class="_ _11"> </span>Studies</div><div class="t m0 x2 h5 y18 fff fs2 fc1 sc0 ls0 wsf6">Preclinical studies are usually conducted in rodents (rabbit<span class="_ _1"></span>, mouse, </div><div class="t m0 x2 h5 y19 fff fs2 fc1 sc0 ls0 wsf7">rat) and dogs or primates (monkeys). The<span class="_ _1"></span>y aim to establish dosage </div><div class="t m0 x2 h5 y1a fff fs2 fc1 sc0 ls0 wsf8">levels b<span class="_ _1"></span>elow which to<span class="_ _0"></span>xicity is not obser<span class="_ _d"></span>ved and to identif<span class="_ _1"></span>y the organs </div><div class="t m0 x2 h4 y1b ffc fs1 fc0 sc0 ls0 ws0">T<span class="_ _2"></span>ypes andSources ofData</div></div><div class="pi" data-data='{"ctm":[1.000000,0.000000,0.000000,1.000000,0.000000,0.000000]}'></div></div>
</div>
<div class="loading-indicator">
<img alt="" src="data:image/png;base64,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"/>
</div>
</body>
</html>
